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ABSTRACT
Prostate tumor cells over-express a prostate-speciﬁc membrane antigen (PSMA)
that can be used as a marker to select these cells from highly heterogeneous clinical
samples, even when found in low abundance. In this study, anti-PSMA aptamers were
immobilized onto the surface of a capture bed poised within a PMMA, microchip, which
was fabricated into a high-throughput micro-sampling unit (HTMSU) used for the
selective isolation of rare circulating prostate tumor cells resident in a peripheral blood
matrix. The HTMSU capture bed consisted of 51 ultra-high-aspect ratio parallel
curvilinear channels with a width similar to the prostate cancer cell dimensions. Using a
linear velocity (2.5 mm s-1) for optimal cell capture in the aptamer tethered HTMSU, a
recovery of 90% of LNCaP cells (prostate cancer cell line; used as a model in this
example) was found. Due to the low abundance of these cells, the input volume
required was 1 mL and this could be processed in 29 min using an optimized linear ﬂow
rate of 2.5 mm s-1. Captured cells were subsequently released intact from the afﬁnity
surface using 0.25% w/v trypsin followed by counting individual cells using a contact
conductivity sensor integrated into the HTMSU that provided high detection and
sampling efﬁciency (100%) and did not require staining of the cells for enumeration.
Next, an alternative fluidic device was designed and fabricated to select E. coli
O157:H7 cells from water samples using antibody-based positive selection followed by
the accurate identification and quantification via RT qPCR. The assay offers the ability
to evaluate recreational water quality without the need for bacterial cell culturing. Due to
the smaller size of these cells (1-2 μm) compared to CTCs (20 μm), fluidic transport
properties of E. coli cells were characterized and found to depend less on centrifugal
forces to increase the encounter rate of the cells with the surface-immobilized
antibodies used for their selection compared to the larger CTCs. Through fundamental
studies to optimize the transport rate, E. coli cells could be recovered at 72%, with the
RT qPCR assay limit-of-detection equal to ~6 cells. The enrichment procedure provided
many advantages compared to existing EPA methods for E. coli analysis; (i) recognizes
O157 antigens from intact and virulent cells and in stressed and non-culturable cells,
which also can produce Shiga-like toxins; (ii) cells enriched on-chip were free from
potential interferences that may hamper the nucleic acid-based measurements; and (iii)
preconcentrate cells by nearly 105 from samples that are 100 mL in total volume.
xx

Finally, I report on a microfluidic technique for selective isolation, enumeration,
and electrokinetic enrichment of low-abundance (~10 cells mL-1) circulating tumor cells
(CTCs) directly from whole blood. Enriched CTCs can then be genetically profiled for
marker mutations which can provide important clinical information. In here I integrated
high-throughput CTC selection ability of HTMSU with electrokinetic enrichment step for
pre-concentration of selected CTCs for molecular profiling of rare genetic mutation in
genomic DNA. SW620 cells (colorectal cancer cell line) over-express the integral
membrane protein EpCAM, and as such could be immuno-specifically selected using
the HTMSU activated with the EpCAM antibodies. Selected CTCs were then
enzymatically released intact from the antibody capture surface and hydrodynamically
transported through a pair of Pt electrodes for conductivity-based enumeration without a
need for fluorescent labeling. Following enumeration, CTCs were hydrodynamically
transported at a flow rate of 1 µL min-1 to an on-chip electro-manipulation unit. At an
electric field strength of 100 V cm-1, the negatively charged CTCs migrated against both
the EOF and hydrodynamic flow and were enriched in the anodic receiving reservoir to
a final volume of 2 µL. The collected CTCs could then be genetically profiled to search
for point mutations using a PCR/LDR/capillary electrophoresis assay.

xxi

CHAPTER 1 MICROSYSTEMS FOR CAPTURE OF LOW-ABUNDANT CELLS
1.1 Low-Abundant Cells

What distinguishes a low-abundance cell from one that is not, and what
applications require the ability to analyze low-abundance cells? On the basis of the data
presented in Table 1.1, we consider any sample containing less than 1,000 target cells
mL−1 to contain low-abundance cells. Typical examples of low-abundance cells are
circulating tumor cells (CTCs), circulating fetal cells, and stem cells. The abundance of
these cells, as well as others, is highly variable and depends upon factors such as the
age of the sample, the stage of the disease, and the cellularity, which is defined as the
state of a tissue or cell with regard to the degree, quality, or condition of cells present.1
However, environmental samples containing biopathogens are categorized on the basis
of the effective infectious dose level that can lead to the outbreak of disease (Table 1.1).
The ability to select and enumerate low-abundance cells and their subsequent
analyses have many important applications (Table 1.1), such as cancer research,2
forensic science, homeland security, space exploration, environmental analysis,3
isolation and characterization of intact fetal cells in maternal blood for noninvasive
prenatal diagnosis,4 use of stem cells for cell-based therapies,5 detection of CTCs in
blood for differential diagnosis and prognosis,6–11 and detection of T lymphocytes for
determining the progression rate of human immunodeficiency virus infections12,13 or
autoimmune disease.14 Another fast-growing area requiring low-abundance cell analysis
is the isolation and detection of pathogens and protozoan parasites such as Escherichia
coli O157:H7, swine influenza virus, and Cryptosporidium in various food and water
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Table 1.1 Low-abundance cell types (<1000 targets mL−1) and methods for their selection
Cell
abundance
-1
(cells mL )

Trophoblasts,
Lymphocytes,
Nucleated
Erythrocytes

MACS, FACS,
Immunoaffinity columns

(6,9,
42,
18)

Maternal and cord
blood

1-15

MACS, FACS, Charge flow
separation, Density
gradient centrifugation
(DGC)

(83)

Multipotent Stem Cells

Peripheral, Cord
blood
Bone marrow

400

MACS, FACS
Immunoaffinity columns,
DGS

(1922)

Sperm

Vaginal swab

380

Differential extraction,
FACS

(84)

HIV infected T cells
S. spp infected
lymphocytes

Peripheral blood
Lymph

300

MACS, FACS
Immunoaffinity columns
ELISA

(23,
24)
(88)

E. hirae, E. gallinarum
E. casseliflavus,
S. pneumoniae
E. coli O157:H7*,
V. Cholerae*

Waste, River,
Drinking Waters

0.01-1

Bacteria Culture,
ELISA, PCR/RT-PCR

(94,
25)
(26)

Adenoviruses*
Enteroviruses*
Hepatitis A and E*

Waste, River,
Drinking Waters

0.01-1

Dengue
Swine flu
Bovine Diarrhea

Peripheral Blood
Lymph

1000
610
10

C. parvum
C. cayetanensis,
E.histolytica, N. fowleri
D. medinensis, S. spp.

Waste, River,
Drinking Waters

0.01-1

Protozoa
/Helminthes

Viruses

Fetal

CTC

<0.7

Stem

Peripheral, Cord
blood, Bone marrow,
Lymph Fluid,
Thymus, Urine

Ref.

Somatic

Lung, Breast,
Prostate, Pancreatic,
Colon, Cervical,
Bladder

Isolation method

Infected

Resident material

Bacterial

Rare cell type

2

(26)
Viral cultures,
Immunoaffinity column,
RT-PCR, ELISA

(25)
(64)

Fluorescence antibody,
Filtration, PCR/RT-PCR,
ELISA

(26)

samples.15–17
The challenge in any analytical strategy for low-abundance cells begins with the
selection of the target cells from a heterogeneous population in which the target is a
minority. For example, in the case of CTCs, in 1 mL of whole blood there are more than
109 red blood cells (RBCs) and typically one to five CTCs, requiring an enrichment
factor less than 109. For the isolation of low-abundance cells, four important metrics
must be considered: (a) throughput, the number of cell-identification or -sorting steps
per unit time; (b) recovery, an indicator of the fraction of target cells collected from the
input sample; (c) purity, which depends on the number of so-called interfering cells
excluded from the final analysis; and (d) viability, that is, whether the isolated cells
retain their biological function after the selection process.27,28 Additionally, highly
efficient quantification of the number of enriched low-abundance cells must be provided
in most cases.29
1.2 Methods for Low-Abundant-Cell Selection

Two basic formats can be used for selecting low-abundance cells from mixed
populations: macro and microscale formats. Macroscale formats provide high
throughput for selecting low-abundance cells due to their ability to process large input
volumes quickly, whereas microscale formats typically lack that ability (see Figure
1.1).30 High-throughput processing is required due to the necessity for sampling large
input volumes to generate a high statistical confidence for successfully securing the
target cells from the processed sample. Throughput is directly proportional to (a) the
cross-sectional area of the conduit through which the sample is delivered and (b) the
rate of sample delivery. The input sample volume required for the assay is determined
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Figure 1.1 Sample-processing time as a function of the fluidic conduit cross-sectional area at
three different linear velocities: 1, 10, and 100 mm s−1.

by the frequency of rare cell appearance. For example, at 5 cells mL−1, a sampling
volume of 1 μL would produce a probability of only 0.5% of finding the target cells in that
volume. Because low-abundance cells appear at frequencies less than 1,000 cells
mL−1, high-volume sampling (≥1 mL) is required to increase the probability of isolating
these rare events. If cross-sectional dimensions of 35 μm×35 μm were employed for a
fluidic conduit to exhaustively search for rare cells, and if the transport rate through the
conduit were 10 mm s−1 with a required input volume of 1.0 mL, the sampling time
would be approximately 278 h. For a single rectangular conduit with dimensions of 150
μm×35 μm under conditions similar to those given above, the sampling time would be
reduced to ∼5.6 h. If the 150 μm×35 μm conduits were highly parallelized through the
incorporation of 51 conduits, the processing time would drop to 0.12 h (Figure 1.1).
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1.2.1 Macroscale Techniques for Selecting Low-Abundant Cells
Commonly used macroscale formats for enriching low-abundance cells include (a)
magnetic capture that employs micrometer-sized ferromagnetic beads coated with
molecular recognition elements, typically referred to as immunomagnetic-assisted cell
sorting

(IMACS);35-37

(b)

size-based

separations

that

use

nuclear-tracked

membranes;38,39 (c) fluorescence-activated cell sorting (FACS);40,41 and (d) reversetranscription polymerase chain reaction (RT-PCR) of messenger RNAs (mRNAs), which
are used as surrogates for cell identification.42 In the following sections, we briefly
discuss these macroscale processing techniques.
1.2.1.1 Immunomagnetic-Assisted Cell Sorting
CellSearch® procedure and OncoQuick® system are two commercially available
immunomagnetic isolation kits for selecting CTCs from peripheral blood samples.43 Both
kits employed anti-epithelial cell adhesion molecules (EpCAM) antibodies for selecting the
cancer cells. Both procedures employed density gradient centrifugation followed by a series
of washes in order to remove the red blood cell (RBC) fraction from the whole blood sample
prior to magnetic isolation of the low abundance cells. Centrifugation of the RBC depleted
sample is next performed at 800×g for 10 min to remove the blood plasma. The resulting
cellular pellets are resuspended in 10 mL of buffer, and incubated with carboxylatefunctionalized

ferromagnetic

particles

that

are

coated

with

anti-EpCAM.

Immunomagnetically-labeled cells are concentrated using an external magnetic field (see
Figure 1.2). Following magnetic isolation, the processed sample is incubated with leukocyte
specific anti-cytokeratin antibodies labeled with Alexa Fluor 555, nuclear specific 4‘,6diamidino-2-phenylindole (DAPI), and a CTC specific anti-EpCAM antibody conjugated to a
fluorescein derivative. Under these conditions, white blood cells and tumor cells harbor blue
5

Figure 1.2 (A-C) Schematic of the immunomagnetic-assisted cell-sorting process. Blue and tan
circles represent normal and circulating tumor cells, respectively. (D) Schematic of a
fluorescence-activated cell-sorting instrument.

fluorescing nuclei; however, the fluorescent signatures of the FITC derivative selectively
placed a green ―halo effect‖ about the blue nuclei of the CTCs. The orange fluorescent halo
from the Alexa Fluor 555 about the nuclei of the leukocytes is used for exclusion. The CTC
recovery rates data is significantly better using the CellSearch system (60% recovery)
compared to the OncoQuick system (26% recovery). In addition, the CellSearch system
requires a smaller input volume compared to the OncoQuick system. The non-metastatic
samples with both kits show the detection of at least one CTC in the blood of healthy
6

individuals in 12% of these samples analyzed. For the confirmed metastatic cancer cases,
CellSearch is capable of producing positive responses in 54% of these samples resulting in
a relatively high rate of false negatives.43 The OncoQuick system demonstrated poorer
detection accuracy as only 23% of the samples are reported positive for metastatic disease.
In 5 of the 6 varieties of cancer studied, CellSearch is twice as effective as OncoQuick at
detecting metastatic disease and CellSearch is also found to be more sensitive in common
positive tests often identifying more CTCs within similar amounts of peripheral blood.
1.2.1.2 Size-Based Selection
Tracked polycarbonate membranes with varying pore sizes (8–14 μm) are
employed to filter large (9.0–18 mL) blood samples spiked with known quantities of
CTCs.36 Prior to filtration using the membrane, the samples are diluted at a 1:1 (v/v)
ratio of spiked blood:PBS containing an anticoagulant EDTA. Simple gravimetric
filtration through these polycarbonate membranes is sufficient to reduce the erythrocyte
content by >105 cells mL-1. After the initial filtration using the polycarbonate filter, the
isolated cells are washed and incubated for 1 h with anti-pan-cytokeratin directed
against cytokeratin 5, 6, 8, 17 and 19)-FITC. After a wash to remove the unbound anticytokeratin antibodies, nuclei-specific propidium iodide is added, and an additional
incubation of 30 min performed. The cells retained by the polycarbonate membrane are
analyzed using a combination of laser scanning cytometry (LSC) and microscopy. After
analysis, all the cytokeratin positive cells are relocated and examined ―by eye‖ to
exclude any false- positive events. Only positive cells with the appropriate
nuclear:cytoplasmic ratio are counted as positive events.
False positives are evident in the case of MCF-7 cells, and the authors attributed
this to the presence of adhesion molecules on the cells‘ periphery. The most prominent
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reduction in leukocyte frequency is demonstrated for 9 mL blood samples that originally
contained 5×107 leukocytes, which is reduced to 7,000 leukocytes after the filtration
step. These membranes are demonstrated to isolate nearly 85–100% of the CTCs, but
significant numbers of white blood cells are also retained due to their similar size with
respect to the CTCs complicating the enumeration process. Also, the process requires
pre or post treatment of retained cells with a variety of fluorescent stains before the LSC
could be utilized.
Microarrays are also used in the isolation of target cells. Various ―cluster of
differentiation‖ (CD) antigens are affinity-captured onto the arrays containing
immobilized antibodies.40 The arrays contain several surface-immobilized antibodies
directed toward target antigenic species, which are used to spatially isolate cells. These
methods are limited by slow mass transport but are promising for multiplexed analyses;
the array elements are not individually addressable making collecting isolated cells from
a multiplexed analysis difficult due to the single chamber of the arrays. Most often in
order to isolate a particular phenotype, subsequent processing is required. Belov et al.
presented an array technique based on cluster of differentiation in leukemia.40 The CD
antigens can be used to phenotype leukocytes based on characteristic abnormal
patterns of antigen expression. Microarray technology is also used to screen HIV
positive blood against normal as well as blood from those undergoing therapy and those
deemed long term non-progressors.41
1.2.1.3 Fluorescence-Activated Cell Sorting
FACS can be used to select low-abundance cells from mixed populations by
monitoring the presence of antigenic species indigenous only to the target cells (see
http://www.abcam.com/technical). FACS samples individual cells in a high-throughput
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fashion (∼50,000 cells s−1) by monitoring the fluorescence signature elicited by each cell
type (Figure 1.2D). For example, FACS has been used to detect and enumerate an
immortalized breast cancer cell line (BT-20 cells) that was seeded into peripheral blood
mononucleated cells (PBMCs) at frequencies of 10−5, 10−6, and 10−7.37 The flow cytometer
employed three excitation wavelengths, 325, 488, and 633 nm, allowing for discrimination
between the PBMCs and the BT-20 cells. A panel of fluorescently labeled antibodies
allowed the BT-20 cells to produce distinct colors for their identification from the PBMCs.
BT-20 cells were also characterized by a cocktail containing three anti-cytokeratin
antibodies, each tagged with a different-colored dye. Through the use of a colordiscrimination algorithm, BT-20 cells were detected with a 20% recovery for frequencies at
10−5 and 10−6. The challenges associated with this assay format were the extensive
amount of time required for the immunofluorescent staining (∼20 h), the need to remove
the RBCs from the blood sample prior to processing, and the extensive equipment required
for the measurements. The recovery was low due to the loss of target cells during removal
of the RBC fraction and the extensive staining and processing steps required. For this
approach to reliably assess rare CTCs at frequencies of 10−7 in the presence of PBMCs,
∼200 mL of blood would be needed.
1.2.1.4 Molecular Methods
Another approach employed for the analysis of low-abundance cells in clinical or
environmental samples is RT-PCR, in which mRNAs are used as markers to report on the
presence of specific low-abundance cells. For example, reports have documented RTPCR‘s ability to detect low-abundance cells in 106 PBMCs via an appropriate marker
panel.38 Gene expression–based assays have high sensitivity but can generate poor
selectivity, which can lead to false-positive results. Also, as with many low-abundance cell–
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based assays for whole blood, the RBC fraction must be removed with, for example, FicollHypaque density-gradient centrifugation (DGC), which can reduce cell recovery. Notably,
these assays are prone to high interlaboratory variability.39
1.2.2 Challenges Associated with Macroscale Methods for Low-Abundant-Cell
Selection
Enrichment of target cells via macroscale systems typically employs either positive
selection (for example, IMACS or FACS) or negative selection. Negative selection gives
low purity (0.01%–0.1%) due to insufficient removal of interfering cells.42 When the sample
matrix is whole blood, negative selection performed on the basis of size is often marred by
interferences resulting from leukocytes, due to the similarity in size between these cells and
the CTCs, for example.45,46 Attempts to further preconcentrate targets and remove WBCs
introduce a significant risk of target loss. For example, monocytes were found to interfere
with the selection of comparably sized stem cells.47
The challenges associated with positive selection using IMACS or FACS assays are
the extensive amount of time required for the immunofluorescent staining (∼20 h) and, in
many cases, the need to remove the RBCs from a blood sample prior to processing.
Furthermore, semi-automated processes requiring operator intervention and the variability
in reagent and laboratory protocols lead to poor interlaboratory standardization and data
collection, assessment, and management.48 Additionally, downstream processing of the
collected rare cells requires samples with high purity that are in a viable form (i.e., following
cell culturing). For example, the magnetic field used for IMACS may produce perturbations
on stem cell differentiation.49 Finally, in the case of positive selection, the recovery can
depend upon the expression level of the antigenic membrane protein used for their
selection.9
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Many macroscale techniques also rely on DGC preselection. Differences in density
between cell types can be small, and individual cell types can be heterogeneous in size
and density.50 Consequently, particular cell types can distribute throughout a densitygradient medium, rather than precisely segregate at a discrete area; this results in reduced
recovery of the desired cells and/or contamination with undesired cell types.45 Procedures
such as DGC that enrich for low-abundance blood cell types, such as hematopoietic
progenitor cells, can lead to significant loss or reduced yields due to poor segregation with
potential interfering cells. For example, conventional density-gradient methods to isolate
progenitor cells (e.g., CD34+ hematopoietic stem cells) from umbilical cord blood results in
significant loss of the desired stem cells.46
1.3 Microsystems for Low-Abundant-Cell Selection
Microsystem technologies allow the dissemination of new sample-processing
capabilities to a broader user community due to their potentially smaller footprint, lower
power consumption, reduced reagent requirements, and process automation, as compared
with their benchtop counterparts. Additionally, improved performance is fundamental to
high-sensitivity cellular analysis technologies.53,54 In particular, microsystem platforms
enable one to handle small numbers of cells without loss. Such a task is difficult to achieve
with instruments such as conventional flow cytometers, which typically require a starting
population of more than 100,000 cells.55 Furthermore, low-abundance cell–selection
mechanisms such as affinity, physical characteristics, dielectrophoresis (DEP), and
magnetic interactions can be integrated into a microsystem, along with downstream
molecular processing of the intracellular contents of the selected cells, to provide important
clinical or environmental information. The challenge for imposing low-abundance cell–
selection assays to microsystems is sampling; to generate a high statistical probability of
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selecting the low-abundance cells, large input volumes (>1 mL) must be processed, and
most microsystems cannot handle large-volume inputs in reasonable times (i.e., they have
poor throughput; see Figure 1.1). Therefore, novel design approaches must be
implemented to accommodate the necessary sampling volume. In the following sections,
we review microfluidic-based systems for selecting low-abundance cells.
1.3.1 Low-Abundant-Cell Selection via Immunoaffinity Interactions
Affinity-based

selection

of

low-abundance

cells

is

often

employed

in

microsystems. This approach exploits the specific but noncovalent interactions between
a ligand, such as an antibody, aptamer, or peptide, and a target-specific receptor, such
as a membrane protein.56 Affinity-based cell selection via microsystems can be carried
out by either positive or negative selection. Negative selection requires the complete
removal of the nontarget cells with minimal target-cell capture and is an attractive
approach when the specific markers for target cells are not fully known. In contrast,
positive selection involves directly capturing the target cell through the use of a
membrane protein(s) unique to that cell type.9
In most cases, cell selection involves a solid phase in which (a) the recognition
element(s) is covalently tethered to the surface of a fluidic conduit and (b) the sample
containing the low-abundance cells is moved through this conduit to invoke the
selection process. The operational criteria mentioned in Section 1 are important to this
phase, as are (a) nonspecific interactions, (b) target cell–recognition element adhesion
strength, (c) conduit architecture, (d) recognition element immobilization chemistry, and
(e) ligand surface density.
As noted in Section 1, throughput—namely, the number of cell-identification or sorting steps per unit time—is a critical metric to optimize. One can improve throughput
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by increasing the transport rate of sample through the selection conduit. However, cell
recovery can degrade at certain transport rates, indicating that there is an optimal flow
rate at which the system can be operated. The analytical model used to explain this
observation is based on cell adhesion between a surface-tethered antibody and a
moving antigen.57 This model describes a two-state process. The first state accounts for
transport of the solution-cell antigen to the surface-bound antibody, which describes the
encounter rate (ko). The second state gives the probability (P) that an association event
will occur during the time the antigen is in close proximity to the tethered antibody. The
encounter rate, ko, increases linearly with flow velocity, whereas P decreases. These
states can be used to calculate the rate of capture per antigen-antibody pair (kf, s−1) via
the following equation:57
kf =ko P

(1)

P can be estimated from Equation 2,
P=ᴧδ/(1+ᴧδ) (2)
where δ is the dimensionless Damkӧhler number (calculated from a2kin/D; kin is the
intrinsic antigen-antibody reaction rate; a is the encounter radius) and ᴧ is the
dimensionless encounter time [calculated from ז/(a2/D); =ז8a/(3Uπ); U is the celltranslational velocity; D is the cell diffusion coefficient].33,57 Equation 1 indicates that the
recovery increases with translational velocity due to increases in ko but that, beyond an
optimal velocity, the recovery degrades due to insufficient reaction time (i.e., lower P).
Critical to affinity-based cell selection that uses surface-immobilized recognition
elements and flow processing is the adhesion force (FA) between the cell and the
antibody-decorated surface, which must be greater than the shear force (FS) generated
by the solution flow to prevent target cell loss. FA can be determined from the bond
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strength between a single antigen-antibody complex (fc), the cell-contact area with the
recognition surface (Ac), and the number of receptors poised on the surface within the
contact area of the cell (Cs). FA is calculated from33
FA=fc×Ac×Cs (3)
If the cell is assumed to be a nondeformable object once it adheres to the capture
surface, the contact area can be calculated from Equation 4,58
Ac=π{rpsin[cos−1(rp –h‘+h)/rp]}2 (4)
where rp is the cell radius and h and h’ represent the characteristic cell-separation
distances from the surface upon binding. When the FS generated by the flow is equal to
or greater than FA, the cell can be removed from the surface. The velocity-dependent FS
can be determined from Stoke‘s law,59
FS=6πηrpνc , (5)
where rp is the cell radius, η is the solution viscosity, and νc is the critical linear velocity
that can induce cell detachment.
The application of mAB based microsystem for CTCs selection kept pace with
their increasing availability. Monoclonal antibody-poised microsystem was designed by
Du et al. to recognize and select cervical cancer cells (HCCC) in a mixed cell
population.60 The channel dimensions of microsystem were rather large, 500 µm×500
µm, and 2.0 cm long. The anti-α6-integrin antibody was immobilized on the surface
against overexpressed α6-integrin antigen on cervical cancer cell membrane. The
capture efficiency of 30% was obtained at average velocity of 1.3 mm s−1 and surface
antibody concentration of 1:50, while normal cell capture efficiency was less than 5%
reported indicating insufficient separation efficiency with low purity to track rare cell
events. It is found that separation purity and cancer cell capture efficiency were altered
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by the specificity of the antibody, flow rate and surface immobilized antibody
concentration. Increasing the flow rate caused both increased dissociation of antigen
and decreased antigen–antibody interaction time. The high non-specific binding of
normal cells at low flow rates were observed and it was likely a result of the high surface
to volume ratio of the microchannel.
Nagrath et al.9 developed a microsystem for selecting CTCs directly from
peripheral blood. The CTCs originated from solid lung, colorectal, breast, prostate, brain,
and neck tumors and were selected through use of anti-EpCAM monoclonal antibodies
tethered to the walls of a microfluidic channel and posts. The device contained 78,000
microposts that were 100 μm tall and 100 μm wide with a total surface area of 970 mm2
(Figure 1.3). Anti-EpCAM monoclonal antibodies provided the specificity for CTC
recovery from unfractionated blood because EpCAM is specifically overexpressed by
adenocarcinomas.9,33 The essential parameters that determined recovery by the CTC
chip were flow velocity, shear force, and cellular EpCAM expression level, as noted in
Equations 1–5. At a flow rate of 1 mL h−1, 65% of the CTCs were recovered, and 98% of
the cells remained viable. As the processing flow rate was increased to 3 mL h −1, the
recovery was reduced to 25%, as shown in Figure 1.3E. Enrichments from whole blood
provided ∼50% purity, and as a result the CTCs had to be differentiated from the major
impurity, leukocytes, through use of fluorescently labeled cytokeratin and CD45
antibodies (Figure 1.3G-N). The same CTC chip was also used to select low-abundance
lung cancer cells from whole blood.59 Extensive clinical studies have been successfully
completed with the use of this CTC chip. For example, with this chip CTCs were
isolated in 100% of patients with early-stage prostate cancer. Furthermore, the potential
utility of this CTC chip in monitoring response to anticancer therapy was also
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Figure 1.3 Isolation of circulating tumor cells (CTCs) from whole blood, performed with a
microfluidic device (CTC chip) fabricated in silicon via reactive ion etching. (A) The workstation
setup for CTC isolation from whole blood. (B) The CTC chip with microposts etched into the
silicon. (C) Micrograph of whole blood flowing through the CTC chip. (D) An image of a captured
NCI-H1650 lung cancer cell spiked into blood (pseudo-colored red). The inset shows a highmagnification view of the captured cell. (E) CTC recovery as a function of flow rate. (F)
Regression analysis of capture efficiency for various target-cell concentrations in whole-blood
samples versus lysed-blood samples. (G-N) High-magnification images of captured CTCs and
hematologic cells stained with 4‘,6-diamidino-2-phenylindole (DAPI), cytokeratin, and CD45.
Merged images identify CTCs in panels G, I, K and M and hematologic cells in panels H, J, L,
and N.

investigated. In a small cohort of patients with metastatic cancer who were undergoing
systemic treatment, temporal changes in CTC numbers correlated well with the clinical
course of the disease.9,59
Adams et al.33 introduced a microchip-based high-throughput microsampling unit
(HTMSU) capable of selecting very low abundance CTCs from whole blood in a single
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step. The HTMSU was fabricated from poly(methylmethacrylate) (PMMA) via
microreplication and consisted of 51 ultrahigh–aspect ratio, parallel, curvilinear channels
and a Pt-conductivity sensor to allow for cell enumeration (Figure 1.4). The capture
channels were functionalized, via a carboxylate scaffold, with anti-EpCAM monoclonal
antibodies. The authors found that the CTC-capture efficiency varied with channel width;
the highest recovery (97%) was obtained for channels that had similar widths (35 μm) to
the CTC dimensions (15–30 μm) (Figure 1.4F). The device was capable of highthroughput operation at an optimal linear fluid velocity of 2 mm s −1 in each channel (51
parallel channels), allowing 1 mL samples to be exhaustively interrogated in ∼37 min.
The captured CTCs were subsequently removed from the capture surface via trypsin
and were quantitatively counted one at a time via conductivity detection.
Microsystems have also been applied to immunoassay-based recognition for
pathogen detection. Static forward light scattering was investigated for the analysis of
bovine viral diarrhea virus in a complex matrix mimicking a body fluid. 61 The assay was
based on the use of microparticles coated with antibodies directed against bovine viral
diarrhea virus, and the reaction was monitored in a Y-shaped poly(dimethylsiloxane)
(PDMS) fluidic device with optical fibers oriented at a 45 ◦ angle to measure light scatter
from single virus cells. Bovine viral diarrhea virus concentrations of 10 TCID 50 mL−1
(where TCID50 stands for 50% tissue-culture infectious dose) were detected with this
microfluidic chip. Application of antigen/antibody-recognition strategies for lowabundance-cell selection is, in some cases, limited by the availability of antibodies
directed against membrane proteins uniquely found on the target rare cells. 62
Additionally, most

positive selection tools require surface immobilization of the

antibody, which can result in reduced recovery or adhesion strength between the cell
17

Figure 1.4 Schematic of a microchip-based high-throughput microsampling unit (HTMSU)
fabricated in poly(methylmethacrylate) via microreplication for selection of circulating tumor cells
(CTCs). (A) An AutoCAD® diagram of the sinusoidally shaped capture channels with bright-field
optical micrographs showing (B) the integrated conductivity sensor consisting of cylindrical Pt
electrodes with a 75 μm diameter and a 50 μm gap; (C) the single port exit, where the HTMSU‘s
width tapers from 100 μm to 50 μm and the depth tapers from 150 μm to 80 μm over a 2.5 mm
region that ends 2.5 mm from the Pt electrodes; (D) the sinusoidal cell-capture channels (5x
magnification); (E) three-dimensional projection of the topology of the HTMSU obtained at 2.5
μm resolution via noncontact optical profilometry (arrows, Pt electrode conduits); and (F) the
capture efficiency of CTCs in spiked whole-blood samples as a function of the cells‘ translational
velocity. The microchannels were 35 μm wide (red down triangles, sinusoid; purple circles,
straight) and 50 μm wide (blue up triangles).

and the surface-tethered antibody due to the stochastic nature of the immobilization
chemistry. Antibodies may also show variation in antigen binding, exhibit instability
when bound to solid surfaces, and have limited binding sites.63 Finally, environmental
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factors may affect antibody-antigen interactions.64,65 Therefore, alternatives to
antibodies for low-abundance cell selection have been investigated.
Aptamers, single-stranded nucleic acid oligomers, possess highly specific
recognition affinities to molecular targets through interactions other than classical
Watson-Crick base pairing.66 Compared with antibodies, aptamers have lower molecular
weights, remain stable during long term storage, sustain reversible denaturation, have
low toxicity, and can be produced against targets via highly automated technologies
[e.g., SELEX (systematic evolution of ligands by exponential enrichment)]. 67 Additionally,
their immobilization chemistry is highly oriented: End-point attachment occurs
exclusively through the 5‘ or 3‘ end of the aptamer, which bears a functional group.
These advantages make aptamers highly desirable as potential molecular recognition
elements for low-abundance-cell selection.68
Aptamers have been employed in a microsystem for the capture of prostate
cancer cells that used a LNCaP cell line as a model. This cell line overexpresses a
prostate-specific membrane antigen (PSMA) that was used as a marker for the
selection of these cells.69 Nuclease-stabilized and in vitro–generated PSMA aptamers
were immobilized onto ultraviolet-modified PMMA capture channels (Figure 1.4A-D).
The authors used carbodiimide-coupling chemistry and the appropriate linker structure
to enhance the accessibility of the surface-bound aptamer to the solution borne cells
(Figure 1.5A). Following selection and isolation, the captured cells were released from
the capture surface via enzymatic digestion of the extracellular domain of PSMA for
subsequent conductivity enumeration. CTCs possess unique electrical properties that
arise from their characteristic chemical composition (compared with those of
erythrocytes.
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Figure 1.5 (A) Chemical steps for the immobilization of aptamers to the surfaces of a
poly(methylmethacrylate) (PMMA)-based high-throughput microsampling unit (HTMSU) used for
the positive selection of LNCaP cells. (B) Conductometric responses generated for 1.0 mL of
whole blood seeded with 20±1 LNCaP cells (red) and 0 LNCaP cells (blue), at a linear flow
velocity of 2.5 mm s−1, processed with an HTMSU. The arrows designate peaks that were
identified as LNCaP cells on the basis of a signal-to-noise threshold of 3.

For example, the overexpression of membrane glycoproteins—such as PSMA
and EpCAM, which are associated with many tumor or cancer cells—results in an
increase in the number of negatively charged sialic acid molecules that cap the
extracellular domains of these integral membrane proteins.58 As shown in Figure 1.5B,
only positive signals were designated as LNCaP cells due to their electrical properties.
The system required no sample pretreatment and provided high throughput (processing
time for 1 mL was 29 min), a recovery of 90%, and a purity of 100%.
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1.3.2

Low-Abundant-Cell Selection via Physical Criteria
Differences in cell size, density, shape and deformability can be exploited in

microsystems to select low-abundance cells on the basis of mechanical restriction. 71,72
Such microsystems are relatively easy to build with common microfabrication
technologies.19
Forensic DNA analysis of sexual assault evidence requires separation of DNA
from epithelial (victim) and sperm (perpetrator) cells collected on vaginal swabs.
Because the cells in sexual assault evidence are rarely viable, biological adhesion is
less likely, but adsorption to the glass is possible and could be used to selectively
isolate the epithelial cells from solution using microsystem, either alone or in conjunction
with the sedimentation rate differences.19 Specific gravity differences are small but
perceptible, with sperm cell density on the order of 1.12 g mL-1 73 and epithelial cell
densities in the range of 1.04-1.08 g mL-1.74 These values characterize differences in
the rate at which cells would settle to the bottom of the inlet reservoir. The microsystem
prepared by Horsman et al. contained a straight channel with the dimensions of 2.5 cm
long, 50 µm deep and 90 µm wide at half-height. The larger surface area of the
epithelial cells and their high concentration of cell surface binding proteins, which are
capable of specific interaction with surfaces, present the possibility for binding to glass
substrates. Because, the method does not use mobilization of the epithelial cells,
clogging of the microchannel by epithelial cells, was not encountered here. Separation
speed and throughput was low, because the flow rates achievable using gravity forces
were slow, not easily controlled. It was demonstrated that increasing the flow rate to
achieve a faster separation can dislodging the epithelial cells from the reservoir. A 20
min separation (~380 sperm cells) provided sufficient material for DNA extraction and
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PCR amplification of a 380-bp fragment of β-globin, which is a representative human
gene. Though the system generated 100% theoretical purity, the real life forensic
samples are contaminated with bacteria and purity of separation can be deteriorated
and bacteria can interfere with effective counting of sperm cells using optical means.
The size and deformation characteristics of fetal nucleated red blood cells
(fNRBCs) were used to isolate them from maternal blood. 19 fNRBCs range between 9
and 12 μm in size and were demonstrated to deform and pass through fluidic obstacles
fabricated in PDMS that were as small as 2.5 μm×5 μm. WBCs ranging in diameter
between 10 and 20 μm could not deform and thus were retained by the fluidic channels
of similar dimensions. The authors19 isolated low-abundance fNRBCs from umbilical
blood that was preconcentrated using DGC. Unfortunately, the low processing rate of
<0.35 mL h−1 posed a major challenge to this system, given that ∼10 mL of blood had to
be processed to accommodate sampling these low-abundance cells.
A series of massively parallel microfabricated sieving structures were used to
separate neuroblastoma (NB) tumor cells from blood constituents on the basis of size
characteristics.72 The reported devices consisted of four successively narrowing regions
of channels. The size-based selection of tumor cells was carried out through the use of
diluted blood (1:10) (v/v) containing the NB cells. As the NB cells traversed the device,
they were retained in the 10 μm×20 μm channels, but other blood cells migrated to the
output. It was observed that in shallow channels NB cells tended to adhere to the walls
upstream of where freely moving cells were retarded. A shorter (3.5 cm) device with
deeper (20 μm) channels reduced the device flow resistance and adhesion problems.
Experiments that used undiluted whole blood (2 mL) took approximately 3 h to analyze.
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The authors72 noted that the enriched cells obtained from the device had low purity and
that the interfering cells were composed of residual erythrocytes and leukocytes.
1.3.3

Low-Abundant-Cell Selection via Dielectrophoresis
DEP uses the electrical polarization of cells in nonuniform fields to induce

translational motion and/or reorientation of the cells.75 The induced polarization depends
on multiple factors related to the cells‘ condition, such as bilipid membrane
characteristics, internal structure, and size of the nucleus.76 DEP has been used to
study the physiology of bacterial,77 yeast,78 plant,79 and mammalian cells80 and to
investigate cellular alterations accompanying physiological changes, such as mitotic
stimulation and induced differentiation. The variability in particular cells‘ response to
electric fields can be used not only to differentiate cell types but also to distinguish the
activation states of similar cells.81 DEP devices can differentiate among cell types by
changing the field frequency or amplitude.82-84
The DEP force (FDEP) acting on a cell can be calculated via85
FDEP=2πεM rp3Re[fCM (ω)]∇E2RMS, (6)
where εM is the permittivity of the suspending medium, rP is the cell radius, ERMS is the
electric field strength, and Re[fCM(ω)] is the real part of the dipolar Clausius-Mossotti
factor. This factor is the relative polarization of the cell versus that of the surrounding
medium and is given by85
fCM (ω)=[ε∗C(ω)−ε∗M (ω)]/[ε∗C+2ε∗M (ω)] (7)
where εC∗ and εM∗ are the complex permittivities of the cell and medium, respectively.
The DEP forces can be either negative, Re[fCM(ω)]<0 (i.e., the cell is repelled by a
region of higher electric field), or positive, Re[fCM(ω)]>0 (i.e., the cell is attracted to a
region of higher electric field). As shown by Equations 6 and 7, the polarizability of the
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cell is frequency dependent; thus, changing ω can result in the selection of certain cell
types.
A dielectric affinity column was used to select tumor cells (MDA231) from diluted
blood,86 from which the cells were captured by balancing gravity, DEP, fluid drag, and
hydrodynamic lift effects (Figure 1.6) and released by reducing the frequency of the
applied electric field. Efficient selection was obtained when (a) the product of the cell
radii and dielectric polarizability was sufficiently different and (b) the ratio of fluid velocity
to the square of the applied voltage was within the specified range, determined by the
type of cell. The column sorted cells at a rate of ∼103 s−1; larger devices increased this
rate by two orders of magnitude. The viability of the excluded cells was 98%, indicating
that the cell-membrane barrier function was maintained. The total number of cells
analyzed with this device in a single run was 1.2×106, and the ratio of tumor cells to
normal hematopoietic cells was 1:3.
The electrical conductivity of RBC membranes increases sharply when they
become infected with malarial parasites such as Plasmodium falciparum. When
challenged by a suspension in a low-conductivity medium, infected cells lose internal
ions, whereas uninfected cells retain them.24 The resulting dielectric differences
between infected and noninfected cells were exploited in order to sort these cells via
DEP.24 Parasitized cells were isolated by steric dielectric field–flow fractionation (DEPFFF) and were focused at the center of a spiral electrode array, identified, and counted.
The spiral microelectrode array had a 2 mm2 surface area and was composed of five
complete turns of four parallel spiral elements. On the spiral array, cells were
distinguished through differences in their DEP properties. More than 99.5% of the
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normal erythrocytes were trapped, and 90% of the parasitized cells were
preconcentrated 50- to 200-fold.

Figure 1.6 Dielectrophoretic separation of MDA231 human metastatic breast cancer cells from
diluted peripheral blood. (A) Initial separation of cells in the chamber inlet well after the electrical
sweep signal was applied. (B) Blood cells focused into bands that flowed between the electrode
tips, leaving the cancer cells behind. (C) Cancer cells that remained on the electrode tips after
the blood cells were swept downstream through the dielectrophoresis column. (D) Close to the
chamber outlet well, where only blood cells in focused bands were moving.

Using a similar approach, Reichmuth et al. developed a microfluidic chip with an
integrated membrane for simultaneous concentration and detection of swine influenza
virus with necessary sensitivity for diagnosis.87 The membrane was created in a small
section (100 µm wide×25 µm deep×150 µm long) of the microchannel. The
Immunoassays recognized the membrane viral proteins using antibodies. Open channel
electrophoresis was used to detect by observing formation of an antibody–antigen (virus
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particle)

complex.
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polyacrylamide membrane were exploited to simultaneously concentrate viral particles
and separate the virus/fluorescent antibody complex from the unbound antibody. The
filtration step eliminated the need for washing, commonly required with surface-based
immunoassays and increased the speed of the assay. With integrated preconcentration,
a LOD of 610 TCID50 mL−1 could be obtained for <50 µL sample in less than 6 min. The
most common failure mode of the chip was accumulation of dust or other particulates at
the membrane element. Therefore, sample prepreparation is required to remove large
particles (> micrometer-size).
Differences in cell-dielectric properties were exploited to separate and identify
cells without extensive cell manipulation.88 For applications such as stem cell research,
it is highly preferable that the isolated cells be unlabeled and minimally manipulated to
preserve their integrity. Vykoukal and coworkers89 applied DEP-FFF for the rapid, labelfree enrichment of progenitor cells from a stromal vascular fraction. Different cell types
were driven to different flow lamina in a DEP-FFF separator on the basis of the
aggregate effect of their density and specific dielectric properties. Low-abundance
putative progenitor cells, NG2 cells (<2% in the starting mixture), were enriched up to
14-fold, yielding 28% NG2+ cells in the most enriched fraction. This device is therefore
ideally suited for batch-mode isolation and recovery of moderate quantities of cells
(<106 cells per run).
Although these approaches are applicable to many cell-processing problems,
they demand that the dielectric properties of the target cells be significantly different
from those of the interfering cells. For this reason, DEP/gravitational field–flow
fractionation (DEP/GFFF), which has a potentially higher discriminatory ability, has been
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developed.90,91 GFFF is a process by which particles are allowed to settle while under
the influence of an axial flow.92 In DEP/GFFF, the balance of DEP and gravitational
forces controls cell position in the gravitational flow profile.91 This technique was applied
to the separation of a breast cancer cell line (MDA435) from RBCs.92 Results suggested
that the MDA435 cells could be separated from erythrocytes in a 10 μL sample
containing a total of ∼50,000 cells. The enriched fractions of the MDA435 cells and
erythrocytes were reported to be >98% and >99%, respectively.
1.3.4 Low-Abundant-Cell Selection via Magnetic Interactions
Target cells can be specifically labeled with antibody-conjugated magnetic beads,
and the selection and enrichment of the low-abundance cells can be achieved through the
use of a magnetic field. Using this principle, Lee and coworkers27 developed an integrated
system capable of selecting RNA viruses, such as dengue virus and enterovirus, through
use of antibody-conjugated magnetic beads and one-step RT-PCR in an integrated
microfluidic system. The target virus in the sample was captured with modified magnetic
beads and manipulated via microelectromagnets (Figure 1.7A). The integrated microfluidic
system performed the entire process automatically with a rotary micropump and
microvalves for fluid control. Following isolation, the viruses selected were subjected to
thermolysis, RNA extraction, and RT-PCR on a single chip. The authors‘ results were
similar to those obtained with benchtop instruments (Figure 1.7B).
Furdui and Harrison adopted this technique in order to enrich Jurkat cells (T cell
leukemia) from blood.93 The model samples contained Jurkat cells to erythrocyte cells
ratios of 1:10,000 with a total of 1-2×1010 RBCs mL-1 with a Jurkat cell frequency of 1×106
mL-1. The magnetic beads were initially functionalized with protein A prior to incubating with
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Figure 1.7 (A) Schematic of an integrated reverse-transcription polymerase chain reaction (RTPCR) chip with a cell-selection unit for the magnetic capture of target cells. A microtemperature
module, a bead-collection module, and a microfluidic control module are integrated into the chip.
(B) A mixture of dengue virus (102 PFU) and enterovirus 71 (102 PFU) was incubated with
antidengue antibody (lanes 1 and 2) or antienterovirus 71 antibody-conjugated magnetic beads
(lanes 3 and 4); RT-PCR was then performed with dengue group–specific primers (lanes 1 and
3) or enterovirus 71–specific primers (lanes 2 and 4). The lanes marked with the letter L
represent signals generated from DNA size markers. Results on the left and right are from a
benchtop instrument and the integrated chip, respectively.

anti-human CD43. The results of the incubation yielded antibody-functionalized beads,
where the antibodies were bound to protein A via their Fc domain. A magnetic zone was
used to selectively isolate the magnetic particles bound to the target cells in the microfluidic
device. Subsequent to a rinsing step, the captured cells were eluted after removal of the
magnetic field and initiation of hydrodynamic pumping. Following optimization, the authors
were able to isolate 37% of the spiked T-cells with a throughput that corresponded to 3 μL
min-1 from a 2 μL sample that consisted of 1,070 Jurkat cells.
28

Beyor and coworkers94 presented an E. coli O157:H7-detectionmicrosystem with
integrated cell capture, sample preparation, and PCR with capillary electrophoresis analysis.
Immunomagnetic beads were coupled to polyclonal antibodies specific to the E. coli
phenotype of interest. Sample volumes ranging from 10 to 100 μL were introduced and
driven through immunomagnetic bead beds to capture the target cells. A detection limit of
0.2 colony-forming units μL−1 was achieved for an input volume of 50 μL.
1.3.5 Microfluidic Fluorescence-Activated Cell Sorting
Replacing the conventional flow chamber in FACS with microfabricated devices
could allow more sensitive optical detection, easier mechanical setup, and more innovative
sorting schemes. Another advantage is that multiple cell sorters can be fabricated in
parallel on a single chip, allowing increased throughput or successive enrichment steps.
Fu et al.95 demonstrated a complete microfabricated fluorescence-activated cell
sorting (μFACS) device for E. coli HB101 cells. The chip was mounted on an inverted
optical microscope, and fluorescence readout with a photomultiplier tube was accomplished
at a T-shaped fluidic junction on the chip, with the cells manipulated electrokinetically. An
advantage of the μFACS system is the small detection volume, typically 250 fL, which
greatly reduces background fluorescence from the cell suspension and chamber material.
Low-abundance cells are sorted by implementing a specific sorting algorithm. When a cell
of interest is detected, the flow is stopped and the cell of interest is recovered by running
the flow backward at a slow speed until the cell is moved into a collection channel. At that
point, the cell is collected, and the device is once again run at a high speed in the forward
direction. This reversible sorting method cannot be performed with standard FACS
machines. The μFACS system offers several advantages over traditional

FACS: (a)

Because the channels are made with micrometersize dimensions, the volume of the
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interaction region can be precisely controlled, eliminating the need for hydrodynamic
focusing; (b) the planar geometry of the device allows for the use of high–numerical
aperture optics, increasing the limit of detection of the optical system; and (c) the
disposability of the sorting device obviates the need for cleaning and sterilizing the
instrument and prevents cross contamination between samples. However, the
throughput obtained with this μFACS is 20 cells s−1, considerably lower than that of
conventional FACS.
Another example of low-abundance-cell sorting via μFACS was presented by
Simonnet & Groisman,94 who attempted to port conventional high-throughput, highresolution cell sorting using flow cytometry to a PDMS microsystem. The integrated cell
sorter was incorporated with various components, including peristaltic pumps, dampers,
and input and output wells, to perform cell sorting in a coordinated and automated
fashion. DEP and pressure switching were used to create a valveless device for the
separation of cells within microchannels. The standard forward and reverse sorting
algorithms were implemented. Conventional FACS uses flow rates of ∼10 m s−1,
corresponding to sampling rates of 1,000–50,000 cells s−1. Using this platform, the
authors processed up to 17,000 cells s−1. An 83-fold enrichment was achieved in a
single pass, yielding 40% recovery. As with the macroscale version of FACS, sorting
and enumerating low-abundance cells require specific staining protocols as well as
sample-preprocessing steps.
1.4 Conclusions
IMACS, FACS, and size-based selection techniques of low-abundance cells can be
transitioned to microscale systems, and they can produce results that are similar if not
superior to their macroscale counterparts. The high automation potential of microﬂuidic
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systems and their ability to process samples in closed architectures provide a venue in
which to analyze mass-limited samples, such as low-abundance cells, which is free
from contamination.
However, Microsystems for rare cell selection need to be designed to sample
larger input volumes in reasonable times (i.e., higher throughput) to accommodate
extremely low abundance cells. In this dissertation, I investigate the use of surface
modification, rare cell enumeration and electro-manipulation techniques in polymerbased microfluidic devices as a means of separation, enumeration and enrichment lowabundance cells in complex matrices such as whole blood and environmental water
samples.

The selection and enumeration of low-abundance cells are often not the

terminal steps in the processing pipeline of these cells. For example, CTCs selected via
immunoafﬁnity, with EpCAM as the molecular target, can originate from a variety of
different cancers, such as colorectal, prostate, bladder, lung, or breast. To determine
the speciﬁc type of cancer, it is necessary to molecularly proﬁle the selected cells. A
major challenge concerns the mass-limited samples encountered when analyzing lowabundance cells. For example, in a single eukaryotic cell two copies of the genome and
approximately 300 copies of each different mRNA molecule are present, requiring highly
sensitive genotyping techniques to characterize these molecular entities.
Therefore, I also investigate to optimize genotyping techniques such as RTqPCR and PCR/LDR/CE for quantitation and molecular profiling of low-abundance
genetic molecular entities. Overall, highly integrated low-abundance cell–based
microﬂuidic devices that can molecularly proﬁle such cells will ﬁnd applications in
medicine at the point of care; national security and counterterrorism; police, paramedics,
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and ﬁre departments; veterinary medicine; and environmental and food safety
monitoring.
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CHAPTER 2 CIRCULATING TUMOR CELLS: A LITERATURE REVIEW
2.1 Introduction
The first observation of blood-borne cells shed from a solid tumor was reported in
the 19th century from an Australian physician named Thomas Ashworth from a patient
who died of metastatic cancer.1 Originally these cells were referred to as
‗carcinocythemia,‘ but now they have been named circulating tumor cells (CTCs).2 A
fraction of these CTCs originate from the primary tumor and consequently, are one of
the initial steps in the process of metastasis, whereas a majority of these CTCs are
derived from metastatic lesions. Because the ultimate fate of cancer patients is largely
determined by metastases and the number of CTCs is likely to reflect the
aggressiveness of a tumor, CTC detection, characterization and enumeration have
been considered to have great potential in the therapeutic management of cancerrelated diseases.3
2.2 Anatomy of Tumor Metastasis
Metastasis is the process by which cancer cells leave the primary tumor site,
disseminate and form secondary tumors at anatomically remote sites. 4 Understanding
the metastatic process is indeed a critical process in cancer fatalities; 90% of cancer
patients do not die from their primary tumor, but from metastatic disease.5 In 1889,
Paget proposed the ‗seed and soil hypothesis‘ for understanding the process of
metastasis. He proposed that metastatic spread was a consequence of particular tumor
cells (‗seeds‘) finding a suitable environment (‗soil‘) in which to develop and grow. 4 An
alternative hypothesis, that of mechanical entrapment, was proposed by Ewing in1928;
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he suggested that CTCs accumulate through entrapment in the first vascular bed they
encounter.4
As such, metastasis is often delineated as a ‗cascade‘ of events (Figure 2.1),
because there are a series of steps that are involved:4,6-8
(1) The development of a new blood supply to the proliferating tumor (angiogenesis).
(2) The elude of tumor cells from the primary tumor mass.
(3) Incursion of, and migration through, the basement membrane (BM) and extracellular
matrix (ECM) surrounding the tumor epithelium and subsequent invasion of the BM
supporting the endothelium of local blood vessels (or lymphatics).
(4) Intravacation of the tumor cells into the blood vessel (or lymphatic), prior to
hematogeneous (lymphagenous) dissemination to distant anatomical sites.
(5) Adhesion of the CTCs to the endothelial cell lining at the capillary bed of the target
organ site.
(6) Incursion of the tumor cells through the endothelial cell layer and surrounding BM
(extravasation) and target organ tissue.
(7) The growth of secondary tumor foci at the target organ site.
Angiogenesis is the formation of new blood vessels from pre-existing vasculature.
Without the formation of an intra-tumor blood supply, tumors would be unable to obtain
the oxygen and nutrients necessary to flourish.7 Angiogenesis is stimulated by the
release of growth factors, such as vascular endothelial growth factor (VEGF) and
fibroblast growth factor (FGF).9 As a result of angiogenesis, tumors gain access to a
blood supply in conjunction with co-option of existing blood vessels and also
vasculogenicmimicry, where the tumor cells themselves carve blood vessel-like
conduits.10
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Figure 2.1 The metastatic cascade. Tumor cells are released from the primary tumor mass, and
thus become circulating tumor cells (CTCs). The CTCs in the blood are subjected to the shear
forces generated by the flow of blood, immune response attack and anoikis. CTCs that do
survive can reach a target organ and attach to the endothelial cell lining within the capillary bed
of the target site. After invading the endothelium, a secondary tumor mass can develop.
Reprinted with permission.8

Loss of cell–cell adhesion within the primary tumor mass permits disaggregation
of tumor cells and hence, aids in the initial phases of dissemination. 11 Cadherin/catenin
expression in the primary tumor is also altered resulting in the loss of cell–cell adhesion.
It has been reported that abrogation of E-cadherin is associated with the metastatic
phenotype.12 During metastasis, the dissolution of the ECM is achieved through the
action of several hydrolytic enzymes, released either by the tumor cells themselves or
by cells surrounding the tumor.13 From model systems, it has been estimated that ~1×
106 CTCs per gram of solid tumor tissue can be introduced daily into the bloodstream.8
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Once released from the primary tumor site, many cancer cells possess the ability
to migrate and do so in several different ways: (1) Moving collectively as groups or as
single cells; (2) adopting an elongated mesenchymal morphology; or (3) crawling in an
amoeboid manner.9 Tumor cells initially attach to the BM and ECM via interactions with
the integrin family of adhesion receptors and subsequently traverse these structures as
proteolytic enzymes help their invasion and ultimately allow the tumor cells access to
the vasculature. Tumor cells also move through collagenous matrices by physically
deforming their shapes.14
The endothelial cells can retract, thus allowing the detached tumor cells to pass
into systemic circulation. Once tumor cells are in the blood stream, they are subject to
events which can threaten their survival including the shear forces generated by the
flow of blood and an immune response attack.15 Upon being shed, the CTCs are fragile
and lack interactions with blood borne fibrin and platelets and as a result, the membrane
can be easily destroyed by shear stress imparted by blood flow.16 In addition, natural
killer cells, Pit cells and Kupffer cells, attack the neoplastic cells immediately upon
release.17,18 It has been reported that the presence of CTCs in the peripheral blood
triggers as much as an 80% increase in the number of natural killer cells present within
peripheral blood in a matter of minutes. As such, the vast majority of carcinoma cells
are killed within a few hours of dissemination through the natural defense system. 19 Also,
most tumor cells are either mechanically destroyed from the shear stress of blood flow
rupturing the cells‘ membrane or the CTC undergoes a process called anoikis, a special
form of cell death resulting from an adhesion deficiency. 20 Single tumor cells are more
likely to be destroyed compared to cells travelling in clumps because the cells at the
center of the complex are physically shielded.21
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Most often, tumors develop in organs proximal to capillary beds owing in part to
metastatic CTCs surviving the natural protections provided by the circulatory system.
Survival is further supported by the CTCs developing a protective barrier consisting of
fibrin and platelets sufficient to prevent lysis from blood flow related shear by providing a
stabilizing reinforcement and barrier-like protective coating from natural killer cells.
Surviving CTCs can eventually reach the capillary bed of a target organ, where
they can adhere to the micro-vessel endothelium, which stimulates endothelial cell
retraction. The CTCs pass through the BM via the action of proteases and thus,
establishing a secondary tumor at a new site. Once tumor cells reach the secondary site,
they may be destroyed – most undergo apoptosis within 24 h, may lie dormant, or they
may proliferate to form secondary tumors. It has been recently revealed that CTCs can
reach the peripheral blood from tumor deposits every few hours and can remain there
for as long as 22 years.8 Recent evidence suggests that tumor cell dormancy may
account for the observation that some tumors – for example, melanoma and breast
cancer – may present metastases many years after eradication of the primary tumor.7
It has been suggested that distant sites may be pre-conditioned to become fertile
ground for the establishment of metastases; the ‗metastatic niche‘. Hematopoietic stem
cells migrate to tissues causing remodeling of the ECM and growth factor milieu, such
that a microenvironment is formed that both attracts tumor cells and supports their
proliferation.22
2.3 Morphology of CTCs
Both solid tumor cells (STCs) and cultured CTCs have been found to have
irregular nuclei. Many CTCs exhibit conspicuous intracellular compartments containing
numerous small vesicles and large amounts of amorphous material. They are also
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surrounded by a ribosome decorated membrane. These inclusions may have a size
equal to or exceeding that of the nucleus and are not seen in STCs. CTCs have a
significantly larger mean cell diameter (CTC-15 µm) and cell volume (CTC-1730 µm3)
compared to STCs (STC-11 µm, STC-735 µm3, respectively). In contrast, STCs have a
larger nuclear/cytoplasmic (N/C) ratio (CTCs-27.1%, STCs-28.9%) and ‗excess‘
membrane (CTCs-46.8%, STC-60.9%).23
The deformability of STCs and CTCs differ significantly as well. Small
deformations are rapid and of similar magnitudes for both cell types, but large
deformations are considerably slower in the case of CTCs. Microscopic observations
indicate that CTCs‘ large nucleus resists deformation. In addition, it has been
speculated that the large, multi-vesicular intracellular accumulations of CTCs contribute
to their low cytoplasmic deformability.24
Marrinucci et al. investigated the morphology of CTCs using metastatic breast
cancer cells. They observed different subcategories of CTCs within the same patient‘s
blood sample. It was discovered that 22.9% of CTCs had a higher N/C ratio than the
surrounding white blood cells (WBCs) (Figure 2.2). They also exhibited a scant rim of
amphophilic to eosinophilic cytoplasm with round to oval to occasionally lobated nuclei
without sharp irregularities. The chromatin was vesicular with
eosinophilic

nucleoli. This

adenocarcinoma cells.25

category

of

CTCs

was

prominent, generally

termed well-differentiated

In addition, their eccentrically located nuclei were slightly

smaller than neighboring WBC nuclei. The chromatin was often coarse and
hyperchromatic in these CTCs with a moderate rim of dense appearing orangeophilic
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Figure 2.2 Example of CTC types identified from the patient with breast cancer. (A) WrightGiemsa–stained CTCs (100x oil). (B) Same cells as (A) showing initial fluorescent image of
corresponding CTCs stained with anti-CK-Alexa Fluor 488 (green) and DAPI (4',6-diamidino-2phenylindole) (blue) (image taken at 20 and enlarged for comparison purposes). (C) Example of
probable CTC undergoing final stages of apoptosis, with no detectable nucleus. These events
are not counted as CTCs in our patient statistics. Reprinted with permission.25

cytoplasm. This category of cells meets the cytological criteria for moderately to welldifferentiated adenocarcinoma cells.26 31.9% and 34.7% of the total CTC population
exhibited morphologic evidence of both early- and late-stage apoptosis (Figure 2.2),
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respectively. Early apoptotic changes included condensation and shrinkage of nuclear
material yielding hyperchromatic glassy-appearing nuclei with loss of nuclear detail on
Wright-Giemsa staining.26,27 Also, clusters of CTCs were noted with a 4% frequency.
Ten doublets, one triplet, and one quartet were observed by Marrinucci et al. The
composition within clusters was a heterogeneous mixture of cell types.25
2.4 Biomarkers Found in CTC Membranes
CTCs express two distinct marker types on their membrane, which are tumor
type-specific and epithelial-specific markers. Tumor type-specific markers are
expressed exclusively on tumor cells that have disseminated from a particular tumor.28
Markers of this type include mammoglobin, HER2-neu, mucin 1 (breast cancer),
prostate specific antigen (prostate cancer), and carcinoembryonic antigen (colorectal
and gastric cancers).3,29 Although these types of markers may offer the potential
advantages of specifically identifying a particular organ tumor cell rather than just
epithelial cells, they also provide some insight into their molecular characteristics.
Epithelial-specific markers are expressed by all tumor cells of epithelial origin as
well as by normal epithelial cells, although they are unlikely to be present in the
peripheral blood stream. The most commonly used markers in this category include the
epithelial cell adhesion molecule (EpCAM, also known as ESA, CD326, HEA125, TROP
II, or TACSTD1) and cytokeratins (CK) 7, 8, 18, 19, and/or 20.30 The majority of
leukocytes do not express epithelial markers, however, they occasionally have been
observed to become positive for such antigens when in an activated state.3,31
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2.5 Abundance of CTCs in Cancer Patients
Allard et al. evaluated the abundance of CTCs in the blood of healthy subjects
and patients with a variety of malignant diseases (Table 2.1).32 The number of CTCs in
metastatic cancer patients ranged from 0 to 23,618 in 7.5 mL of patient‘s blood. The
Table 2.1 Summary of CTC counts in 7.5 mL of blood from patients with various types of
carcinomas

Subject
Healthy
Nonmalignant
Metastatic
cancer type
Prostate
cancer
Unknown
cancer
Ovarian cancer
Breast cancer
Gastric cancer
Colorectal
cancer
Bladder cancer
Renal cancer
;Lung cancer
Pancreatic
cancer
Assorted other
cancer
Combined
cancers

No. of
patients

No. of
specimens

Mean
±SD

Median

No. (%)

No. (%)

No. (%)

No. (%)

with ≥2

≥2

≥5

≥10

≥50

145
199

145
199

0.1±0.2
0.1±0.3

N/A
3

0(0)
1(1)

0(0)
0(0)

0(0)
0(0)

0(0)
0(0)

123

188

75±333

13

107(57)

77(41)

61(32)

27(14)

11

27

16±35

13

14(52)

13(48)

8(30)

2(7)

29
422
9

53
1316
13

6±16
84±885
24±83

9
10
3

20(38)
489(37)
4(31)

12(23)
340(26)
1(8)

1(23)
256(19)
1(8)

9(17)
129(10)
1(8)

196

333

4±11

5

99(30)

56(17)

30(9)

5(2)

7
11
99

7
12
168

42±107
1±1
30±178

146
2
9

2(29)
3(25)
34(20)

2(29)
0(0)
24(14)

1(14)
0(0)
16(10)

1(14)
0(0)
10(6)

16

21

2±6

3.5

4(19)

1(5)

1(5)

0(0)

41

45

1±4

11

5(11)

4(9)

3(7)

0(0)

964

2183

61±696

9

781(36)

530 (24)

386 (18)

176(8)

NOTE. The group labeled unknown are patients with metastatic disease with unknown primary
tumor; the assorted others are carcinomas with <5 specimens.
Abbreviation: N/A, not applicable. Reprinted with permission.32

highest proportion of positive specimens was seen in patients with metastatic prostate
cancer, followed by patients with metastatic cancer of unknown origin, ovarian cancer,
and breast cancer.33 The presence of CTCs and the mean number of CTCs varied
widely in samples. Differences in carcinomas, vascularization of the tumors, sites of
metastasis, and aggressiveness of the tumor were factors that contribute to these
differences.34
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It has also been found that the CTC frequency varies highly depending on the
form of therapeutic treatment. Studies carried out on pancreatic and colorectal cancer
patients indicated that decreases in CTC numbers were seen immediately after
surgery.35 By contrast, radiofrequency ablation of liver secondaries led to an immediate
increase in CTC number and there was speculation that coagulative necrosis caused by
the energy waves might induce cancer cell seeding.36
Correlation between CTC number and the response of the primary tumor to
chemotherapy was not observed, which is unusual given the fact that CTCs levels are
normally correlated to treatment response.37 This observation was explained by the
discovery that CTCs can be different from the primary tumor in terms of their
genome and protein expression patterns, such as p53 mutations and expression of
Bcl-2, heat shock proteins, topo-isomerase II-a, ER/PR, and HER2.38 For example, a
subset of patients with HER2-negative primary tumors developed HER2-positive CTCs
during disease progression and this change might have consequences as to the
response of the tumor cells to therapy.30
2.6 Clinical Significant of CTCs
Elucidating the presence and number of CTCs in peripheral blood is emerging
as an effective tool for differential diagnosis and prognosis, risk determination, disease
recurrence, screening, and prediction of specific benefits from particular therapies for
the management of cancer-related diseases.20 Moreover, the growing ability to detect
and analyze CTCs could galvanize the development of drugs designed to block
metastasis. Compared to waiting for secondary tumors to appear, monitoring CTC
numbers may provide a simple way to determine whether an anti-metastasis drug works
for a particular patient.30
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The initial primary tumor specimen may not always be representative of
metastatic deposits. A primary example is prostate cancer, which often presents itself
with multifocal localized disease and may recur many years later with bony lesions that
are not readily biopsied.39 CTCs can reflect the molecular changes in a person‘s cancer
that would point toward particular and effective treatments (i.e., personalized medicine).
For example, only women with breast cancer whose tumor cells express the receptor
HER2 respond to the drug Herceptin. It has been found that some women whose
primary tumors were HER2-negative later had CTCs that were positive for HER2,
suggesting their cancer had mutated.40 Monitoring CTCs might therefore identify women
who were initially ineligible for Herceptin but who would later qualify for the drug. These
important observations support the argument that the detection of CTCs and
determination of their gene amplification, mutation or expression can be used for better
tailoring therapies.
Researchers have also begun to analyze CTCs for certain gene variants or
proteins that indicate a patient‘s tumor is susceptible to a particular drug.41 This kind of
―liquid biopsy,‖ will allow physicians to follow cancer changes over time and tailor the
treatments. Also driving the interest in CTCs has been the recent development of
molecularly targeted cancer therapies that work best on patients whose tumors have a
particular mutation.42
Receptor profiles of tumors change over time; it was noted that epidermal growth
factor receptor (EGFR) is consistently expressed in CTCs for patients with metastatic
breast cancer.43 In patients with non-small cell lung cancer, EGFR-activating mutations
have been detected in CTCs as well, including the T790M mutation that confers drug
resistance. The ability to stain CTCs directly for a variety of markers and potentially
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analyze the mutations within them could enable therapeutic trials to be designed with
CTC-based endpoints.39
It was recently reported that highly tumorigenic cells possessing properties
consistent with those of stem cells can be isolated from human cancers. These cancer
stem cells may be detectable in the peripheral blood and bone marrow of patients.44
The identification of these CTC subpopulations is likely to further the discovery of tumor
stem-cell biomarkers and help resolve the issue of what exactly a cancer stem cell is.
Hence, the development of therapies specifically targeting cancer stem cells will have
great benefit for patients.
2.7 Statistical Considerations for CTC Analysis
The success of rare CTC detection is affected by many parameters, including
quality of the starting sample, frequency of the events of interest, sample preparation,
specificity and expression level of the chosen markers, robustness of the assay, and
objective and reproducible readouts.29 All of these factors contribute to the statistical
probability of accurately detecting and quantifying CTCs and therefore, are important to
consider when designing and interpreting CTC assays for clinical use.
The

CellSearch™

system

employs

the

Kaplan-Meier

statistic

for

the

interpretation of CTC counts at baseline and follow-up blood collections of the patient
(Figure 2.3). The survival curves are compared using log-rank testing and cox
proportional hazards regression to determine univariate and multivariate hazard ratios
for overall survival.45,46 For example, a threshold of 5 CTC/7.5 mL was used to stratify
patients with metastatic breast cancer into those with favorable outcomes (CTC <3 or
<5) and those with unfavorable outcomes (CTC ≥3 or ≥5). These statistical outcomes on
CTC levels were used to predict survival, therapeutic benefits and stratify patients into
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low-risk, moderate-risk, and high-risk groups (Figure 2.3).35 It was found that both
univariate and multivariate analysis of CTC levels were significantly correlated with
overall survival.47,48
In most cases, Poisson statistics apply when accounting for randomly distributed
CTCs due to limitations with the volume of blood that can be sampled. Another
important consideration is whether the blood sample volume is large enough to detect

Figure 2.3 Kaplan-Meier estimates of probabilities of progression-free survival and overall
survival in patients with metastatic breast cancer for those with <5 CTCs per 7.5 mL of whole
blood and those in the group with >5 CTCs in 7.5 mL of whole blood at the first follow-up visit
after initiation of a newline of therapy. All patients in the trial (n=177) are included in these
Figures. (A) progression-free survival from baseline. (B) overall survival from baseline.
Reprinted with permission.35

and enumerate a very small number of CTCs.29 For cell-based assays, the size
of sample (n) that will provide a given precision is given by;28
n = (100)2 (1)
CV
where CV is the coefficient of variation of a known positive control. From the
perspective of CTCs, to reduce the CV to ∼10% (and hence improve the accuracy),
many events would need to be assessed. Therefore, analysis of multiple blood samples
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from the same patient at the same time significantly improves the probability of
accurately detecting rare CTCs.
These statistical factors also suggest that some caution should be employed
when using a threshold number (i.e., ≥5 CTC versus <5 CTCs) to stratify cancer
patients into poor prognosis versus good prognosis groups for the purposes of clinical
decision making. From a statistical point of view, there is a higher probability of correctly
identifying CTCs when >5 are detected, and/or there is a greater probability of incorrect
identification when 1–4 CTCs are detected.48
2.8 Conclusions
CTC presence is one of several crucial steps in the metastatic process of solid
malignancies. CTCs are detected in peripheral-blood samples, which are easy to obtain
(with minimal discomfort for patients) compared with other sites, such as bone marrow
and lymph nodes, where minimal residual disease might be present. Therefore, the
detection of CTCs is emerging as an attractive strategy for tailoring cancer treatment on
a single-patient basis. Because metastatic cells can have a very different molecular
profile from the solid tumor of origin, sensitivity to conventional chemotherapeutic drugs
and molecularly targeted anticancer agents might be better tested in CTCs than in the
primary tumor. Accordingly, any advance in the knowledge of CTC biology might lead to
significant progress in both anticancer drug development and better definition of patient
diagnosis and prognosis.
However, many investigators have reported a positive correlation between
detection of CTCs and patient diagnosis and prognosis, but the number of clinical trials
enrolled in each case is low (50-1,000 patients). Therefore, implementation of CTC
detection in biological studies of large-scale clinical trials must prove the prognostic
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power of CTC detection. In addition, CTCs are low-abundance cells scattered among
millions of peripheral-blood mononucleated cells. The application of novel technologies,
such as high-throughput technologies, single-cell genomics and proteomics must fulfill
the promise of comprehensively describing the molecular signature of CTCs of solid
malignancies. Dissection of CTC biology should define the molecular profile of those
CTCs that can metastasize. These insights should enable investigators to identify an
ideal marker (or set of markers) to detect only prognostically informative CTCs and/or to
design more effective anticancer drugs.
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CHAPTER 3 HIGHLY EFFICIENT CAPTURE AND ENUMERATION OF LOWABUNDANT PROSTATE CANCER CELLS USING PROSTATE-SPECIFIC
MEMBRANE ANTIGEN APTAMERS IMMOBILIZED TO A POLYMERIC
MICROFLUIDIC DEVICE
3.1 Introduction
Prostate cancer is the most common non-cutaneous malignancy, accounting for
9% of all male cancer-related deaths in the US; there is a 1 in 6 probability of men in the
US developing prostate cancer.1,2 In 2007, ~220,000 new cases of prostate cancer were
recorded and 27,050 prostate cancer related deaths occurred in the US alone.3 For
more than a decade, determinations of prostate-specific antigen (PSA) levels in human
serum followed by digital rectal examination have been the predominate diagnostic
methods for prostate cancer screening.4 Men with an abnormal digital rectal
examination, as evidenced by the existence of poll ups, or elevated PSA levels are
typically referred for biopsy to assess the presence of prostate cancer. The five-region
prostate biopsy technique is typically utilized in conjunction with a sextant biopsy.5
Using these rather invasive diagnostic strategies, up to 30% of prostate cancers are still
undiagnosed.6 Unfortunately, certain medications (e.g. Finasteride), ejaculation, and
prostate manipulation (e.g. catheterization, prostate massage) can alter PSA levels and
as such, the determination of PSA levels in clinical settings remains controversial.4
Mortalities associated with malignant tumors are primarily due to metastasis,
which results from the invasionof tissues and organs distant from the primary tumor.7
The early detection of metastasis is a critical factor for determining the probability of
survival for many cancers.8 At present, reports have noted that circulating tumor cells
(CTCs) can be present in peripheral blood for many adenocarcinomas prior to detection



Reproduced with permission from Electrophoresis
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of the primary tumor via conventional screening modalities.9 Therefore, elucidating the
presence and number of CTCs in peripheral blood is emerging as an effective tool for
risk determination, screening, differential diagnosis and prognosis, disease recurrence,
and prediction of specific benefits from particular therapies for the management of
cancer-related diseases.10
CTCs are an extremely rare component within human blood (~101 cells mL-1 of
whole blood) with the majority cellular components being erythrocytes (~109 cells mL-1
of whole blood) and leukocytes (~106 cells mL-1 of whole blood).11 To discriminate CTCs
from these highly abundant species, morphological or chemical differences between the
target CTCs and normal hematopoietic components have been exploited,12 but typically
provide low recovery and/or purity.
Disseminated prostate tumor cells can infiltrate the bone marrow, peripheral
blood, lymph nodes, stomach, or the penis and the question becomes; can these
disseminated tumor cells be used as a clinical marker for prostate cancer staging?
Certain cell lines derived from prostate cancers can be used as model systems for the
design and evaluation of new assays directed toward prostate cancer using for example
CTCs as the diagnostic marker. These cell lines are categorized as to their final
metastatic destination, such as bone metastasis – PC3, lymph node metastasis –
LNCaP, and those localized to prostate – 22Rv1.13 Lymph node based metastasis occur
in the very early stages of prostate cancer where high cure rates abound, whereas bone
metastasis typically occur in the advanced stages of this disease and is accompanied
by significantly reduced quality of life.14 It has been hypothesized that tumor cells
released from a primary tumor site into peripheral blood can be correlated with patient
survival or other indicators, such as the presence of regional lymph node metastases.
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But the use of CTCs as a diagnostic marker is unclear due to the lack of efficient tools
for their isolation and enumeration.15 Therefore, the development of highly efficient CTC
isolation and detection systems to search peripheral blood for LNCaP type cells can
potentially generate an effective diagnostic/prognostic tool for prostate cancer.
LNCaP-like cells typically possess a high-expression level of the integral
membrane protein, prostate-specific membrane antigen (PSMA). PSMA is a
homodimeric type II transmembrane glycoprotein consisting of 750 amino acids having
a molecular weight of 100 kDa,16 making PSMA an excellent candidate for tracking
LNCaP-type cells to diagnose prostate cancer or to monitor its progression and/or
therapeutic response to treatment.17–19
Due to the low abundance nature of CTCs in peripheral blood with respect to
erythrocytes and leukocytes, the efficiency of CTC isolation is basically characterized by
throughput, recovery and purity.20 Until now, different techniques, such as flow assisted
cell sorting and immunomagnetic selection have been employed for the isolation of rare
cells from complex clinical samples and are typically fraught with the limitation of
choosing between high purity with poor recovery or high recovery with low purity.21,22
While microfluidic systems are emerging as effective tools for biomedical
research and diagnostics having such advantages as low reagent consumption, short
analysis times and process integration,22 they are fraught with some limitations, for
example the inability to exhaustively sample large input volumes required to search for
extremely rare events, such as CTCs in peripheral blood. Two recent examples have
appeared in which rare cellular events were accumulated from clinical samples using a
microfluidic platform. Nagrath et al. described an immunoaffinity approach in which antiepithelial cell adhesion molecules (EpCAM) antibodies were affixed to micropillars
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poised within a microfluidic chip capable of extracting CTCs from peripheral whole blood
samples with ~50% purity.11 A polymer-based high-throughput microfluidic system was
described by Adams et al. in which EpCAM-specific monoclonal antibodies were
tethered to parallelized-high-aspect ratio microchannels, which were employed to
isolate breast cancer cells (MCF-7) from whole blood demonstrating a recovery of 97%
and nearly 100% purity.20 A compelling attribute of this microfluidic device was its ability
to specifically enumerate the CTCs on-chip using an integrated conductivity sensor,
which demonstrated a single-cell detection efficiency of 100% without requiring cell
labeling.20
Though various techniques have been applied to isolate and characterize CTCs,
many of them share a similar principle, they use antibody-based selection with integral
membrane protein antigens. Application of this molecular recognition strategy for CTC
detection is limited by the availability and specificity of antibodies directed against the
necessary biomarkers, such as membrane proteins found on different tumor cells.9 In
addition, most of these cell selection tools require surface immobilization of an antibody,
which can result in reduced cell recoveries or adhesion strength between the cell and
the surface-tethered antibody due to the stochastic nature of the immobilization
chemistry.
Aptamers, single-stranded nucleic acid oligomers, possess highly specific
recognition affinities to molecular targets through interactions other than classical
Watson-Crick base pairing.23 Compared with antibodies, aptamers have lower
molecular weights, demonstrate faster tissue penetration, remain stable during longterm storage, sustain reversible denaturation, low toxicity, and can be produced against
targets, such as membrane proteins, using highly automated technologies (i.e.
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SELEX).24 In addition, a wealth of literature exists on the immobilization of aptamer
recognition elements to solid supports, such as glass,25 polymers,26 and gold.26
Additionally, the immobilization chemistry is highly oriented with end-point attachment
occurring exclusively through the 50- or 30-end of the aptamer, which bears a functional
group, such as a primary amine. These advantages make aptamers highly desirable as
potential molecular probes for diagnostics.27
Many aptamers have been developed to target the extracellular domains of
integral membrane proteins that are over-expressed on cancer cells.28 Lupold et al. first
reported RNA aptamers directed against the tumor-associated PSMA membrane
antigen and the first application of RNA aptamers that targeted LNCaP cells via the
PSMA biomarker. The affinity of this aptamer for PSMA was quantified and suggested
that the aptamer identified a unique extra-cellular domain of PSMA.29
Herein, we report on the use of PSMA-specific aptamers tethered to a highthroughput micro-sampling unit (HTMSU) with an integrated conductivity sensor
employed for the highly efficient isolation and enumeration of rare circulating prostate
tumor cells (LNCaP used as a model in these studies) from whole blood without the
need for preprocessing of the blood prior to introduction into the microfluidic device nor
staining of the CTCs for enumeration. Nuclease stabilized and in vitro generated RNA
aptamers were immobilized onto ultraviolet (UV)-modified curvilinear capture channels
comprising the capture bed contained within the microfluidic device using carbodiimide
coupling chemistry and the appropriate linker structure to enhance the accessibility of
the surface-bound aptamer to the solution-borne cells.30 The linear velocity of sample
introduction into the device was optimized in order to achieve high-CTC recovery from
blood. After selection and isolation, the captured cells could be released from the
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capture surface via enzymatic digestion of the extra-cellular domain of PSMA using
trypsin for subsequent conductivity enumeration.20 Recently, Phillips et al. has reported
on the use of aptamers decorating PDMS microchannel walls for the selection of T-cell
acute lymphocytic leukemia cells seeded in an aqueous buffer that was also loaded with
a noncancerous cell line.31 Unfortunately, this work did not use whole blood as the input
sample, which contains extremely high levels of interfering cells and the cell
concentration was much higher (~1×106 cells mL-1) than typically encountered for CTCs
found in clinical samples (~10 cells mL-1). The results reported here used whole blood
as the input with CTC concentrations as small as 10 cells mL-1.
3.2 Materials and Methods
3.2.1 Buffers and Reagents
PMMA was used as the HTMSU substrate and cover plate (0.5 mm thickness) and
were purchased from Good Fellow (Berwyn, PA). Platinum wires for the conductivity sensor
were purchased from Alfa Aesar (Boston, MA). Polyimidecoated fused silica capillaries
were purchased from Polymicro Technologies (Phoenix, AZ). Chemicals used for
thePMMA surface cleaning and modification included reagent grade isopropyl alcohol, 1ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride (EDC), N-hydroxysuccinimide
(NHS), fetal bovine serum and 2-(4-morpholino)-ethane sulfonic acid (MES) and these
were purchased from Sigma-Aldrich (St. Louis, MO). The nuclease-resistant RNA aptamer,
(NH2-(CH2)6-(OCH2CH2)6-(ACCAAGACCUGACUUCUAACUAAGUCUACGUUCC),

was

obtained from Eurogentec (San Diego, CA). Random sequence oligonucleotides were
obtained from Integrated DNA Technologies (Coralville, IA). Monoclonal anti-EpCAM
antibody was obtained from R & D Systems (Minneapolis, MN). The LNCaP (prostate
cancer cell line), MCF-7 (breast cancer cell line), growth media, HEPES buffer, PBS and
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trypsin were all purchased from American Type Culture Collection (Manassas, VA).
Citrated rabbit blood was purchased from Colorado Serum Company (Denver, CO). Trisglycine buffer was obtained from Bio-Rad Laboratories (Hercules, CA). All solutions were
prepared in nuclease-free water, purchased from Invitrogen (Carlsbad, CA). Nuclease-free
microfuge tubes were purchased from Ambion (Foster City, CA) and were used for
preparation and storage of all samples and reagents. A fluorescein derivative, PKH67,
which contained a lipophilic membrane linker for cell staining, was purchased from SigmaAldrich.
3.2.2 Cell Suspensions
LNCaP and MCF-7 cells were cultured to 80% confluence in Dulbecco‘s Modified
Eagle‘s Medium supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A 0.25% trypsin solution
was prepared in 150 mM PBS and used to harvest the LNCaP and MCF-7 cells from the
culturing plate.
LNCaP and MCF-7 cells were stained with PKH67 for microscopic visualization
experiments using fluorescence. A modified protocol for cell staining was implemented
whereby the dye concentration was increased twofold resulting in more evenly distributed
fluorescent labels over the cell‘s periphery. Cell counts for seeding experiments into whole
blood were determined by counting three aliquots of cells in succession using a
hemacytometer. The cell count accuracy was ±10%.
3.2.3 HTMSU with Integrated Conductivity Sensor Fabrication
A detailed description of the HTMSU fabrication has been given by Adams et al.
with a schematic of the device shown in Fig. 3.1A.20 Briefly, the HTMSU was hot
embossed into PMMA substrates via micro-replication from a metal mold master. The
61

HTMSU consisted of a series of 51 high-aspect ratio curvilinear channels that in concert
formed the cell capture bed. Each channel was 150 µm (depth)×30 µm (width) and
shared common inlet/outlet ports. Curvilinear shaped capture channels were used to
improve the cell capture efficiency. The cell-free marginal zone apparent in straight
channels was not observed in curvilinear channels and the cell radial distribution was
unaffected by changes in cell translational velocity. Cells migrate to the outside of the
curved channels due to centrifugal forces acting on the cells and the cross-stream
velocity component due to the reversal of the direction of curvature.20 The result is an
increase in the aptamer/antigen encounter rate as the cells moved through the capture
beds at the relatively high-linear velocities used here. The channel width of the cell
capture bed (30 µm) was comparable with the average target cell diameter, which was
used to increase the probability of cell–aptamer interactions with the solution-borne
target cells. The large channel depth (150 µm) was selected to reduce the pressure
drop in high-volume flow rates and also, to increase sample processing throughput.
Appropriately cleaned PMMA HTMSUs devices and cover plates were exposed
through a mask to UV radiation resulting in the formation of carboxylate moieties only in
the exposed areas of the PMMA. The exposed areas were restricted to only the cell
capture bed region of the device.20 UV irradiation was performed through an aluminum
mask for 10 min at 15 mW cm-2 to facilitate the formation of the carboxylated scaffold.
These parts were then aligned and clamped together between two borosilicate plates.
The cover plate was thermally fusion bonded to the substrate by placing the clamped
pieces inside a convective oven and heating to ~101 °C, slightly above the glass
transition temperature of the UV-modified material. The temperature was increased
from 50 to 101 °C at a rate of 20 °C min-1 and held at 101 °C for 15 min. Polyimide62

coated fused silica capillaries were then inserted into the inlet port of the assembled
HTMSU to provide the introduction of samples into the device using a programmable
syringe pump (Harvard, Holliston, MA).
Pt electrodes (d=76 µm) served as the contact conductivity sensor in the
detection zone of the HTMSU and were placed into guide channels that were positioned
orthogonal to the fluidic output channel following thermal assembly. Insertion of the
electrodes was monitored using a microscope to carefully control the inter-electrode gap
(50 µm). The cell constant of the Pt conductivity sensor, K, was ~0.01 µm-1, which
allowed for the specific detection of LNCaP cells based on their average size (diameter=
25 µm).
3.2.4 Antibody Immobilization to the HTMSU
Antibody immobilization was carried out in a two-step process. The UV-modified
thermally assembled HTMSU device was loaded with a solution containing 4 mg mL-1
EDC, 6 mg mL-1 NHS in 150 mM MES (pH=6) for 1 h at room temperature to obtain the
succinimidyl ester intermediate. After this incubation, the EDC/NHS solution was
removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0 mg
mL-1 of the monoclonal anti-EpCAM antibody solution contained in 150 mM PBS
(pH=7.4) was introduced into the HTMSU and allowed to react for 4 h. The device was
then rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound antiEpCAM antibodies.
3.2.5 Aptamer Immobilization onto PMMA Films and the HTMSU Device
A schematic of the aptamer immobilization process is given in Fig. 3.1B. Aptamer
immobilization to PMMA surfaces was carried out in a single step. Following PMMA
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Figure 3.1 (A) Diagram of the HTMSU made via micro-replication into PMMA from a metal mold
master. The capture bed consisted of curvilinear channels that were 30 µm wide and 150 µm
deep (51 channels). (B) Process operation of the HTMSU used for the positive selection of
LNCaP cells. Also shown is the chemistry used for the immobilization of the cell selection
elements, aptamers, to the PMMA surface. The first step involved the UV-irradiation (15 mW
cm-2) of PMMA and in this case, the irradiation was carried out on just the capture bed so that
positive cell selection occurred only in this region.
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activation using UV light to generate the carboxylic acid functional scaffold, the
activated PMMA surfaces were incubated with a solution containing 10 mM of an
oligonucleotide with a random sequence or the PSMA aptamer, 4 mg mL-1 EDC and 6
mg mL-1 NHS in 150 mM MES (pH=6), and allowed to incubate for 3 h at room
temperature. For PMMA films, the planar surface was immersed in the reaction solution.
Following reaction, the PMMA surface was rinsed with a solution of PBS (pH=7.4) to
remove any non-specifically bound constituents.
In the case of the HTMSUs, the assembled devices were loaded with a 10 mM
anti-PSMA aptamer solution also containing 4 mg mL-1 EDC and 6 mg mL-1 NHS in 150
mM MES (pH=6). This solution was allowed to incubate in the device for 2 h at room
temperature. The device was then rinsed with a solution of PBS (pH=7.4) at 20 mL min-1
flow rate to remove any non-specifically bound constituents.
3.2.6 Determination of Aptamer Surface Density on UV-Modified PMMA
A clean SPR gold sensor surface was coated with 300 µL of a PMMA solution
(1.0 mg of PMMA in 10 µL of CH2Cl2) in a custom built spin coater and spun at 1500
rpm for 1 min. The PMMA film was then subjected to UV light and aptamer
immobilization was undertaken using identical conditions as those described in Section
2.5. The SPR response, which was measured using a BIACORE X SPR instrument
(Piscataway, NJ), was recorded after each treatment using DI water as a buffer. The
difference in SPR response before and after aptamer immobilization was determined
and the SPR response unit was converted into molecules cm-2 using the manufacturer‘s
conversion factor of 10 response unit=1 ng cm-2 and the molecular weight of the
aptamer.30
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3.2.7 LNCaP Cell Capture Using the HTMSU
To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV)
was placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix,
AZ). This was then attached to the capillary that was sealed to the input port of the
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell
suspension was introduced at the appropriate volumetric flow rate to produce the
desired linear velocity in each microchannel comprising the capture bed. Next, a postcapture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1 to remove any
non-specifically adsorbed cells.
In cases where the cells required optical visualization to assist in the operational
optimization of the HTMSU, the PMMA devices were fixed onto a programmable
motorized stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) microscope and
video images were collected during each experiment at 30 frames per second using a
monochrome CCD (JAI CV252, San Jose, CA). A Xe arc lamp was used to excite the
fluorescent dyes incorporated into the cells‘ membrane.
3.2.8 LNCaP Cell Release from the HTMSU
Following a post cell capture rinse performed with 0.2 mL of 150 mM PBS, a
trypsin solution consisting of 0.25% w/v trypsin in Tris-Glycine buffer (pH=7.4) was
infused into the HTMSU. The captured cells could be observed (microscopically) until
they were removed by the tryptic digestion and Stoke‘s force using both brightfield video
measurements to evaluate release efficiency.
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3.2.9 Conductivity Enumeration of Released Cells
The released cells from the capture surface were traversed at 1 mL min-1 volume
flow rate through a set of Pt electrodes. We used a specially designed circuit as
described earlier20 to measure the changes in solution conductivity due to single cells as
a function of time to create the desired conductivity trace from which cell numbers were
determined.
3.3 Results and Discussion
Although sophisticated imaging reagents and hardware have been developed for
the diagnosis and prognosis of many cancer-related diseases, there are still significant
advancements that need to be made that can provide earlier diagnosis and staging of
cancers following surgical intervention or monitoring disease recurrence.15 In this work,
we exploited the potential utility of CTCs as a diagnostic and prognostic marker for
cancer using microfluidics for the high-efficiency recovery and subsequent enumeration
of prostate tumor cells. The molecular recognition of these cells from clinical samples,
such as blood, was enabled by the expression of PSMA into lymph node metastasized
LNCaP cells. The selective isolation of these cells directly from whole blood was
affected through the use of immobilized anti-PSMA aptamers decorating the walls of a
capture bed poised within a HTMSU fabricated in a polymer, which could process large
input volumes and search for extremely rare events. The HTMSU contained a
conductivity sensor that was used to enumerate the isolated LNCaP cells following
chemical release from the capture surface.
3.3.1 LNCaP Cell Selectivity and Specificity Using Aptamer Recognition
Specific selection of LNCaP cells was based on the recognition capabilities of
anti-PSMA aptamers that were tethered to the HTMSU capture beds to select only cells
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Figure 3.2 (A) Brightfield (left) and fluorescence (right) images for the positive selection of
LNCaP cells infused into the HTMSU at a constant volumetric flow rate. The cells were
suspended in a PBS buffer (~1000 cells mL-1) and following infusion of the cell suspension, the
device was washed with PBS buffer prior to imaging. In all cases, the entire capture bed was
imaged by scanning the microscope stage. The cells were stained with the fluorescein
membrane probe prior to introduction into the HTMSU to allow fluorescence visualization. (B)
Comparison of LNCaP cell capture efficiencies using anti-PSMA aptamers or anti-EpCAM
antibodies cell recognition elements. In both cases, the HTMSU capture bed was modified with
UV light to create the functional scaffold for covalent attachment of the antibody or 50-labeled
aptamer. The graph shows the cell capture efficiency versus cells‘ translational velocity. Red
squares and blue circles represent the capture efficiencies for anti-PSMA aptamers and antiEpCAM antibodies, respectively. In these experiments, ~1000 LNCaP cells were seeded into a
PBS buffer (pH=7.4) with the number of captured cells determined via brightfield microscopy
and subsequently verified using fluorescence microscopy.
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that expressed PSMA even when these cells were of extremely low abundance. The
specificity of the PSMA-mediated cell selection by aptamers was investigated by using
different surface chemistries, pristine PMMA, UV-modified PMMA, and a capture bed
surface decorated with random DNA sequences or PSMA-specific aptamers. These
initial experiments used the HTMSU with the adhered cells determined via inspection
with fluorescence and brightfield microscopy. In these experiments, the LNCaP cells
were seeded into PBS buffer (pH=7.4) at ~1000 cells mL-1 and pumped through the
HTMSU using a syringe pump (linear velocity=2.5 mm s-1). Because fluorescence
microscopy was used for visualization, the cells were fluorescently stained using a
fluorescein membrane probe. From these experiments, we noticed negligible amounts
of cell adhesion of the LNCaP cells to the channel walls of pristine PMMA. UV
irradiation of the polymer modifies the PMMA surface by introducing carboxylic acids
and other carbonyl groups onto its surface, making this surface more hydrophilic
compared with pristine PMMA.32 When the LNCaP cell suspension was pumped
through this HTMSU device, no LNCaP cells were found to adhere to the UV-modified
PMMA surface. Repeating this experiment using a UV-activated PMMA surface that
was reacted with 50-amine containing DNA oligonucleotides possessing a random
sequence, no LNCaP cells were detected in the capture bed following fluorescence and
brightfield microscopic interrogation. These results suggested that the adhesion forces
of the LNCaP cells to these surfaces were not strong enough to withstand the
hydrodynamic shear produced by the laminar fluid flow. The random DNA sequences
tethered to the PMMA surface did not possess recognition capabilities for the PSMA
integral membrane protein. However, when PSMA-specific aptamers were tethered to
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the capture bed walls, microscopic inspection of the capture beds clearly indicated the
presence of captured LNCaP cells (see Fig. 3.2A).
3.3.2 Cell Translational Velocity Optimization
Because the capture aptamers are tethered to the channel walls, dynamic
interactions between the cell membrane‘s receptors and the channel wall containing the
recognition elements is important in determining the recovery of the rare cells. Chang‘s
model

33

of cell adhesion in flowing systems has been applied in previous reports to

describe the encounter rate between the solution-borne cells and the surface-tethered
cell selection elements.20 When the flow velocity is beyond an optimal value, a decrease
in the interaction time between a particular cell‘s membrane antigen and the capture
molecule available for binding is observed, thereby reducing the number of potential
binding events. This model also predicts that too small of a velocity leads to a decrease
in the encounter rate between the cell bound antigen and the immobilized recognition
element. Therefore, an optimal linear velocity would be expected for each flowing
system to guarantee the highest frequency of binding between capture molecules and
antigen based on a balance between the interaction time and the encounter rate.33 In
addition, because the solution is driven hydrodynamically through the capture bed,
shear force can cause release of the captured cells if the shear force is greater than the
adhesion force, which in this case is determined by the PSMA/aptamer dissociation
constant and the number of molecular association complexes between the surface and
cell.29
We therefore carried out experiments to determine the optimal linear velocity to
provide the maximum recovery of rare tumor cells found in peripheral blood using
aptamer recognition elements. The results of these investigations are presented in Fig.
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3.2B. From these results, the maximum cell capture efficiency was found to occur at a
translationalvelocity equal to 2.5 mm s-1 under the conditions employed in this study.
LNCaP cell capture studies using an EpCAM antibody-tethered HTMSU followed the
same capture efficiency trend for that observed for the anti-PSMA aptamer, indicating
that the cell capture efficiency is governed by the same principal as that described by
the Chang model and seen in our previous work for anti-EpCAM captured MCF-7 cells
using this HTMSU.20 However, the optimum linear cell translational velocity for
maximum cell capture for the anti-EpCAM immobilized HTMSU was slightly lower (2.0
mm s-1) than that observed for the anti-PSMA aptamer (2.5 mm s-1) indicating that the
reaction rate for the anti-EpCAM/EpCAM interaction is slightly less than that observed
for the anti-PSMA aptamer/PSMA interaction. The molecular weight of EpCAM, 33
kDa ,34 is far less compared with 100 kDa for PSMA.16 The extra-cellular domain of
EpCAM contains only 242 amino acid residues whereas PSMA contains 707 extracellular amino acid residues potentially giving extended accessibility of the extracellular
domain of PSMA to its recognition element. However, the rate of association will
depend also on the location of the recognition epitope as well as the conformational
reorganization occurring during a binding event. These factors may provide a faster rate
of reaction observed in the case of the anti-PSMA aptamer/PSMA complex. In addition,
the expression level of PSMA (1×106 molecules cell-1) is approximately twice the
expression level of EpCAM within the LNCaP cell‘s membrane.35–37 This higher
expression level and the bulky extra-cellular domain of PSMA may hinder accessibility
of anti-EpCAM/EpCAM interactions due to molecular crowding effects. Moreover, the
smaller molecular weight anti-PSMA aptamer, 10 kDa, is able to efficiently bind to the
larger

molecular

weight

PSMA

due

to
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its

capability

to

quickly

fold

into

thermodynamically stable secondary and tertiary structures to form complexes through
molecular forces that specify target interaction.38
Another issue that must be addressed is the adhesion strength between the
captured cell and its surface immobilized recognition element due to the fact that the
shear force exerted by the solution can potentially dislodge the cell from the capture
surface. This would occur if the adhesion strength (or force) was less than the shear
force (FS). The adhesion force (FA) between the cell and the anti-PSMA aptamer
decorated surface can be determined from the bond strength between a single antigen–
aptamer complex (fC), the cell contact area with the PMMA surface (AC) and the number
of receptors poised on the PMMA surface within the contact area of the cell (CS) from: 20
FA = fC×AC×CS (1)
If the cell is assumed to be a non-deformable object upon adhesion to the
capture surface, the contact area can be calculated using;39
AC = ∏(rpsin(cos-1(rp- h’+h)/rp2 (2)
where rp is the cell radius and h and h’ represent the characteristic cell separation
distances from the surface upon binding. Using h and h’ as 100 and 400 A°,
respectively,40 the calculated contact area was determined to be 1.88 µm2 for the
LNCaP cells (rp≈12.5 µm). If the cell is assumed to flatten and elongate after contact, as
observed experimentally (see Figs. 3.2 and 3.3), the resulting contact area AC was
calculated to be ~380 µm2.41
The single PSMA-anti-PSMA aptamer adhesion force was estimated using the
formalism by Bell,42 who developed the following expression for deriving the critical
force required to break a single bond;
fC=kT/roaC (3)
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where k is Boltzman‘s constant, T is the absolute temperature, ro is the separation
distance between receptors at the minimum breaking force and aC=KDCS (KD=PSMAanti-PSMA aptamer equilibrium constant). Using a value of KD=4.76×108 M-1,29 and
ro=0.5 nm,33 the value calculated for the adhesion force per association complex was

Figure 3.3 Brightfield and fluorescence micrographs showing anti-PSMA aptamer captured
LNCaP cells in a PMMA microchannel. (A) Brightfield micrographs taken at 40x magnification
and (B) the corresponding fluorescence micrographs verifying the captured cell is the
fluorescently labeled LNCaP cell. The inset shown in panel (B) is a fluorescent-stained LNCaP
cell in a PMMA microchannel that was not decorated with anti-PSMA aptamers indicating the
spherical shape of these cells.

determined to be 4.55×10-11 N. For the LNCaP cells shown in Fig. 3.3A, FA was
calculated to be 5.5×10-5 N.41 FS was determined from Stokes‘ law;43
FS = 6∏ηrpvC (4)
where rp is the cell radius (~12.5 µm for LNCaP cells),44 η is the solution viscosity (4.8
CP for whole blood with a hematocrit level of 0.4)45 and vC is the critical linear velocity
that can induce cell detachment. Rearrangement of Eq.4 produced a value of 6.0×103
cm s-1 for vC. This value is significantly greater than the linear velocities used in the
present experiments for optimizing the capture efficiency. Several captured cells were
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observed continuously during experiments in which linear velocities up to 10.0 cm s-1
were implemented and no cell damage or disruption of cell–wall adhesion was observed.
3.3.3 Selection of Other CTC-Types Using the HTMSU with Immobilized PSMA
Aptamers
Non-specific adsorption or recognition of other CTC-types was also evaluated
using a breast cancer cell line (MCF-7) as an example, which does not express PSMA,
but does overexpress the EpCAM. The existence of PSMA genes in normal and nonprostate-specific tumor cells, such as the MCF-7 cell line, has been reported, however,
protein assay results for the MCF-7 cell lines failed to detect the PSMA antigen.46 Our
results indicated that no MCF-7 cells were found in the PMMA capture beds when
decorated with the anti-PSMA aptamers as deduced from microscopic interrogation of
these beds using brightfield microscopy (data not shown). These cell capture
experiments were carried out under dynamic laminar flow conditions in the HTMSU
microfluidic channels using the optimized LNCaP linear velocity of 2.5 mm s-1. Therefore,
the presence of the hydrodynamic shear would most likely detach any non-specifically
bound material due to weak adhesion forces exerted on these cells.
3.3.4 Cell Detachment from the Capture Surfaces
Releasing the cells intact from the capture bed was critical for the subsequent
conductivity enumeration of the LNCaP CTCs. The mechanism we evaluated for cell
release was the use of enzymatic digestion of the extra-cellular domain of the PSMA
protein using trypsin to reduce the cell‘s adhesion strength to the aptamer surface.
There are two main biosynthetic forms of PSMA within the LNCaP cell membrane,
which are either mannose-rich PSMA (PSMAM) or the glycosylated form of PSMA
(PSMAC). PSMAM is completely sensitive to trypsin, whereas PSMAC is trypsin resistant
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Figure 3.4 (A) Time-lapse micrographs showing trypsin enzyme mediated release of a captured
LNCaP cell upon application of 0.25% w/w trypsin in PBS buffer (pH=7.4). (a) At t=0 or prior to
exposure of the captured cells to the trypsin releasing buffer. (b) At t=2.0min, disruption of the
binding complex is evident. (c) At t=6.5min, the cell appears to be released from the capture
surface. (d) At t=7.5min, the cell was completely released from the surface and swept away
from the capture surface to the detection region by the hydrodynamic flow. (B) Plot of cell
release efficiency versus time. In each experiment the number of cell releasing events, >25, in
three curvilinear channel were counted. The error bars represents the standard deviation of the
results obtained for three replicate experiments.

due to transport blockage at the Golgi complex associated with their secretory
pathway.47
Introduction of a trypsin solution into the capture bed to allow for tryptic digestion
of PSMA to provide release of the captured LNCaP cells was found to effectively
release these cells from the aptamer-decorated surface indicating the dominate
component was PSMAM as the attachment partner between PSMA and the anti-PSMA
aptamers. Figure 3.4A represents time-lapse micrographs of a captured cell that was
processed using a trypsin digestion solution. Close investigation of the time-lapse
micrographs indicated efficient release of the intact LNCaP cells from the capture
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surface. The cell releasing efficiency increased with increasing incubation time
according to Fig. 3.4B. Complete cell detachment (~100%) was achieved in less than 7
min of incubation time. We also note that brightfield inspection at the Pt electrode pair
readout point of the device was performed of the released cells following trypsin
processing and these inspections confirmed that the cells were intact at this point.
3.3.5 Conductivity Enumeration of the CTCs
The conductivity detector, which consists of a pair of Pt electrodes with a 50 µm
spacing (cell constant=0.01 µm-1), was fabricated specifically to transduce the larger
CTCs compared with the smaller leukocytes and/or erythrocytes that may appear in the
enumeration phases of the assay providing false positive signals due to the universal
nature of the conductivity response. Also, the CTCs possess unique electrical properties
due to their characteristic chemical composition compared with erythrocytes and
leukocytes to provide efficient conductivity readout.48 For example, the over-expression
of membrane glycoproteins, such as PSMA, associated with many tumor or cancer cells
result in an increase in the number of negatively charged sialic acid molecules that cap
the extra-cellular domains of these integral membrane proteins.20 This can produce a
cell with a higher electrical conductivity compared with one that does not over-express
these types of proteins.
One milliliter of whole blood was seeded with 20±1 LNCaP cells and was
processed using the HTMSU. The captured cells were subsequently released using the
trypsin releasing buffer and enumerated with the conductivity transducer with a typical
data stream shown in Fig. 3.5A. The conductivity transducer measured changes in the
conductivity releasing buffer induced by the presence of single CTCs between the Pt
electrode pair. Therefore, the responses generated in the data shown in Fig. 3.5A were
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Figure 3.5 (A) Conductometric responses generated for 1.0 mL of whole blood seeded with 20
±1 LNCaP cells (black) or 0 LNCaP cells (red) at a linear flow velocity of 2.5 mm s -1 processed
using the HTMSU. The captured LNCaP cells were released from the capture surface using the
release buffer comprised of 0.25% w/w trypsin and transported through the conductivity sensor
at a volumetric flow rate of 0.05 mL min-1. The arrows designate peaks that were identified as
LNCaP cells based on a signal-to-noise threshold of 3. The crossed arrows represent nonLNCaP cell events. The insets shown in the figure represent a magnified view of sections of the
data stream. The blue line represents the threshold level, which represents 3x the average
background level, which was used to differentiate ‗‗true‘‘ events from noise. The data presented
here was smoothed by the Savitsky-Golay method (25 point smoothing function). Also shown in
this plot is a sample of whole blood containing no LNCaP cell that was processed with the
HTMSU device (red line). (B) Calibration plot (m=0.990, r2=0.99997) for the number of LNCaP
cells seeded (10–250 cells mL-1) into 1.0 mL of whole blood versus the number of conductivity
responses using the Pt-conductivity sensor.
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generated from single cells. Tris-Glycine buffer was selected as the major component in
the release buffer due to its low conductance, hence, the sensitivity of the conductivity
detection for single cells was enhanced and the resultant peaks should exhibit a positive
response due to the higher conductance of the LNCaP cells with respect to the release
buffer. There were 18 peaks in the conductance response given in Fig. 3.5A that could
be assigned to single LNCaP cells based on a signal-to-noise threshold of 3 (99.7%
confidence level) giving a recovery of ~90% (see insets to Fig. 3.5A showing the
discrimination threshold used). As seen in Fig. 3.5A, only positive signals were
designated as LNCaP cells and the negative spikes were assigned to particulates due
to their lower conductance compared with the Tris-Glycine buffer. Variation of the peak
response for each cell is most likely due to differences in the cells‘ morphology and
chemical composition, which is determined by the state of mitosis of the cell.
One milliliter of a blank sample, which consisted of whole blood seeded with no
LNCaPs cells, was analyzed by the HTMSU and enumeration via conductivity under the
same conditions as described for the whole blood sample seeded with LNCaP cells and
the resultant trace is shown in Fig. 3.5A. In this case, no single-cell spikes were seen in
the data trace indicating that the signal spikes seen in the conductivity trace for the
LNCaP seeded whole blood was indeed due to these tumor cells. Therefore, the purity
of LNCaP cell selection was determined to be 100%.
The HTMSU with conductivity enumeration was further evaluated for the
detection of various seed levels of LNCaP cells into whole blood to produce a
calibration plot. A range of 10–250 LNCaP cells per mL of whole blood was evaluated.
The best-fit linear function to the data plotted in Fig. 3.5B had a slope of 0.990 with an
intercept near zero (r2=0.9997). Interestingly, even at the lowest LNCaP cell load, the
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data still fit along this linear function indicating that even at extremely low levels of
LNCaP cells found in whole blood, we could still quantitatively analyze these cells using
the HTMSU. We should note that for 1 mL of whole blood, ~2.5×109 erythrocytes are
present. Therefore, the enrichment factor for this assay can be calculated as 2.5×108 for
the lowest LNCaP cell load investigated. At the 2.5 mm s-1 employed to provide
maximum LNCaP recovery, the processing time for exhaustively processing 1 mL of
blood would be ~29 min.
3.4 Conclusions
The HTMSU described in this manuscript utilized an aptamer-based positive
selection approach for the isolation of prostate-specific CTCs (LNCaP) directly from
whole blood with subsequent quantification of these rare cells using a non-labeling
approach. The compelling advantage of this methodology is that no sample pretreatment was necessary and the throughput (29 min processing time for 1 mL input),
recovery (90%) and purity (100%) were extremely high, contrary to what is seen in other
rare cell selection formats utilizing size or affinity capture. The ability to quantify the
selected cells with near 100% detection efficiency using a conductivity readout format
allows for the use of this simple system at the point-of-care for the management of
cancer-related diseases from a simple blood test. In addition, molecular profiling of the
selected CTCs could be used for determining therapeutic treatment regimens as well as
identifying the organ of origin of the selected CTC from whole blood. Molecular profiling
of rare CTCs in whole blood could not be done directly on the clinical sample due to the
low copy number of the mutated DNA originating from the CTCs as well as potential
interferences on downstream molecular processing by the highly abundant red and
white blood cells found in whole blood. We are currently in the process of developing
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sensitive genotyping assays that can be performed directly on the selected CTCs for
providing this valuable clinical information.
Previously, it has been reported20 a positive selection of MCF-7 breast cancer
cells from peripheral blood using anti-EpCAM antibodies and this HTMSU. In this report,
aptamers were used for the positive cell selection, in this case for selecting LNCaP cells
from peripheral blood. The recovery, purity, and throughput were similar in both cases
as well as the specificity for the target cells. The attractive features of aptamers
compared with antibodies is the ordered nature of their attachment to the solid surface
(50-end attachment) as opposed to a stochastic one associated with antibodies (primary
amine groups on the antibody), the ability to carefully control the aptamer/surface
distance to improve accessibility and the robust nature of the molecular recognition
elements. For example, aptamers can be stored at room temperature without degrading
their recognition performance, whereas antibodies must be stored in more controlled
conditions to maintain their activity.
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CHAPTER 4 ENRICHMENT AND DETECTION OF ESCHERICHIA COLI O157:H7
FROM WATER SAMPLES USING AN ANTIBODY MODIFIED MICROFLUIDIC
CHIP
4.1 Introduction

Threats to human health from Escherichia coli contamination of aquatic
environments are becoming highly prevalent. Several major waterborne outbreaks have
been reported in aquatic systems ranging from freshwater to marine, where E. coli
accumulates in the water column and sediments.1,2 To better understand E. coli ecology
in aquatic environments, to provide monitoring over time scales appropriate for the
study of E. coli outbreaks,3-5 and to protect human populations, monitoring techniques
for E. coli are needed that have low detection thresholds even for extremely rare cells
and rapid processing times.
The U.S. EPA allowable levels of E. coli are 0, 200, and 1000 cfu per 100 mL of
drinking, swimming, and recreational (boating) waters, respectively, and the minimum
infectious dose is very low, ∼10 cells.6 To detect E. coli corresponding to doses this low,
preenrichment of cells is required, especially in drinking and recreational waters, by
processing large input volumes to accommodate the readout phases of the
measurement assay. There are different technologies for isolating rare cells from
heterogeneous samples to aid in their analysis such as fluorescence assisted cell
sorting,7 flow-through filtrations,8 enzyme linked immunosorbent assays (ELISA),9 and
immunomagnetic assisted cell sorting.10 These methods, however, rely on timeconsuming culturing protocols.
The U.S. EPA has approved an E. coli detection test for the examination of
drinking water, which is based on ß-D glucuronidase, an enzyme associated with E. coli
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colonies.11 This method (EPA Method 1603) detects the presence of all coliforms but
not specifically the E. coli O157:H7 strain due to a two-base frame shift insertion within
its genome that yields an inactive uidA gene and lack of ß-D glucuronidase
production.12 Detection of pathogenic E. coli O157:H7 is usually performed with EPA
Method 9260F,13 which employs a series of incubations at low temperatures for
extended periods of time (72 h).
The presence of naturally and anthropogenically derived dissolved substances in
aquatic systems, such as humic materials and residual pharmaceuticals,14 along with
other dominant native bacterial species, can act as interfering agents that may alter the
accuracy of the aforementioned colorimetric tests. In addition, microbiological studies
have indicated that stressed E. coli O157: H7 become nonculturable even though they
may be viable and still capable of producing Shiga-like toxin.15 More recently, nucleic
acid-based methods for pathogen detection, such as polymerase chain reaction (PCR),
have been developed to target unique bacterial genes. PCR itself, although very
sensitive, detects the presence of bacteria but does not allow isolation of rare bacterial
cells, which is required to determine the etiological agent responsible for an outbreak.16
Recent work has shown that cells can be accumulated from biological samples
using a microfluidic platform.17-19 These microfluidic devices utilized the surface of a
microchannel or beads trapped within a microchannel for positive cell selection. Liu et al.
generated a device for processing E. coli cells from input volumes of 1 mL with the cell
limit-of-detection (LOD) of ∼1 cfu μL-1.20 Beyor and co-workers reported a microfluidic
system that could process ∼50 μL of input and search for target cells, such as K-12 or
O157:H7 E. coli.21 The LOD reported was 0.2 cfu μL-1. With an E. coli O157:H7
concentration level of <200 cells per 100 mL, the probability of securing a target cell in
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50 μL would only be 0.01. Therefore, sampling statistics would require processing larger
input volumes to provide higher confidence that a target could be processed.
We present a method for the isolation, identification, and quantification of E. coli
O157:H7 cells from recreational waters. Once the cells were enriched, their
quantification was accomplished using off-chip real-time quantitative PCR (qPCR). We
used an engineered chip consisting of high-aspect ratio capture beds decorated with
polyclonal antibodies (pAbs) specific for antigenic membrane proteins expressed in E.
coli O157:H7. The method was further demonstrated to be capable of detecting E.coli
O157:H7 cells in lake and wastewater samples. The benefits of this methodology
include: (i) preselectivity, which is extremely important because the detection is often
difficult due to the combination of the high number of nonpathogenic bacteria and the
low number of pathogens of interest;16 (ii) the microfluidic chip provides a cell
purification platform (cells are washed while attached to the surface) and prepares the
selected cells for immediate qPCR analysis free from potential interfering agents; and
(iii) rapid analysis as compared to conventional methods relying on culturing.
4.2 Materials and Methods
4.2.1

Reagents and Buffers
Heat-inactivated E. coli O157:H7 cells and goat polyclonal anti-E. coli O157

antibodies were purchased from K & P Laboratories Inc. (Gaithersburg, MD). Reagents
used for the PMMA microfluidic chip surface cleaning and modification included reagent
grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride
(EDC), N-hydroxysuccinimide (NHS), and 2-(4-morpholino)-ethane sulfonic acid (MES),
which were purchased from Sigma-Aldrich (St. Louis, MO) and used as received.
Phosphate buffered saline (PBS) was purchased from American Type Culture
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Collection (Manassas, VA). Cellstripper™ was obtained from Mediatech, Inc.,
(Manassas, VA) and used as received. For the fluorescence visualization experiments,
E. coli cells were stained with a fluorescein-based cell membrane stain, PKH67,
according to the manufacturer‘s protocol (Sigma-Aldrich, St. Louis, MO). All bacterial
cells used (Staphylococcus aureus, Micrococcus luteus, Bacillus subtilis, Enterobacter
aerogenes, Escherichia coli K12) were purchased from Sigma-Aldrich (Milwaukee, WI),
and Escherichia coli O157:H7 cells were purchased from Kirkegaard & Perry
Laboratories Inc. (Gaithersburg, MD). A stock solution of E. coli cells was prepared at a
concentration of 3×109 cfu mL-1 and cell suspensions required for testing were prepared
through serial dilution.
4.2.2

Microfluidic Chip Fabrication and Assembly
The microfluidic fabrication procedure involved the following four major steps: (i)

mold fabrication using high precision micromilling (HPMM); (ii) hot embossing of the
microfluidic structures in a PMMA substrate; (iii) post-processing of the microfluidic
including drilling of sample reservoirs, UV-photoactivation of the immobilization beds,
cover plate assembly; and (iv) antibody attachment to the capture channel surfaces.
Microstructures were milled onto the surface of a 6.3 mm thick brass plate (alloy 353
engravers brass, McMaster-Carr, Atlanta, GA, USA) using a high-precision micromilling
machine (KERN MMP 2522, KERN Micro- und Feinwerktechnik GmbH & Co. KG;
Germany) as reported previously.22 PMMA was used as the chip substrate and cover
plate (0.5 mm thickness) and were purchased from Good Fellow (Berwyn, PA). The
microstructures were hot embossed into PMMA substrates via micro-replication from
the brass mold master. Before final assembly (attachment of the cover plate to enclose
fluidic channels), chips were washed with ~0.5% Alconox solution, rinsed with DI water,
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2-propanol, and ultrasonicated for 10 min in DI water. PMMA devices and cover plates
were exposed through a mask to ultraviolet radiation (254 nm, 10 min at 15 mW cm-2)
resulting in the formation of carboxylate moieties only in the UV exposed areas of the
PMMA, which in this case was the cell selection bed. The density of the carboxylic acid
groups on the surface after a 10 min exposure to UV light has been determined to be
6.6×10-10±0.8×10-10 mol cm-2.17 UV-modified PMMA parts were clamped together
between two borosilicate glass plates and the cover plate was thermally fusion bonded
to the substrate using a convective oven set to 101 °C, slightly above the glass
transition temperature of the UV-modified material. The temperature was increased
from 50 °C to 101 °C at a rate of 20 °C min-1 and held at 101 °C for 15 min. Polyimidecoated fused silica capillaries (100 μm i.d., Polymicro Technologies, Phoenix, AZ) were
inserted and glued into the inlet port of the assembled device to provide an interconnect
for sample introduction into the device.
Each of the 8 devices contained 9.5 mm long, 16 curvilinear channels that were
15 μm in width and 80 μm in depth with a radius of curvature of 120 μm (see Figure 4.1).
The surface area of the 16 channels, which defined the cell selection bed, was 40 mm 2
with a volume of 250 nL. The chip output following selection and release was directed
into a PCR microtube. A precell selection rinse of the chip was performed with 100 μL of
150 mM PBS at 50 mm s-1. A programmable syringe pump (Harvard, Holliston, MA) with
a syringe equipped with both a luer lock (Hamilton, Reno, NV) and a luer-to-capillary
adapter (Inovaquartz, Phoenix, AZ) were used to infuse the water sample into the chip.
Then, a cell suspension or water sample was infused into the chip at 0.5, 1.0, 5, 10, 40,
80, and 100 mm s-1 linear velocities. A postcapture rinse with 100 μL of 150 mM PBS at
50 mm s-1 (55.6 μL min-1) was used to remove any nonspecifically adsorbed material.
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Figure 4.1 (A) A picture of the PMMA fluidic system for the positive selection of rare E. coli cells
containing 8 different devices with each device comprised of 16 selection channels. (B)
Schematic of the entire cell selection chip and (C) an expanded via of an individual cell selection
device. Each device contained 9.5 mm long 16 curvilinear channels that were 15 μm in width
and 80 μm in depth with a radius of curvature of 120 μm with respect to the channel center. (DE) SEM of the brass molding tool.

Cells were then stripped from the channel walls using a Cellstripper solution and eluted
from the chip in 5 μL of PCR buffer.
4.2.3

Antibody Immobilization
Antibody immobilization onto the photoactivated PMMA chip surface was carried

out in a two-step process.7 The UV-modified, thermally assembled device was flooded
with a solution containing 4 mg mL-1 EDC, 40 mg mL-1 NHS in a 150 mM MES (pH=6)
and kept for 1 h at room temperature to obtain the succinimidyl ester intermediate. After
this incubation, the EDC/NHS solution was removed by flushing nuclease-free H2O
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through the device. Then, an aliquot of 10 μL of 1.0 mg mL-1 of the polyclonal anti-E.
coli O157 antibody solution in 150 mM PBS (pH=7.4) was introduced into the channels
and allowed to react for 4 h in a high humidity box. The device was then rinsed with a
solution of PBS (pH=7.4) to remove any non-specifically bound anti-E. coli O157
antibodies. The molecular weight of pAb was provided by the manufacturer and
reported as ~150 kDa. IgG antibodies possesses three discrete domains, two Fab
fragments and one Fc, known to be flexible, but difficult to predict the exact
conformation when immobilized to a solid surface. 8 Roberts et al. determined IgG
molecular dimensions of passively adsorbed IgG antibodies on a polystyrene surface to
be 16-19 nm.23 Dong et al. determined the diameter of covalently attached IgG to a gold
surface to be 52.4 nm and determined that ~22% of the Abs were active after covalent
attachment.24 Assuming a 52.4 nm IgG diameter, we calculated the pAb density on the
PMMA surface to be 4.6×1010 molecules cm-2 assuming a full monolayer coverage that
was limited by the molecular dimensions of the pAb, which is supported by the higher
surface density of carboxylic acid functional groups on the PMMA surface following UV
exposure.25,26
4.2.4

Fluorescence Microscopy
Observations of fluorescently-labeled cells in the chip‘s selection channels were

accomplished using a Zeiss Axiovert 200M Inverted Microscope with a 40x fluorescence
objective equipped with a 480 nm excitation filter. The microscope was fitted with a JAI
CV 252 monochrome video camera. The images were captured directly to the hard
drive of a Dell Precision 500M workstation via a Pinnacle Systems DV500 video capture
card that was interfaced to a Pinnacle Systems Bluebox (Pinnacle Systems, Inc.,
Mountain View, CA). Adobe Premiere 6.0 (Adobe Systems, Inc., San Jose, CA) was
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used for image acquisition and processing. In order to analyze the cell flow profiles and
cell radial distribution in the selection channels, trajectories of fluorescently labeled E.
coli O157:H7 cells flowing in an unmodified channel were investigated. Cell trajectories
were captured via video microscopy and micrographs containing one half of the curved
channels were extracted from the video. One hundred cellular events were located in
the micrographs and the distance between the center of the cell event and the channel
wall was determined using ImageJ 1.38x software (National Institute of Health, USA).
4.2.5

Flow Dynamics
To evaluate the flow dynamics of bacterial cells in the microchannel operated

with hydrodynamic pumping, the Reynolds numbers (Re) were calculated27 using the
equation, Re=ρUdh/μ, where, ρ, U, and μ are the density (997.04 kg m-3), velocity (m s-1),
and viscosity (8.9×10-4 Pa s-1) of the fluid, respectively, and dh is the hydraulic diameter,
defined as 2wh/(w+h), where w and h are the channel width and height, respectively.
For a rectangular channel with 15 μm×80 μm dimensions, dh=2.53×10-5 m. Re was
calculated to be in the range of 0.01 to 2.83, for 0.5, and 100 mm s -1 linear velocities,
respectively, indicating fully developed laminar flow within the tested flow range.
4.2.6

Water Sample Collection
Lake water samples were secured from two different sites: (i) Baton Rouge

University Lake, LA (USA), which is a small man-made lake on the LSU campus
created in the early 1920s with the damming of Bayou Duplantier, and (ii) Lake
Granbury, TX (USA), which is a reservoir on the Brazos River constructed in 1969. The
sampling depth was about 6 in. below the water surface. The University Lake is a part of
the Lakes District System, which consists of six man-made lakes located approximately
1.2 miles east of the Mississippi River and 2.5 miles southeast of downtown Baton
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Rouge, LA. Creation of the lakes began in the early 1920s with the damming of Bayou
Duplantier, which flooded the old cypress swamp. There are approximately 140 outflows
entering the lakes from storm drains of the watershed. University Lake is the largest
lake of the system at approximately 195 acres in size. The lake has an average depth of
1.5 feet with some areas as low as 0.5 feet and a hydraulic retention time of ~50 days
(http://www.mvn.usace.army.mil/pd/projectsList/ProjectData/108824/reports/University%
20Lakes% 20PRP.pdf).
Lake Granbury‘s surface area and volume are 34 km 2 and 167×106 m3, with
inflows primarily through the Brazos River. Upstream of Lake Granbury, the Brazos
River watershed is dominated by rangeland. For extended periods of the year, inflows
can be near-zero. When inflow events occur, they last several days and can exceed
flushing rates of 20 d-1.28 Much of the shoreline of Lake Granbury is residential, with
only a portion of this area serviced by a sewage system. In addition, some areas of
Lake Granbury are protected from flushing (i.e., coves with longer hydraulic residence
times). E. coli concentrations can become problematic in this lake system (Roelke,
unpublished data), where the likely source of contamination is aging septic systems that
leak into the lake. E. coli concentrations are able to accumulate in areas of low flushing.
For this study, water samples were collected by hand from multiple coves of Lake
Granbury.
4.2.7

Water Sample Filtration
Water samples from recreational lakes (100 mL) and wastewater samples (1 mL)

were filtered using hydrophilic (PVP-coated) polycarbonate track etched membranes
(PCTE, Sterlitech, Kent, WA) membrane filters. The pore size of the membranes used
was 10 μm for the prefiltration to remove large particulates and 0.1 μm for further
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filtration and volume reduction prior to input into the microfluidic device. Water samples
were filtered through the 10 μm pore size membranes at 10 mL min-1, and the effluent
was collected and filtered through the 0.1 μm pore size membranes at 2.5 mL min-1.
The membrane was rinsed with ∼1 mL of pure water to exhaustively remove material
from the surface and used as the input to the microfluidic chip. The 10 μm pore size
membrane filter did not change the total volume of the sample; however, it did remove
solid particulates and debris.
4.2.8

E. coli Detection via Culturing
E. coli were in some cases analyzed from membranes using a modified

membrane-Thermotolerant E. coli agar (Modified mTEC EPA Method 1603), which uses
a membrane filter procedure for the detection and enumeration of E. coli bacteria in
ambient waters and disinfected waste waters. The modified medium contained a
chromogen (5-bromo-6-chloro-3-indolyl-ß-D-glucuronide), which is catabolized to
glucuronic acid producing a red- or magenta-colored compound by E. coli that produces
the enzyme, ß-glucuronidase. A sample was filtered through a 0.1 μm pore diameter
membrane, which retained the bacteria. After filtration, the membrane was placed on a
selective and differential medium, modified mTEC agar, incubated at 35±0.5 °C for 2±
0.5 h to resuscitate injured or stressed bacteria and then incubated at 44.5±0.2 °C for
22±2 h. The target colonies on the modified mTEC agar are red or magenta in color
after incubation and can be counted manually via visual inspection.
4.2.9

Polymerase Chain Reaction (PCR) and Real-Time qPCR
The primer sequences used for the PCR were as follows: slt1, forward primer

(FP) – CAG TTA ATG TGG TGG CGA AGG (Tm=56.3 °C), reverse primer (RP) – CAC
CAG ACA ATG TAA CCG CTG (Tm=56.2 °C) product size – 348 bp; uidA, FP – GCA
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AAA CTG TGG AAT TGG G (Tm=54.8 °C), RP – TGA TGC TCC ATA ACT TCC TG (Tm
=52.0 °C), product size – 252 bp. These primers were previously reported by Cebula et
al. for recognition of E. coli O157:H7 through a mismatch amplification mutation assay. 6
PCR cocktails consisted of 0.5 μM primers, 0.2 mM dNTP‘s, 1x PCR buffer, 5 U of Taq
DNA polymerase, DNA template and ultrapure water. The PCRs were carried out using
a commercial thermal cycling machine (Techne, Burlington, NJ) with cycles consisting
of an initial denaturation step at 94 °C for 5 min followed by 30 cycles of the following:
94 °C for 30 s, 58 °C for 40 s, 72 °C for 60 s. A final extension at 72 °C for 7 min was
followed by a cooling step at 4°C. Real-time qPCRs were performed on a Stratagene
Mx4000 real-time PCR machine with Brilliant® II SYBR® Green QPCR Master Mix
(Stratagene, La Jolla, CA). The reactions (50 μL) were prepared by combining
nuclease-free water, master mix, primers (final concentration=40 nM), and reference
dye (ex/em=584/612 nm) to a final concentration of 30 nM. The volume of the
template/unknown sample added to the reaction was 5 μL and was the total volume of
the pre-concentrated cells eluted from the microchip (chip pre-concentration factor = 2×
102). The PCR protocol used involved a three-step cycling procedure: (1) 10 min at
95 °C; (2) 46 cycles 30 s at 95 °C, 60 s at 58 °C, 60 s at 72 °C; and (3) a dissociation
step consisting of 81 cycles of ramping the temperature between 55 and 95 °C (0.2 °C
s-1). Standard calibration curves were constructed and PCR amplification efficiencies
were determined among different experiments.
4.2.10 Slab Gel Electrophoresis

PCR products were electrophoresed using a 2% agarose gel (Bio-Rad
Laboratories, Hercules, CA) pre-stained with ethidium bromide. The sample volume
loaded onto the gel was 5 μL with 1 μL of the loading dye. Amplicons were indexed
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against a DNA sizing ladder (50-1,000 bp, Molecular Probes, Eugene, OR). Separation
was performed at 4.8 V cm-1 in 1x TBE (Tris/Boric Acid/EDTA, Bio-Rad Laboratories).
Gels and culturing plates were imaged using a Logic Gel imaging system (Eastman
Kodak).
4.3 Results and Discussion
4.3.1

Low-Abundant E. coli O157:H7 Cell Processing
Scheme 4.1 presents an overview of the processing strategy used for the

selection and identification of E. coli O157:H7 cells. The processing steps involved: (i)
chip preparation; (ii) sample filtration using PCTE membranes to remove large
particulates from the sample and to provide pre-enrichment; (iii) sample processing on
the chip and cell release; and (iv) benchtop real-time qPCR quantification of the
selected cells. For the recreational water, the time required to filter a 100 mL input using
both the 10 and 0.1 μm filters to reduce the total volume to 1 mL was 50 min, producing
a volume reduction of 100-fold and, thus, a 102 pre-enrichment assuming 100%
recovery. Processing a total input volume of 1 mL using the 8 devices poised on the
microfluidic chip (Figure 4.1) at a linear flow velocity of 5 mm s-1 (5.3 μL min-1) required
24 min and produced an enrichment factor of 2×10 2. Therefore, the 0.1 μm filter and
microfluidic chip generated a total enrichment factor of 2×10 4 with a processing time of
74 min. Membranes before and after filtration were inspected under a microscope and
showed that the majority if not all of the solid material had been removed from the
sample prior to chip processing (see Figure 4.2). To achieve maximum recovery of
bacterial cells from the 0.1 μm filter, the filter was washed with 1 mL of water and
control experiments with known amounts of cells were performed. Previously, Wang et
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Scheme 4.1 Overview for the Processing Strategy Adopted for Analysis of Extremely Low
Abundant E. coli O157:H7 and Other Serotypes Using Positive Selection and Enrichment via a
Microfluidic Chip with Subsequent Quantification through Real-Time qPCR

al. evaluated the performance of these types of membrane filters with pore sizes
ranging from 0.1 to 0.45 μm to determine the effect of cell shape and size on bacterial
filterability and determined that bacterial shape, rather than their absolute size, was a
key factor in determining cell recovery.29 We recovered 92±5% (n=4) of E. coli O157:H7
microbial material using the 0.1 μm. Bacterial cells were not lysed while on the
membrane because this process would not guarantee the high quality quantitative
analysis of DNA. A DNA extraction step should be performed to free the sample from
any potential inhibitors present on the membrane surface.30 In our approach, the
immunocapture of the pathogens of interest using microfluidic channels followed by an
extensive wash and subsequent release from the capture surface produced high quality
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Figure 4.2 A and C are pictures of 0.1 μm PCTE membranes after filtration and washing,
respectively, while B and D correspond to 40x microscope images of the same membranes
after filtration and washing, respectively. The insert in B shows a micrograph of the membrane
before filtration. The sample processed here was that taken from Lake Granbury in Texas.

qPCR results that were not seen in the case using E. coli washed directly from the 0.1
μm filter (data not shown). In addition, the use of the microfluidic device provided high
preconcentration factors due to the small selection bed volume, improving the limit-ofdetection for the qPCR.
4.3.2

Water Sample Filtration
The water samples (100 mL) were first filtered using a 10 μm pore size

Polycarbonate Track Etched membranes (PCTE). Using a vacuum pump with the filter
allowed processing water samples at a volume flow rate of 10 mL min -1. This step
ensured that large debris was removed from the sample before it entered the
microfluidic device. Effluent from that step was subsequently filtered on a 0.1 μm pore
size PCTE membrane, on which bacteria and debris larger than 0.1 μm and smaller
than 10 μm were retained. Samples were processed at 2.5 mL min -1 volume flow rates.
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The next step involved washing residual material from the 0.1 μm pore membrane using
1,000 μL of water, which also resuspended the retained bacterial material. This was
performed thoroughly making sure none of the retained material was left on the
membrane. Membranes before filtration, after filtration and washing were inspected
under a microscope. Figure 4.2 presents results from these evaluations.
4.3.3

E. coli Flow Dynamics in Microfluidic Channels
As we demonstrated in our previous work discussing the positive-selection of

cells via surface-immobilized Abs, hydrodynamic flow through low Re channels can
produce a cell-free layer near the channel wall due to focusing effects, significantly
reducing cell:wall interactions and thus, cell recovery.17,18 This focusing effect is flow
rate dependent, but can be reduced using a channel geometry that is sinusoidally
configured, at least for relatively large cells such as tumor cells. Therefore, we
investigated cell flow dynamics and possible focusing artifacts for much smaller cells,
such as E. coli, in curved channels. Radial cell distribution histograms for 1, 5, 40, and
100 mm s-1 linear flow velocities are presented in Figures 4.3A-D. Cell distributions
indicated that the number of cells at the outer edge of a single curved region increased
only slightly with flow velocity compared to the number within the inner edge. For
example, the ratio of cells at the outer-to-inner edges of a curve were 1.6, 2.0, 2.5, 3.0,
and 11.0 for 1, 10, 40, 80 and 100 mm s -1 flow rates, respectively. Similar observations
were reported by Mayeed et al.31
Previously, we reported that sinusoidal channels were more effective than
straight channels for recovering circulating tumor cells at relatively high linear velocities
due to the lack of a cell-free marginal zone adjacent to the outer-edge of the wall for a
single turn. This resulted from centrifugal forces acting on the cells and increased
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Figure 4.3 Histograms of the radial position of bacterial cells in an unmodified sinusoidallyshaped microchannel at linear velocities of (A) 1, (B) 5, (C) 40, and (D) 100 mm s-1. The dashed
lines designate the channel walls. The cells were imaged using fluorescence microscopy with
the cells stained using PKH67. The coordinate system adopted used 0 as the channel centroid,
(-) values refer to locations with respect to the outer edge of the channel and (+) values
represent radial positions in the direction of the inner edge of the channel.

cell:wall interactions generating higher cell recoveries.17 In the data presented in
Figure 4.3, these effects were much less dramatic for the E. coli cells most likely due to
the smaller size of these cells. In fact, as can be seen from Figure 4.3C, the E. coli cells
did not cross flow lines through the turns with fully developed laminar flow. Therefore,
a much more uniform cellular radial distribution was observed, which indicates that
higher flow rates could be used to increase sample processing throughput based solely
on the cells‘ flow dynamics.
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4.3.4

Nonspecific Cell Selection
Even though the affinity purified pAb were directed against E. coli O157:H7, other

types of E. coli serotypes such as O157:H12, O157:H42, O157:H29, O157:H19, and
O157:H45, could potentially be selected using this reagent as well as other species,
such as S. sonnei or C. freundii (see www.kpl.com). However, even if these bacterial
types were selected during microchip enrichment, they would not be transduced during
the enumeration process using real-time qPCR because of a lack of the specific marker
genes used for reporting specifically on E. coli O157:H7.32 We tested the nonspecific
selection of E. coli K12. Cells were infused into the microfluidic channels at 5 mm s-1,
the same conditions used for E. coli O157:H7 selection. After a postcapture rinse,
fluorescence micrographs indicated that no E. coli K12 cells were found in the selection
beds when decorated with the E. coli O157 pAbs.

Figure 4.4 Fluorescence images of a microchannel with (A) E. coli O157:H7 cells and (B) E.
coli K12 cells captured on an antibody modified PMMA surface. The dashed lines designate the
edges of the channel.

Figure 4.4 shows fluorescence micrographs taken after introducing both types of
cells. In Figure 4.4A, one can clearly see multiple events of anchored E. coli O157:H7
cells (indicated with arrows), while in Figure 4.4B, there was a lack of any such events
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poly(methylmethacrylate), PMMA, channel surface was also found (data not shown) due
to the weak adhesion forces and the presence of hydrodynamic shear that could
remove any nonspecifically bound cells.17
4.3.5

E. coli O157:H7 Cell Release from the Channel Surface
Due to the strong adhesion between the captured cells and the antibody-modified

capture surface, hydrodynamic release from the capture surface to provide intact E. coli
O157:H7 cells for real-time qPCR interrogation was found to not be feasible (data not
shown). Following a postcell capture rinse performed with 150 mM PBS, a Cellstripper
solution was infused into the channels to dislodge antibody-induced adhesion of cells to
the channel wall. The use of the Cellstripper™ solution, a non-enzymatic cell
dissociation solution formulated with a proprietary mixture of chelators, for the release of
antibody-captured cells without causing cell disassembly was investigated.
Figure 4.5 shows time-lapse micrographs of a surface-captured cell that was
subjected to Cellstripper™ processing. Stoke‘s forces induced by hydrodynamic shear
produced from laminar flow in the presence of the Cellstripper™ solution allowed for
efficient release of these cells in less than 4 min. Twenty-five cells were monitored, and
the average time required for their release was determined to be 3.4±0.3 min. Following
incubation with the stripper solution, the released cells were flushed from the selection
amplification. We determined that a concentration of Cellstripper up to 10% in the realtime qPCR cocktail did not affect these results (see Figure 4.6A-D).
4.3.6

Cell Recovery
In order to maximize the recovery of E. coli O157:H7 cells from water samples

and maintain high sampling throughput, the processing linear flow velocity thru the
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Figure 4.5 Time-lapse micrographs showing Cellstripper™ and hydrodynamic shear-mediated
release of a captured fluorescently-labeled E. coli O157:H7 cell (circled in red) from the capture
surface. (A) A brightfield image prior to exposure of the captured cell to the stripping solution. (B)
A fluorescence image of the same spot at t=0.1 min following incubation with the Cellstripper™
solution. (C) A bright field image at t=3.4 min after introduction of the Cellstripper™ solution was
infused into the channel and disruption of the binding complex was evident by the bacterial cell
being released from the surface. (D) A fluorescence image at t=3.5 min following introduction of
the stripping solution – the cell appears to be released from the capture surface. The stripping
solution was hydrodynamically pumped through the fluidic chip at a linear velocity of 25 mm s-1.

selection microchannels was optimized. E. coli O157:H7 capture efficiency at different
flow rates and different cell densities (3-30×103 cfu mL-1) were determined using realtime qPCR. Linear flow velocities were varied between 0.5 and 100 mm s -1. The results
of these experiments are depicted in Figure 4.7A as a plot of E.coli O157:H7 capture
efficiency (%) vs linear velocity (mm s-1). We observed that a linear flow rate of 5 mm s-1
produced the highest recovery; 71.6±1.4% (n=5). The general trends observed in the
plot shown in Figure 4.7A can be explained based on the Chang/Hammer model for
mobile cell interactions with immobilized association elements.17,33 Basically, the two
processes that primarily dictate a successful antibody/cell interaction involve: (i) the
encounter rate, which describes the rate of delivery of cells to the channel surface and
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Figure 4.6 Real-time PCR amplification plots for the slt1 gene using RT qPCR with a master
mix containing different concentrations of Cellstripper™ in standard samples (indicated with
arrows in the figure). The protocol involved a three-step cycle: (1) 10 min at 95 °C, 46 cycles; (2)
30 s at 95 °C, 60 s at 58 °C; and (3) 60 s at 72 °C. The PCR products were observed in realtime using a SYBR Green dye.

is flow rate dependent with this rate increasing with linear velocity, and (ii) the reaction
probability between the surface tethered antibody and the mobile cell antigenic target,
which is dependent on the reaction kinetics between the antigen/antibody complex with
this probability decreasing at high linear velocities.17 Therefore, the observed optimal
linear velocity (∼5 mm s-1) results from a balance between the reaction kinetics and the
encounter rate.
Capture efficiency decreased with increasing channel width as well 17,18 (see
Figure 4.7B). We evaluated the recovery of E. coli cells using channels with variable
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Figure 4.7 (A) Capture efficiency data of E. coli O157:H7 as a function of the cells‘
translational velocity using the microfluidic chip shown in Figure 4.1. The number of captured
cells was determined via real-time qPCR. (B) Cell capture efficiency as a function of the channel
width using a translational velocity of 5 mm s-1. Channels used contained a variable width (10,
20, and 30 μm) but the same depth (30 μm) and length (3 cm). (C) Standard curves for the realtime, qPCR analysis of E. coli O157:H7 using slt1 (filled squares) and uidA (filled circles) genes.
Ct values of known samples were plotted against the corresponding cfu of the bacteria. The
linear regression analysis for slt1: y=-3.456log(x)+37.12 (r2=0.997) and uidA: y=3.373log(x)+40.99 (r2=0.996). (D) A fluorescence agarose gel image of the 252 bp and 348 bp
PCR products for uidA and slt1 genes, respectively. The amplicons were generated with 10×
103 cfu/reaction of the E. coli O157:H7 serotype.

widths but the same depth (30 μm) and length (3 cm) and cells flowing at 5 mm s-1
linear velocity. We observed much higher recoveries for narrower channels as opposed
to wider channels (68%±2%, 49%±2%, and 18%±5% for channel widths of 10, 20, and
30 μm, respectively). We previously demonstrated that cell recoveries are maximized
when the channel width approaches the average cell diameter.17 Unfortunately, we were
limited by the micromachining technique employed here to a channel width of 10 μm,
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but the use of narrower channels will most likely increase the recovery by increasing the
number of cell/wall contacts. Narrower channels can be fabricated using optical
lithography to make the molding tool as opposed to high precision micromilling. 34
4.3.7

Cell Enumeration in Water Samples
The selective enumeration of E. coli O157:H7 used real-time qPCR and two sets

of primers targeting the slt1 and uidA genes. Primers for these genes were reported by
Cebula et al.34 and were extensively tested for specificity in comparison to other
serotypes of E. coli. Additionally, we tested these primers with other microbes, some
potentially present in the sample. No PCR products were observed for S. aureus, B.
subtilis, E. aerogenes, M. luteus, or E. coli K12 using the uidA and slt1 specific primers.
PCR products with the size appropriate for the particular gene being interrogated for E.
coli O157:H7 were observed (see Figure 4.7D).
Calibration curves for E. coli O157:H7 were generated using serial dilutions of
standard E. coli O157:H7 cell suspensions between 1 cfu and ∼3×106 cfu (see Figure
4.7C) in samples containing 100 mL of water. The linearity between the C t values and
the number of target cells was observed over 5 orders of magnitude (r2≥0.996). The
slope of the calibration curve, which is directly related to the average amplification
efficiency throughout the cycling reaction (efficiency) 10(-1/slope)-1), was found to be 3.593±0.231, yielding a 98.5±1.7% efficiency (n) 5) for slt1, and -3.616±0.372, for an
89.2± 2.4% efficiency (n=5) for the uidA gene. The limit-of-detections (expressed as the
amount of cells detected in the 100 mL sample at least 95% of the time) were calculated
to be 6 cfu for the slt1 gene and 10 cfu for the uidA gene. Similar or higher real-time
qPCR limits-of-detections were reported.35
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Plots of the real-time normalized fluorescence intensity as a function of cycle
number for the slt1 gene for different cell numbers are presented in Figure 4.8A. The
analysis of dissociation curves, plotted as the first derivative of the reference dyenormalized fluorescence intensity reading multiplied by –1(–Rn´(T)), as a function of
temperature displayed one population with a transition temperature of 80-82 °C,
indicating the presence of only a single PCR product of the anticipated sequence
content (see Figure 4.8B). Standard curves were generated using serial dilutions of
standard E. coli O157:H7 cell suspensions ranging from 1 cfu to ~10 6 cfu per reaction
for both slt1 and uidA genes. The linearity between the Ct values and the number of
target cells was observed over five orders of magnitude. The Ct values of the known
standards were plotted versus logarithm of the cell count for each standard, creating
calibration curves from which the unknown concentrations were determined.
Control samples (single blinded studies) were also evaluated in which E. coli
O157:H7 samples were spiked at levels of 30-800 cfu per 100 mL input. This data was
used to construct a calibration plot of Ct versus log (cell density, see Figure 4.7C). For
example, the number (n=3) of E. coli O157:H7 cells determined from the calibration plot
was 34±4 (RSD of 12%) at the 30 cfu spike level. At a 400 cfu spike level, the average
cell count for the assay was 405±5 with an RSD of 1.2%. A blank sample was also
analyzed, and no E. coli O157:H7 was detected.
We next evaluated the microchip/real-time qPCR assay to assess the quality of
different water samples. These samples consisted of samples from two lakes and sewer
water from a purification plant in Baton Rouge. We should also note that E.coli obtained
directly from the 0.1 μm filter and tested via realtime qPCR without processing in the
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Figure 4.8 (A) Amplification plots for the slt1 gene using real-time qPCR for serial dilutions of E.
coli O157:H7 (6 – 60×103 cfu/reaction). (B) Dissociation curves for amplicons obtain in (A). The
PCR protocol used involved a three-step procedure: (1) 10 min at 95 °C; 46 cycles consisting of
(2) 30 s at 95 °C, 60 s at 58 °C, 60 s at 72 °C; and (3) 81 cycles of ramping the temperature
between 55 and 95 °C (0.2 °C s-1).

microchip produced failed PCR results due most likely to the presence of potential PCR
inhibitors that were removed in the fluidic chip following cell selection and rinsing.
In the Lake Granbury sample, the total E. coli levels were detected at 5 cfu 100
mL-1 and E. coli O157:H7 serotype at 4 cfu 100 mL-1. Water from University Lake in
Baton Rouge was evaluated only for the total E. coli level using EPA Method 1603 and
was determined to be 15 cfu 100 mL-1 (see Figure 4.9A). After performing the assay
using the microfluidic chip, we determined that for both of these water samples, the
level of E. coli O157:H7 was below the limit of-detection. This is understandable given
the fact that the recovery is 72%, and therefore, the approximate numbers of E.coli
O157:H7 from Lake Granbury would be ∼3 cells, which is below the limit-of-detection
for both the slt1 and uidA genes.
Next, we evaluated wastewater samples using EPA Method 1603 and found E.
coli levels of 2.6×106 cfu 100 mL-1 (see Figure 4.9B). In wastewater samples, we
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Figure 4.9 E. coli colonies formed on the modified mTEC agar surface. The E. coli colonies are
respresented as dark spots. (A) Baton Rouge Lake water, filtered volumes: a – 100 mL sample,
b – 25 mL, c – 10 mL, d – 5 mL, e – 0.1 mL, f – blank. The membrane filter in sample (a) was
used to calculate the number of colonies of E. coli per 100 mL of water. The E. coli
concentration was calculated as (# colonies/volume processed)×100. (B) A waste water sample
processed using the mTEC agar surface; volumes processed: a – 1 mL; b – 0.1 mL; c – 0 mL
(blank). The membrane filter in sample b has the acceptable number of colonies to calculate the
number of E. coli per 100 mL of waste water.

detected 0.96×106±0.2 cfu 100 mL-1 of E. coli with the serotype O157:H7. Also, we
calculated the cell capacity of the microchip selection beds possessing a surface area of
40 mm2, and this value was determined to be 260×106 cells. Thus, the level of cells
collected from the wastewater sample is well below the saturation limit.
4.3.8

Cellstripper™ Effects on Real-Time Quantitative PCR (RT qPCR)
The effect of the non-enzymatic cell dissociation solution on the efficiency of RT

qPCR was investigated. The amplification plots of baseline-corrected, reference dye108

normalized fluorescence (dRn) as a function of the cycle number for the slt1 gene for
different concentrations of Cellstripper™ with different cell numbers are presented in
Figure 4.6A-D. Typically, the reproducibility of qPCR assays determining cell numbers
from multiple runs in the absence of the Cellstripper solution was observed to be 2-10%.
Based upon these results, variabilities between the Cellstripper and no Cellstripper
qPCRs of ≤5% for concentrations of Cellstripper™ up to 10% in the RT qPCR cocktail
were concluded to not significantly affect these results (see Figure 4.6B).
4.4 Conclusions

I demonstrated the ability to select and quantitatively enumerate the E. coli
O157:H7 serotype free from other serotype interferences, which is important due to the
large number of E. coli types and the O157:H7 serotype health-related issues. The
strategy developed offered the ability to monitor water quality without the need for a
time-consuming cell culture step. I also showed the ability to recover cells with ∼72%
efficiency from 100 mL input volumes with the real-time qPCR step providing a limit ofdetection of 6-10 cfu. The entire series of processing steps can be implemented in
under 5 h, and this could significantly be reduced by transitioning more of the
processing steps to the chip. For example, increasing the throughput of the fluidic chip
through the use of more fluidic vials that are deeper can provide the opportunity to
process 100 mL of input directly without the need for the intermediate 0.1 μm filtering
step. In addition, moving the real-time qPCR step to the chip can also reduce
processing time significantly due to the more efficient thermal management properties
of microscale PCR.36
The microchip enrichment procedure provided the following advantages: (i) the
enrichment step can recognize O157 types in intact and virulent cells and in stressed
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and nonculturable cells; (ii) cells enriched on the chip can be isolated from potential
contaminants that can interfere with nucleic acid-based analysis; and (iii) the chip can
preconcentrate cells to a detectable level with an enrichment of 2×102 in its current
rendition. I envision the potential to probe for a large number of different strains of
enterohemorrhagic E. coli, which includes more than 100 different non-O157 strains.3739

By proper choice of pAbs and specific probes for the real-time qPCR, one could

monitor a large panel of suspected E. coli strains from a single sample.
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CHAPTER 5 HIGH-THROUGHPUT SELECTION,ENUMERATION, ELECTROKINETIC
MANIPULATION, AND MOLECULAR PROFILING OF LOW-ABUNDANT
CIRCULATING TUMOR CELLS USING A MICROFLUIDIC SYSTEM
5.1 Introduction

Colorectal cancer (CRC) accounts for nearly 1,000,000 new cases and 550,000
deaths worldwide each year; it is the fourth most common form of cancer in the United
States and the third leading cause of cancer-related deaths in the western world.1
Diagnostic and/or prognostic tests of CRC consist primarily of looking for bleeding in the
stool (fecal occult blood test, FOBT) and/or endoscopic examinations of the colon
and/or rectum. While FOBT has reduced mortality rates by 15-33% over the last 30
years, FOBT is more sensitive for the diagnosis of invasive cancer than it is toward
advanced adenomas or early-stage lesions.2 On the other hand, endoscopic
examinations, such as colonoscopy or flexible sigmoidoscopy, can detect early stage
lesions but misses proximal lesions when the distal colon is examined. Even in cases
where both stool samples and endoscopy are employed, 25% of cases are expected to
be missed.3
In cancer patients with either metastatic or localized disease, there is growing
evidence that the presence of circulating tumor cells (CTCs) in the blood may be an
important indicator of the potential for metastatic disease and thus, poor prognosis. 4
Various epithelial-based cancers are known to release CTCs into circulation for
example breast, bladder, prostate, lung, colorectal, cervical, and pancreatic cancers.
The attractive attribute associated with CTCs is their ease of securing the sample; a
simple blood draw (~7.5 mL) can be used to allow for the selection and enumeration of
these cells.5 CTCs can provide valuable clinical information as well, such as early
diagnosis of relapse, monitoring the effectiveness of adjuvant therapy and serving as an
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independent prognostic factor. For example, while surgical resection of the diseased
tissue in conjugation with chemotherapy is seen as an effective mode of treatment for
highly localized CRC diseases, 30-50% of these patients ultimately experience
recurrence and die.6
The high rate of recurrence for CRC could be due to heightened levels of CTCs
in peripheral blood following surgery; indeed elevated levels of CTCs were found postoperatively for CRC patients.7 Finally, tumors contain genetically heterogeneous cell
subpopulations with different propensities to spawn metastatic disease and therefore, if
the CTC population responsible for metastasis could be identified through unique
genetic profiles, oncologists could match proper therapy to the individual patient. 8
Early results for CTCs as a biomarker for CRC have been somewhat
controversial due to the proximity of the colon to the liver, which can act as a filter to
remove malignant cells. In spite of this controversy, promising results have appeared in
the literature.9 For example, progression free survival and overall survival for metastatic
CRC patients with less than 3 CTCs per 7.5 mL of peripheral blood was significantly
longer than those with CTC numbers >3 per 7.5 mL of blood. In addition, the diversity of
targeted therapies is often times hampered by the acquisition of solid biopsy samples
and the use of CTCs has been demonstrated to serve as an important, noninvasive
biomarker for pharmacodynamic assessment of new treatment regimens for CRC. 5
The challenge in any platform directed towards the isolation and preconcentration of low abundance cells begins with the selection of the target cells from a
heterogeneous population in which the target is a minority. However, technological
advances have now facilitated the selection, enumeration, and characterization of CTCs
using methods such

as PCR,10 flow cytometry,11 image-based immunologic
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approaches,12 immunomagnetic techniques,13 and microchip technology.14 The FDA
accepted modality for CTC selection has been the use of the Veridex CellSearch™
system, which uses magnetic beads coated with monoclonal antibodies directed against
the epithelial cell adhesion molecule, EpCAM. The processed sample is incubated with
ferromagnetic

particles

coated

with

anti-EpCAM

antibodies

and

the

immunomagnetically-labeled cells are isolated by an external magnetic field. A rigorous
evaluation of the performance metrics associated with the CellSearch™ system has
indicated that the CTC recovery is ~85%.4 Challenges with this technology are the low
throughput (8 samples per day) it affords and the high cost per assay. 15 In addition,
once selected, the cells must be extracted from the isolation cassette and placed in the
imaging station for enumeration. This requires the vessel containing the cells to be
opened to the environment, which can run the risk of contamination, especially in a
centralized laboratory where many samples are processed.
Microchip technology has the potential to select with high recoveries, enumerate,
and characterize rare CTCs in cancer patients, which will provide opportunities for
identifying the potential for metastatic disease at very early stages, managing risk
stratification in the adjuvant setting, monitoring response to treatment, identifying
disease recurrence, and the prospective development of targeted therapies based on
molecular characterization of CTCs (i.e., personalized medicine). For example, Nagrath
et al. developed a microfluidic device for selecting CTCs directly from peripheral
blood.16 The CTCs originated from a variety of epithelial-based tumors and were
selected through the use of anti-EpCAM monoclonal antibodies tethered to a fluidic
channel containing 78,000 microposts. Anti-EpCAM monoclonal antibodies provided the
specificity for CTC selection from unfractionated blood because EpCAM is
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overexpressed only by adenoma carcinomas. The potential utility of this CTC chip in
monitoring response to anti-cancer therapy was also investigated.16 RT-PCR analysis of
the selected CTCs indicated the opportunity for CTC-based molecular analyses.
Adams and Dharmasiri et al. generated a polymer–based fluidic device for the
high-throughput and high recovery selection and enumeration of CTCs directly from
peripheral blood using either anti-EpCAM antibodies or PSMA-specific aptamers as the
molecular/cellular recognition elements.17,18 The cells were selected directly from whole
blood in less than 40 min of processing time with recoveries exceeding 90%. In addition,
the selected CTCs could be released from the capture surface and counted
quantitatively using a contact conductivity sensor.
Unfortunately, the aforementioned work did not perform any type of molecular
analyses on the selected CTCs with the selected CTCs simply dumped to waste
following their selection from whole blood. Molecular profiling of CTCs can provide
important clinical information that cannot be garnered simply by enumerating the
selected cells. As noted, mutations in certain gene fragments carried by CTCs can be
used to guide therapy and provide opportunities for personalized treatment of a patient.
In the case of colorectal cancer (CRC), patients with mutated K-ras oncogenes do not
benefit from anti-EGFR mAB therapy, whereas patients with wild-type K-ras genotypes
do benefit from cetuximab and panitumumab-based treatments.20 Yang and coworkers
recently found that 90% of metastatic CRC patients had a K-ras mutational status of
CTCs similar to the primary tumor as determined by genotyping mRNA surrogates. In
addition, it has been noted that non-tumor epithelial cells can also be present in the
blood and express antigens that would select these cells. Therefore, to discern
differences between CTCs and normal epithelial cells shed into peripheral blood,
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molecular profiling is necessary.21 The significant challenge with genotyping gDNA from
mass-limited samples, such as CTCs isolated from cancer patients, is the small copy
number of the assays input material. Indeed, most studies in which molecular profiling
has been invoked on CTCs, in particular CRC, has focused on using reverse
transcription

PCR

with

mRNA

surrogates

to

record

gene

activity

or

the

presence/absence of mutations due to the higher copy number of the transcripts
compared to the gDNA.22 Therefore pre-concentration of the selected CTCs in a
microfluidic for subsequent molecular profiling is crucial for detecting low copy number
gDNA mutations.
Many techniques exist to physically manipulate and pre-concentrate cells such
as blood, tumor and bacterial cells using microfluidics including optical tweezers,23
acoustic forces,24 magnetic forces, electromagnetic fields, dielectrophoresis (DEP) and
surface modification.25 Magnetoquasistatic fields have been used to manipulate cells
either due to their intrinsic magnetizability, such as the iron found in red blood cells, 26 or
by attaching magnetic materials to the cells for magnetically activated cell sorting.27 The
resulting force is due to the interaction of a magnetic dipole with a non-uniform magnetic
field and is known as magnetophoresis. Magnetophoresis has the important attribute of
being highly specific because the vast majority of material does not respond strongly to
magnetic fields. The drawback is that the technique requires a label (except for red
blood cells). Electromagnetic fields are the most general case and are commonly used
to manipulate particles when used as optical tweezers.28 At low frequencies or in
systems that are small compared with the wavelength of the field, the electric and
magnetic components of the electromagnetic field decouple and one will dominate.23
Optical tweezers typically are able to handle only one or a few cells at once. DEP
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systems are less suitable due to potentially cytotoxic buffers and/or high temperatures
induced by Joule-heating.29,30
Overall, cell manipulation techniques thus far are rather inefficient with the
efficiency, defined as the ratio of the number of cells successfully collected to the total
number of input cells, is only 10-20%.31,32 The low efficiency may not be a problem in
many cell assays, but it is a concern when working with cell-limited samples, such as
the case with CTCs. To address these limitations, a family of emerging technologies,
such as microfluidic, and electrophoresis, can be combined for CTC handling with the
potential for high-throughput processing with efficient collection of the target cells for
molecular profiling. Electrophoresis has already been demonstrated for the manipulation
of biological particles, such as cells, bacteria and viruses.30 Electrophoresis is based on
the intrinsic electrical properties of the particles being manipulated and does not require
a label, thus it can potentially be more universal and simpler to implement. The small
volume liquid handling capability of microfluidic chips should also permit the
manipulation of only a few cells within a network of channels with highly efficient
recovery.
Detecting mutations in cancer patients can be difﬁcult due to the highly variable
nature of the cancer cells in terms of their mutational status with respect to the stage of
tumorigenesis and the location and proximity of the sampling site with respect to the
primary tumor site.32,33 The success and accuracy of genotyping many cancers, such as
CRC, depends on the ability to detect low copy numbers of mutated sequences in a
vast majority of wild-type DNA. However, through the use of a microfluidic device that
can enrich low-abundance CTCs from a mixed-population and recover them with high
efficiency and their subsequent release can provide effective molecular profiling results
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from low-copy number inputs and alleviate the problem of large wild-type DNA
backgrounds.
Ligase detection reaction (LDR) coupled to a primary PCR can be used to
identify extremely low abundant mutant DNA due to the double amplification steps the
assay employs, even when implemented in a multiplexed fashion. 33 Following PCR
ampliﬁcation of the appropriate genes containing the loci of interest, the amplicon is
mixed with two complementary primers (a common primer and a discriminating primer)
that ﬂank the mutation locus of interest. The discriminating primer contains a base at its
3‘ end that coincides with the single-base mutation site being interrogated. Facilitated by
a highly speciﬁc thermally stable ligase, the allele-specific LDR primers become
covalently ligated to adjacent fluorescently labeled primers to form an LDR product if
and only if the nucleotide at the potential mutation site is complementary to the 3‘ end of
the discriminating primer. This LDR can then linearly amplify the products during
subsequent thermal cycles. The ﬂexible design of the primers used for the LDR assay
has allowed for the detection of successful ligation events via a variety of analytical
formats,34 such as low-density DNA microarrays,35 high-resolution electrophoresis,36
and spectroscopic techniques employing ﬂuorescence resonance energy transfer.37-39
In this report, we describe a microfluidic electrokinetic micromanipulation method
for the selection and electrokinetic collection of low-abundance CTCs affinity-selected
from whole blood for subsequent molecular profiling of point mutations in the gDNA of
the CTCs. The electric field strength and hydrodynamic flow velocity were optimized for
the effective collection of CTCs released from the surface containing antibodies specific
to the CTCs. The CTCs were directed into a reservoir (2 µL) for molecular interrogation
of potential point mutations within their gDNA. Finally, the optimized system was
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integrated to a micro-scale high-throughput microsampling unit (HTMSU) for CTC
selection and enumeration directly from whole blood. We recovered SW620 cells, a
CRC cell line used as a model, following seeding into peripheral blood. The selected
cells were enumerated using an on-chip conductivity sensor and the enumerated cells
directed into a reservoir for pre-enrichment. The enriched CTCs were lysed and their
DNA was extracted for genotyping gDNA for potential K-ras mutations. Because most
K-ras mutations are localized to codon 12 and to a lesser extent, codons 13 and 61, the
PCR/LDR assay was performed on codon 12 of the K-ras oncogene to detect the
presence/absence

of

point

mutations

possessing

clinical

relevance

for

the

diagnosis/prognosis of colorectal cancers.
5.2 Materials and Methods
5.2.1

Reagents and Cells
PMMA substrates and cover plates (0.5 mm thickness) were purchased from

Good Fellow (Berwyn, PA). Platinum wires were purchased from Alfa Aesar (Boston,
MA). Polyimide-coated fused silica capillaries were purchased from Polymicro
Technologies (Phoenix, AZ). Chemicals used for the PMMA surface cleaning and
modification included reagent grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl]
carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum and
2-(4-morpholino)-ethane sulfonic acid (MES) and these were purchased from SigmaAldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody was obtained from R & D
Systems (Minneapolis, MN). The SW620 (colorectal cancer cell line), growth media,
HEPES buffer, phosphate buffered saline (PBS) and trypsin were purchased from
American Type Culture Collection (ATCC, Manassas, VA). Citrated rabbit blood was
purchased from Colorado Serum Company (Denver, CO). Tris-Glycine buffer was
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obtained from Bio-Rad Laboratories (Hercules, CA). All solutions were prepared in
nuclease-free water, Invitrogen (Carlsbad, CA). Nuclease-free microfuge tubes were
purchased from Ambion (Foster City, CA) and were used for preparation and storage of
all samples and reagents. A fluorescein derivative, PKH67, was purchased from SigmaAldrich. Oligonucleotide probes and primers were obtained from two different sources,
Integrated DNA technologies (Coralville, IA).
5.2.2

Cell Culturing
SW620 cells were cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s

Medium supplemented with high glucose containing 1.5 g L -1 sodium bicarbonate
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper solution
was prepared in 150 mM PBS and was used to harvest the SW620 and HT29 cells from
the culturing plate. SW620 cells were stained with PKH67 for microscopic visualization
experiments using fluorescence microscopy. A modified protocol for cell staining was
implemented whereby the dye concentration was increased twofold resulting in more
evenly distributed fluorescent labels over the cell‘s periphery. Cell counts were
determined by counting three aliquots of cells in succession using a hemacytometer.
The cell count accuracy was within 10%.
5.2.3

Microscopy
In cases where the cells required optical visualization to assist in the operational

optimization of the CTC selection, enumeration and manipulation assay, the PMMA
devices were fixed onto a programmable motorized stage of an Axiovert 200M (Carl
Zeiss, Thornwood, NY) inverted microscope and video images were collected during
each experiment at 30 frames s-1 using a monochrome CCD (JAI CV252, San Jose,
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CA). A Xe arc lamp was used to excite the fluorescent dyes incorporated into the cells‘
membrane.
5.2.4

Fabrication of HTMSU
The HTMSU and electro-manipulation unit were hot embossed into PMMA

substrates via micro-replication from a metal mold master. Fabrication of the HTMSU
followed steps previously reported.17 The HTMSU consisted of a series of 51 highaspect ratio curvilinear channels that in concert formed the cell selection bed. Each
channel was 150 µm (depth)×30 µm (width) and shared common inlet/outlet ports
(Figure 5.1A). Curvilinear-shaped capture channels were used to improve the cell
capture efficiency as described previously.17,18 The cell-free marginal zone apparent in
straight channels was not observed in curvilinear channels and the cell radial
distribution was unaffected by changes in cell translational velocity. Cells migrate to the
outside of the curved channels due to centrifugal forces acting on the cells and the
cross-stream velocity component due to the reversal of the direction of curvature. 17 The
result is an increase in the antibody/antigen encounter rate as the cells moved through
the capture beds at the relatively high-linear velocities used here, which resulted in high
recoveries of the CTCs. The channel width of the cell selection bed (30 µm) was
comparable to the average target cell diameter, which was used to increase the
probability of cell–antigen interactions with the solution-borne target cells. The large
channel depth (150 µm) was selected to reduce the pressure drop in high-volume flow
rate operation and also to increase sample processing throughput.
The electro-manipulation unit possessed one entry, through (a), (see Figure 5.1A)
and two exits, via (b) and (c). Entry (a) was connected to a T intersection labeled (e) in
Figure 5.1A. All of the channels were rectangular in shape with dimensions of 50 µm×
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100 µm, width and depth, respectively. Before final assembly, 1 mm holes were drilled
into the electro-manipulation unit for reservoirs, input port and electrodes. Then, the
electro-manipulation unit chips were washed with ~0.5% Alconox solution, rinsed and
ultrasonicated with DI water followed by rinsing with 2-propanol, and again
ultrasonication for 15 min in DI water. The channels were examined under a microscope
to ensure they were not filled with debris.
Appropriately cleaned HTMSU substrates and cover plates were exposed
through a mask to UV radiation resulting in surface photooxidation only in the exposed
areas of the PMMA. The exposed areas were restricted to only the cell selection region
of the device. UV irradiation was performed through an aluminum mask for 10 min at 15
mW cm-2 to facilitate the formation of the activated surface, which also included a
carboxylic acid scaffold.18
Pt electrodes (d=76 µm) served as the contact conductivity sensor in the
detection zone of the HTMSU and were placed into guide channels that were positioned
orthogonal to the fluidic output channel following thermal assembly. Then, Pt wires
positioned in the HTMSU and the cover plate were aligned and clamped together
between two borosilicate plates. Insertion of the electrodes was monitored using a
microscope to carefully control the inter-electrode gap (~50 µm). The cell constant of
the Pt conductivity sensor, K, was ~0.01 µm-1, which allowed for the specific detection of
SW620 cells based on their average size (diameter≈23 µm).17
The embossed devices were assembled by heat annealing a cover plate made
from the same material to the substrate. The cover plate and substrate were clamped
together and placed in a convection oven for ~20 min at 101 °C for the UV-modified
HTMSU and 105 °C for pristine PMMA electro-manipulation unit. After successful heat
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annealing, 125 µm diameter Pt wires/electrodes wrapped Cu electrodes were placed
into the drilled holes in the electro-manipulation unit.
5.2.5 Antibody Immobilization to the HTMSU
Antibody immobilization was carried out in a two-step process. The UV-modified
thermally assembled HTMSU device was loaded with a solution containing 4 mg mL -1
EDC, 40 mg mL-1 NHS in 150 mM MES (pH = 6) for 1 h at room temperature to obtain
the succinimidyl ester intermediate. After this incubation, the EDC/NHS solution was
removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0 mg
mL-1 of the monoclonal anti-EpCAM antibody solution contained in 50 mM PBS (pH=
7.4) was introduced into HTMSU and allowed to react for 4 h. The device was then
rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound antiEpCAM antibodies.17
5.2.6

SW620 Cell Capture/Release and Enumeration Using the HTMSU

To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV) was
placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix,
AZ). This was then attached to the capillary that was sealed to the input port of the
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s -1
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell
suspension was introduced at the 27.5 µL min-1 (2 mm s-1) volumetric flow rate, which
was optimized by Adams et al.17 Next, a post-capture rinse was performed with 0.2 mL
of 150 mM PBS at 50 mm s-1 to remove any non-specifically adsorbed cells.
Following a post cell capture rinse, a 0.25% trypsin solution in 0.2 mM Tris/19.2 mM
Glycine buffer (pH=8.3) was infused into the HTMSU. The captured cells could be
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observed using a microscope until they were enzymatically removed with Stoke‘s forces
acting on the cells as well to facilitate release.
5.2.7

Electrokinetic Cell Manipulation
The released cells from the cell selection surface were subjected to electrokinetic

cell manipulation after the enumeration. The released cells from the selection surface
were traversed into the electro-manipulation unit at 1 µL min-1 (3.3 mm s-1) transport
rate from inlet (a) (see Figure 5.1A). The electric field was applied between (b) and (c)
reservoirs in the electro-manipulation unit when the buffer solution containing cells were
introduced from the inlet reservoir.
The programmable high voltage power supply was assembled in-house. The unit
consisted of 4 individual power supplies (Model UR5PN, Matsusada Precision Inc.,
Santa Clara, CA) capable of delivering -5 to +5 kV. Each power supply was equipped
with an independent Reed relay (Model RR1A07P06, Ross Engineering Corporation,
Campbell, CA) that was used to toggle the polarity, ground, and floating states of the
power supply. The power supply was computer controlled with a 4 channel 12 bit digitalto-analog board (Model CYDDA 04P, CyberResearch Inc., New Haven, CT) with
peripheral component interface (PCI) and software written in Labview (National
Instruments, Austin, TX). All experiments were carried out at room temperature. Caution:
The electrophoresis uses high voltages and special care should be taken when handling
the electrodes.
Cell migration velocities in the present study were calculated by measuring
consecutive cell events observed in the video, which had a frame capture rate of 30
frames s-1. The average velocity was based on values obtained from 5 different cell
events.
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5.2.8

Measurement of the Electroosmotic Flow (EOF)
The EOF in assembled devices was measured using the method described by

Zare and co-workers.40 EOF values in 0.2 mM Tris/19.2 mM Glycine buffer (pH=8.3)
and 0.25% trypsin in 0.2 mM Tris/19.2 mM, Glycine buffer (pH=8.3) were calculated.
The procedure involved filling the entire chip with a 0.2 mM Tris and 19.2 mM Glycine
buffer. After filling, one reservoir was emptied and filled with the same type of buffer, but
of lower ionic strength (0.2 mM Tris/19.2 mM Glycine). An electric field (100 V cm-1) was
applied to the reservoirs containing the low and high ionic strength buffers. The current
was monitored continuously using a strip-chart recorder (Kipp and Zonen Inc., Bohemia,
NY). The time needed for the current to reach a plateau was measured from the plot
and the linear velocity calculated. Dividing the linear velocity by the electric field
strength produced EOF values (cm2 V-1 s-1). The electric field was supplied by a
Spellman high-voltage power supply (CZ1000R, Plainview, NY). The electroosmotic
flow measurements were carried out on pristine PMMA microchips. Electroosmotic
mobility data were obtained at room temperature. Each data point was the average of
five measurements.
5.2.9

DNA Extraction from SW620 Cells
Genomic DNA (gDNA) was extracted from CTCs using Lyse-and-Go PCR

reagent (Pierce Biotechnology, IL, USA). Following manufacturer‘s recommendations, 5
µL of Lyse-and-Go PCR reagent was added to the selected CTCs and thermocycled
using the following temperatures: 65 °C for 30 s; 8 °C for 30 s; 65 °C for 90 s; 97 °C
for 180 s; 8 °C for 60 s; 65 °C for 180 s; 97 °C for 60s; 65 °C for 60 s. Prior to the
addition of the PCR cocktail, the samples were placed at 80 °C.
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5.2.10 PCRs, LDRs, Gel Electrophoresis and Capillary Electrophoresis

PCR ampliﬁcations were carried out to generate 300 bp amplicons from SW620
CTCs using the gene-speciﬁc primer sequences: exon 1 forward –5‘ TTA AAA GGT
ACT GGT GGA GTA TTT GAT A 3‘, (Tm=55.4 °C ) and exon 1 reverse – 5‘ AAA ATG
GTC AGA GAA ACC TTT ATC TGT 3‘(Tm=56.3 °C). Forty-five µL of PCR cocktail
consisting of 10 mM Tris–HCl buffer (pH=8.3) containing 50 mM KCl, 1.5 mM MgCl2,
200 µM dNTPs, 0.4 µM of each forward and reverse primers was added to the lysate
previously held at 800C in the thermocycler. After a 2-min initial denaturation, 1.5 U of
AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) was added
under hot-start conditions and ampliﬁcation was achieved by thermally cycling for 30
cycles at 95 °C for 30 s, 60 °C for 2 min, and a final extension at 72 °C for 3 min.
To test the fidelity and yield of the PCR, slab gel electrophoresis was run on an
aliquot of each reaction. From each aliquot, either 2 µL PCR product for standard cell
solutions or 3 µL PCR product from microchip processed solutions was mixed with 1 µL
loading dye and 3 µL of 1x TBE buffer for the standard cell solution or 2 µL of 1x TBE
buffer for a microchip-processed solution. The mixture was then loaded into an
individual well of an ethidium bromide prestained 3% agarose gel (Bio-Rad Laboratories,
Hercules, CA). The slab gel electrophoresis was typically run at 5 V cm -1 for 30 min. The
developed slab gel images were captured using Gel Logic 200 Visualizer (Carestream
Molecular imaging, New Haven, CT)
LDRs were executed in a total volume of 20 µL in 0.2 mL polypropylene
microtubes using a commercial thermal cycling machine (Eppendorf Thermal Cycler
(Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail typically employed
in this work consisted of 10 mM Tris–HCl (pH=8.3), 25 mM KCl, 10 mM MgCl2, 0.5 mM
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NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme), and 0.01% Triton
X-100,

2

µL

of

100

nM

of

the

discriminating

primer:

5‘

AAACTTGTGGTAGTTGGAGCTGT 3‘ (Tm=71.3 °C) and fluorescently labeled freshly
phosphorylated common primer: 5‘ Phos/TGGCGTAGGCAAGAGTGCCT/Cy5.5Sp 3‘
(Tm=63.5 °C) and 2 µL of the PCR product as template. 40 U of Taq DNA ligase (New
England Biolabs) was added to the cocktail under hot-start conditions and the reactions
were thermally cycled 20 times for 30 s at 94 °C and 2 min at 65 °C. The LDR products
were stored at 4 °C until needed for capillary gel electrophoresis (CGE). The LDR
products were separated using a CEQ 8000 Genetic Analysis System (Beckman
Coulter, Fullerton, CA, USA). Data acquisition was performed using the Beckman
P/ACE software.
5.3 Results and Discussion

In the present work, we were interested in the ability to enumerate and enrich
CTCs using a microfluidic system with their subsequent molecular characterization by
looking for point mutations within certain gene fragments. In these studies, the SW620
cell line was used as a model for CTC selection, enumeration, and enrichment via an
integrated HTMSU. SW620 cells over-express the EpCAM membrane antigen and
harbor K-ras c12.2V oncogene mutations. Circulating colorectal cancer cell line, HT29,
which do not harbor K-ras c12.2V oncogene mutation, was used as the wild-type for
comparison. SW620 and HT29 cells are typically 15-30 μm in diameter (Avg≈23 μm)41
and EpCAM occurs at a frequency of 1×106 and 2.5×105 molecules per cell,
respectively.42 In the work presented herein, we focused on: (1) The selection and
enumeration of low-abundance SW620 cells from peripheral blood; (2) release of the
cells from the antibody selection surface; (3) electrokinetic enrichment of the selected
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SW620

cells;

and

(4)

molecular

profiling

of

low-abundance

cells

using

a

PCR/LDR/electrophoresis assay (see Scheme 5.1). Release of the cells intact is critical
because the enumeration process depends on counting via conductivity whole cells and
the molecular profiling is performed on rare cells selected from peripheral blood and as
such, the genetic material to be analyzed should not be diluted extensively or mixed
with potential interfering materials.

Scheme 5.1 Overview for the cell selection, enumeration, electrokinetic enrichment and
molecular profiling strategy adopted for analysis of extremely low-abundant SW620 cells
resident in peripheral blood.
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5.3.1

SW620 Cell Selection
The highly specific selection of SW620 CTCs was based on the recognition

capabilities of anti-EpCAM antibodies that were tethered to the HTMSU selection beds.
Dynamic interactions between the CTC membrane‘s receptors and the channel wall
containing the recognition elements are important in determining the recovery of these
rare CTCs from blood. Curvilinear-shaped channels were employed to provide high
recovery.17 As such, the cell-free marginal zone apparent in straight channels was not
observed in these curvilinear channels and the cell radial distribution was unaffected by
changes in cell translational velocity.17 Chang‘s model of cell adhesion in flowing
systems has been applied in previous reports to describe the encounter rate between
the solution-borne cells and the surface-tethered cell selection elements.43 Therefore,
an optimal linear velocity would be expected to guarantee a high probability of binding
between the target molecules and the antigen based upon a balance between the
interaction time and the encounter rate. The optimum linear velocity for selection of
MCF-7 CTCs, which has the same mean diameter as SW620 CTCs, using EpCAM/antiEpCAM antibodies (KD=3.3×108 M-1)44 was found to be 2.0 mm s-1. Thus, according to
the Chang and Hammer model for cell adhesion, efficient CTC/mAb adhesion was
determined by two factors; the encounter rate (ko) and the probability (P) of interaction
between the membrane bound antigen and the channel wall‘s tethered antibody. 43 As
such, MCF-7 and SW620 CTCs should have a similar optimum linear cell selection
velocity of 2 mm s-1, which we employed in these experiments for the selection of
SW620 CTCs. The selected cells were observed using fluorescence and brightfield
microscopy as shown in Figure 5.1B. As Adams et al. and Dharmasiri et al. reported
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Figure 5.1 Diagrams of the microfluidic system made via micro-replication into PMMA from a
metal mold master. (A) Cell selection HTMSU. The capture bed consisted of curvilinear 51
channels that were 30 µm wide and 150 µm deep. (Electro-manipulation unit consists of 80 µm
wide, 100 µm deep and 5 cm long linear channels. The solution flow H arriving from HTMSU is
divided at the T junction into a major flow (Heb) and a minor flow (Hec). Conductometrically
enumerated SW620 cells were introduced to system at ‗a‘ entrance port. The ‗a‘ entrance port
connects with b-c channel at the T intersection. ‗b‘ exit is the sample waste reservoir and c exit
is cell reservoir. Both ‗b‘ and ‗c‘ reservoirs host Pt external electrodes; cathode and anode
embedded in sample reservoir, ‗b‘ and waste reservoir,‗c‘, respectively. (B) Brightfield (left) and
fluorescence (right) micrographs (43x) for the positive selection of SW620 cells infused into the
HTMSU at a constant linear velocity flow of 2 mm s-1. The cells were suspended in a whole
blood (100 cells mL-1) and following infusion of the cell suspension, the device was washed with
PBS buffer prior to imaging. In all cases, the entire capture bed was imaged by scanning the
microscope stage. The cells were stained with the fluorescein membrane probe prior to
introduction into the HTMSU to allow visualization. (C) The selected SW620 cells enriched in
the sample reservoir at the end of c channel. Positive Pt electrode is also in the Figure. Total
volume of the reservoir is 2 µL.
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that the CTCs appear to be flattened and elongated upon capture giving better adhesion
between the CTC and selection wall. As observed experimentally (see Figure 5.1B), the
resulting contact area was determined to be 448±18 μm2. The anti-EpCAM antibody
density on the selection bed wall was reported to be 2.3×10 11 molecules cm-2.17
Therefore, 2.4×105 EpCAM/anti-EpCAM antibody interactions were involved in one
cell/antibody binding event. A CTC recovery of 96±4% was found at a translational
velocity of 2.0 mm s-1 under the conditions employed in this study.
5.3.2

Cell Detachment from the Capture Surface
Release of intact CTCs from the capture bed is critical for the subsequent

conductivity enumeration followed by electrokinetic manipulation and molecular profiling
as noted above. Enzymatic digestion of EpCAM and anti-EpCAM was achieved using
the proteolytic enzyme, trypsin. Microscopic investigations (data not shown) revealed
that the average time for release of the captured SW620 CTCs was ~16 min, which was
higher than the values recorded for MCF-7 CTC release (~7 min).17 This difference
could be accounted for by the EpCAM expression level difference between the two cell
lines (MCF-7=5×105 and SW620=1×106 EpCAM molecules per cell).18 Due to the higher
expression level of EpCAM present within the SW620 membrane, higher numbers of
EpCAM/anti-EpCAM interactions must be degraded.
5.3.3

Conductivity Enumeration of the CTCs
The selected and released CTCs were subsequently enumerated using a

conductivity sensor. A typical data streams are shown in Figure 5.2A. The transducer
measured changes in the conductivity of the release buffer with respect to the buffer in
the presence of a single CTC between the Pt electrode pair. It was found that the peak
width for a single CTC was ~150 m s (see inset to Figure 5.2A). Tris-Glycine buffer was
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Figure 5.2 (A) Conductometric responses generated for 1.0 mL of whole blood seeded with 10
SW620 cells (a) 0 SW620 cells (ash) (b) and 32 HT29 (c) at a linear flow velocity of 2.0 mm s -1
processed using the HTMSU. The captured SW620 cells were released from the capture
surface using the release Tris-Glycine buffer comprised of 0.25% w/v trypsin and transported
through the conductivity sensor at a volumetric flow rate of 1 µL min-1. Peaks were identified as
SW620/HT29 cells based on a signal-to-noise threshold of 3. The insets shown in the figure
represent a magnified view of sections of the data stream. The data presented here was
smoothed by the Savitsky-Golay method (25 point smoothing function). The conductometrically
enumerated cell samples were subjected to PCR followed LDR analysis. Two µL of amplicons
from PCR were used for analyzing point mutation in the K-ras gene. The LDR products were
analyzed using capillary electrophoresis. The capillary electrophoresis responses for the sample
after processing blood with no SW620 (B), Sample after processing blood with 50 HT29 cells (C)
and sample after processing blood with 10 SW620 cells (D). Peak ‗a‘ represents the primer and
peak ‗b‘ is the LDR product for SW620.
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selected as the major component in the release buffer due to its low conductance,
which improved the SNR for the conductivity detection of single CTCs. There were 10
peaks observed in the conductance response shown in Figure 5.2A (a) that could be
assigned to SW620 cells based on a SNR threshold of 3 (99.7% confidence level)
giving a recovery and detection efficiency of ~100% in this case (seed level=10 CTCs
mL-1). Enumeration of HT29 cells followed cell capture showed 32 events (seed level=
50 CTCs mL-1) in the conductivity response attributed to HT29 cells as shown in Figure
5.2A (b). HT29 recovery was found to be 72% likely due to its lower EpCAM expression.
The variations in the peak response for CTC was most likely due to differences in the
cells‘ morphology and chemical composition.
One milliliter of a blank sample, which consisted of whole blood seeded with no
SW620 CTCs, was analyzed by the HTMSU and enumeration via conductivity under the
same conditions as described for peripheral blood seeded with SW620 CTCs. The
resultant trace c is shown in Figure 5.2A. In this case, no single-cell spikes were
observed in the conductivity data trace indicating that the signal spikes seen for the
SW620 seeded peripheral blood sample was indeed due to CTCs.
The trace for the SW620 spiked blood sample showed a higher background level
as well as a slight response drift compared to the blank sample. These artifacts may
have been due to non-specific accumulation of dissolved membrane proteins on the Pt
electrode surface. Because these deposits are subjected to Joule effects, the electrode
surface temperature could change during the readout phases of the measurements,
affecting the conductance response.45
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5.3.4

Electrokinetic Enrichment of SW620 Cells
In the electro-manipulation unit, the total flow (H) arriving from the inlet (a) was

divided at the T junction into a major flow (Heb) and a minor flow (Hec) (see Figure 5.1A).
The ratio between Heb and Hec was equal to 9:1, which was set by the pressure drop
ratio (ΔPeb/ΔPec=0.1 at 1 µL min-1) between the two channels. As such, the device was
designed to have only 10% of the hydrodynamic driven input volume from the HTMSU
entering the CTC collection reservoir ((c) in Figure 5.1A). Therefore, 90% of the
hydrodynamic driven fluid would flow into reservoir (b) as seen in Figure 5.3A-C.
To provide efficient pre-concentration of the selected CTCs, we applied an
electric field to specifically select solution-born CTCs from the hydrodynamic flow and
divert them into the collection reservoir (c). As shown in Figure 5.1C, cells were
electrophoretically diverted from the hydrodynamic flow into (c) due to their intrinsic
electrophoretic mobility and the applied electric field, which overcame the force exerted
on the cell by the pressure-driven flow. The volume of reservoir (c) was 2 µL in this case,
providing a 500x enrichment factor for the CTCs (input volume=1 mL). The electric field
applied between (b) and (c) generated an electrokinetic flow. We placed the anode at
the exit reservoir of channel (c) and the cathode at reservoir (b).
According to the Smoluchowski equation, the electrophoretic mobility of cells is
determined by the surface bound charged groups, such as the sialic and carboxylic acid
groups, lysine side chain amino groups, sulfhydryl groups and alkaline phosphatasesusceptible phosphate groups.46 Thereby CTCs possess a net negative surface charge
(Q) at pH=8.3 of;
Q=4 ρ ∏rp2 (1)
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whereas ρ is the charge density, -5.8×10-14 C µm-2,48 and rp is the cell radius, 11.5 µm
for CTCs. Therefore, the average net surface charge (Q) of a typical CTC is
approximately -9.6×10-11 C. Because Q is set by protonation/deprotonation of
membrane-bound proteins and other groups, the CTCs‘ charge can be controlled by
altering the properties of the buffer solution (i.e., pH, ionic strength, salt composition).
This along with the size of the CTC and its zeta potential will determine its
electrophoretic mobility.
The electrophoretic force acting on a particle with a net charge Q under an
electric field strength of V/q is given by;52
FEP=Eq=QV/d (2)
where V is the applied voltage and d is the distance between cathode and anode.
Therefore, the electrophoretic force acting on the cell was calculated to be 9.6×10 -9 N.
In this study we used PBS (50 mM) and Tris-Glycine buffer in preliminary cell
manipulation studies. It was observed that SW620 cells resident in 50 mM PBS were
subjected to lysis at the electric field strength of 100 V cm -1. The cell migration velocity
calculated to be 100±16 µm s-1 at 100 V cm-1 electrical field strength. On the other hand,
utilization of Tris-Glycine buffer (0.2 mM Tris/19.2 mM Glycine) improved the CTC
manipulation conditions dramatically. Tris-Glycine buffer is a lower ionic strength buffer
and it has been found to increase the target cells‘ zeta potentials and mobility. 49 Buffers
of low ionic strength have the additional advantage of minimizing ohmic losses50 and
consequently, heating effects.
In addition, because electrolysis occurs at the electrodes, the buffer must negate
possible changes in pH and maintain a constant charge on the cells being manipulated.
Therefore, the SW620 cells were not found to lyse at 100 V cm-1 throughout the course
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Figure 5.3 Micrographs (43x) showing SW620 cell manipulation in the elecro-manipulation unit.
The SW620 cells resident in Tris-Glycine buffer were introduced from inlet of channel ‗a‘. A, B,
C) The cells are travelling at 1 µL min-1 flow rate. The hydrodynamic flow direction is given in
white arrow. The majority (90%) of the cells are travelling from a-b, which has less pressure
drop (0.7 psi at 1 µL min-1) compared to the pressure drop of a-c (7 psi at 1 µL min-1). D, E, F)
The SW620 cells movement in the presence of electric field strength of 100 V cm -1. The
electrophoretic movement direction of cells is given in red arrow.
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of the cell manipulation and the cell migration velocity was calculated to be 130±15 µm
s-1. This field may cause membrane permeation but did not result in cell lysis. 51 It took
approximately 5 min for the cells to migrate from the T junction to the (c) sample
reservoir. We applied higher electric field strengths to speed up the cell migration rate,
however, an electric field ≥200 V cm-1 resulted in a higher velocity 160±17 µm s-1, but
also extensive cell lysis. We also found that applying an electric field strength of 100 V
cm-1 along with a hydrodynamic flow rate of 1 µL min -1 (linear velocity=3.3 mm s-1) was
sufficient for the CTCs to be effectively collected into (c) reservoir with nearly 100%
efficiency. Figure 5.3 D-F illustrates two cells moving in the direction toward the anode.
Above 1 µL min-1 flow rate, cells were not diverted toward the anode and they
maintained their traveling direction with the hydrodynamic flow towards the waste
reservoir.
For an incompressible Newtonian fluid of low Reynolds number, the fluid motion
is governed by the Stoke‘s equation. In the T junction, The Stoke‘s frictional force on a
charged particle is due to the relative motion of the particle with regard to the EOF and
is given by;52
FStoke’s = -6∏ηrp(Uh+UEOF) (3)
For the present experiments, η the solution viscosity is 7.98×10-4 N s m-2,54 rp is the
radius of the cell, and Uh is linear velocity of the hydrodynamic flow of Heb (3.0×10-3 m s1

), which is the 90% of optimum linear velocity (3.3×10-3 m s-1) for cell manipulation into

reservoir (c). The EOF value for 0.25% w/v trypsin/0.2 mM Tris/19.2 mM Glycine buffer
solution has been determined to be 3.1×10-4±0.23×10-4 cm2 V-1 s-1 at pH=8.3. Therefore,
the linear velocity (UEOF) for corresponding EOF is 3.1×10-4 m s-1. For pristine PMMA,
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the apparent surface pKa value was found to be 4.2, indicative of carboxylic acid
functional groups present on the surface. At pH=8.3, the PMMA surface consists of
negatively charged functional groups producing a cathodic EOF 53 in the same direction
as the hydrodynamic flow of Uh in the e-b section of the channel. The total Stoke‘s force
on the SW620 cell at the T junction was calculated to be 5.0×10-10 N.
At junction T, the electrophoretic force (9.6×10-9 N) is larger than the Stoke‘s
force (5.0×10-10 N) acting on the cell. Therefore, CTCs are diverted into the collection
reservoir (c) (see Figure 5.3D-F). In addition, the linear velocity (U’h) of the
hydrodynamic flow of Hec (3.0×10-4 m s-1), which is the 10% of optimum linear velocity
(3.3×10-3 m s-1) for cell manipulation into reservoir (c) is in opposite direction to the
linear velocity (3.1×10-4 m s-1) of EOF in the e-c section of the channel. As such,
hydrodynamic flow force is cancelled out by the electroosmotic flow in the e-c section of
the channel. The apparent electrophoretic mobility of the SW620 cells was calculated to
be 1.23 cm2 V-1 s-1. This value is closely correlated to the experimental value of 1.30
±0.15 cm2 V-1 s-1.
Chip-to-chip reproducibility of the measured cell flow velocities varied slightly
however, the direction of the cell transport was reproducible from chip-to-chip. For
example, in 3 different PMMA devices, the RSD for the velocities were 10–15%.
It was found that smaller cells moved slightly faster and thus could climb over
the larger cells moving in front, if the centers of the cells were not located on the same
line parallel to the applied electric field. The net charge on the cell also depends on its
mitosis stage and surface area.46 Thus, cells with different negative surface charge
densities migrated at different speeds.
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In preliminary studies, we used channels of 80 µm×100 µm and 50 µm×100 µm
of width and depth, respectively. We observed a near-wall enhancing effect, which was
reported by Xuan et al.55 As such, the cell velocity observed for the 80 µm×100 µm
channel was lower (110 µm s-1±10) at 100 V cm-1 than the velocity observed for 50 µm
×100 µm channels (130 µm s-1±15) at 100 V cm-1. When the particle–wall separation
distance became smaller, the local electric field in the gap became stronger and hence,
the electric force dominated over the viscous friction and the electrophoretic motion
increased. In addition to the translational electrokinetic motion, the spherical particle
also has a rotational motion due to the asymmetry of the electric field and the flow field.
The particle rotational motion was more obvious in the 80 µm×100 µm channels, where
the boundary effect was more dominant.56
Downstream PCR and LDRs required very sensitive analysis of low-abundant
point mutations in the gDNA, and this could be inhibited by the presence of trypsin.
However, we were able to perform PCR/LDR reactions effectively; we noted that the
trypsin did not inhibit PCR/LDR assays. The cell releasing agent, 0.25% trypsin,
possessed a net positive charge at pH=8.3 (pI=10.3).57 Therefore, trypsin migrated
toward the cathode with the EOF facilitating efficient separation of the CTCs and trypsin.
In addition, the surface ―softness‖ (i.e., the rigidity and ion permeability of glycocalices)
may be influenced by trypsin treatment of the CTCs.58 We did not observe significant
variation of the electrophoretic mobility of the CTCs with and without treatment of trypsin
for ~30 min; it appeared that proteases may remove negative charges from the cell
surface but still maintain the electrophoretic mobility.59
Because fluorescence microscopy was used for initial cell visualization, the cells
were fluorescently labeled using fluorescein derivative, fluorescein isothiocyanate
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(FITC), which has a net negative charge at pH=8.3.60 In the cell staining process, FITC
conjugates with membrane lipids could produce more net negative charges on the cell
surface, producing a greater electrophoretic mobility 1.35±0.11 cm2 V-1 s-1 than for cells
that were stained.
From these experiments, we noticed negligible amounts of cell adhesion of the
SW620 cells to the channel walls of the electro-manipulation unit. It was noticed during
device operation that some of the immobilized/adsorbed cells could be removed by
applying higher electric fields. This was partially caused by an increase in the number of
collisions between the flowing and stagnant cells as well as stronger fields that were
able to ‗‗lift‘‘ cells from the polymer surface, suggesting that the adhesion forces of the
cell to the polymer surface were not strong enough to withstand the electric force. We
have observed less cell adhesion for devices with 50 µm×100 µm channel dimensions
compared to those of 80 µm×100 µm dimensions. This effect may arise from higher
frequency of collisions between moving cells and the adhered cells in the smaller
channels.
5.3.5

PCR and LDR Mutation Profiling
A method that can detect single point mutations in DNA is the ligase detection

reaction (LDR) coupled to a PCR (see Scheme 5.1) and this was used to search for
point mutations in the enriched CTCs.35,61-68 Following PCR amplification of the
appropriate gene fragments, which contain sections of the gene with point mutations,
the amplicon is mixed with two LDR primers, a common and discriminating primer that
flank the point mutation of interest. The discriminating primer contains a base at its 3‘end that coincides with the single base mutation site. If bases are mismatched, ligation
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of the two primers does not occur. A perfect match, however, results in a ligation of the
two primers and a product length that is the sum of the two oligonucleotides primers.
In our experiment, enriched CTCs were lysed and the PCR/LDR assay was
performed to search for point mutations in codon 12 of the K-ras gene (c12.2V). Most Kras mutations for colorectal cancer patients are localized within codon 12, but are also

Figure 5.4 Agarose gel electrophoresis of the PCR products. PCR was set for 32 cycles, with
initial denaturation of 2 min and final extension of 7 min. Each cycle consisted of: 94 °C (30 s),
60 °C (30 s), 72 °C (40 s). Gel stained with ethydium bromide were run at 4.8 V cm -1. (A) Gel
electropherogram for PCR performed on standard SW620 samples (a) no gDNA template,
Negative control; (b) DNA from 10 SW620 cells; (c) DNA from 20 SW620 cells; (d) DNA from
50 SW620 cells; (e) DNA from 100 SW620 cells; (f) DNA from 500 SW620 cells; (g) DNA from
1,000 SW620 cells; (h) DNA from 5,000 SW620 cells; (i) gDNA template from SW620, Positive
control; Lanes a-i contains 3 µL of DNA amplicons. (B) Gel Electropherogram for PCR
performed on SW620 cells obtained from HTMSU selection followed by electrokinetic
enrichment (a) gDNA template from SW620, Positive control; (b) PCR product from 10 SW620
cells selected from whole blood using HTMSU (c) PCR product from whole blood with no
SW620 cells (d) no gDNA template, negative control. Lanes a-d contains 3 µL of DNA
amplicons.

present in codons 13 and 61;69-76 they are found in nearly 35–50% of all patients with
colorectal cancer.77-79 Once acquired, K-ras mutations are conserved throughout the
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course of disease progression. The PCR phase of the assay was first evaluated using
different numbers of SW620 cells, ranging from 10-5,000 cells in control experiments. In
these experiments, the required number of cells was added to a PCR tube, thermally
lysed and the PCR reagents added to the tube. As shown in Figure 5.4A, cells ranging
from 5,000 to as low as 10 were successfully amplified to yield 300 bp PCR products
based on the primers used for the PCR amplification of codon 12 of the SW620 cells.
To demonstrate the capability of our integrated HTMSU with cell enrichment for
subsequent molecular profiling, 1 mL of whole blood containing low-abundance CTCs
was processed. Ten SW620 cells were selected and enriched from 1 mL of whole blood
and subjected to PCR yielding the results shown in the Figure 5.4B lane (b). The
success of the PCR reaction on 10 CTC was confirmed by the positive and negative
control experiments as shown in the Figure 5.4B lane (a) and (d) respectively. As
expected, no PCR amplicon was generated from the whole blood as shown in Figure
5.4 lane (c). The presence of mutations within the amplicon (~300 bp) was analyzed by
LDR. The LDR common primer possessed a Cy5.5 ﬂuorescent label and a 5‘
phosphorylation modification to facilitate covalent coupling with the discriminating primer
for the detection of successful ligation events produced as a result of the LDR and the
subsequent analysis using capillary gel electrophoresis with laser-induced fluorescence
detection. Point mutations were identified through the observation of a 43 nt product.
The capillary gel electrophoresis results of LDR products generated from different
numbers of CTCs processed using the HTMSU and electro-manipulation unit are shown
in Figures 5.5A-G. Clearly, the results indicated the ability to identify point mutations
from as few as 10 CTCs seeded into the whole blood sample and subjected to CTC
selection and enrichment. The HT29 (wild-type) lacks K-ras c12.2V point mutation in the
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K-ras gene, which was confirmed by the absence of 43 nt LDR product, as shown by
capillary gel electrophoresis results of the LDR products generated from 50 HT29 cells
in Figure 5.5H. Three samples, one containing whole blood without CTCs, a second one

Figure 5.5 The LDR mixtures with a discriminating and common primers for K-ras c12.2V, could
selectively detect this mutation. Two µL of amplicons from PCR with SW620 (mutant) and HT29
were used for analyzing point mutation in the K-ras gene. LDR was set for 20 cycles. Initial
denaturation 95 °C for 2 min. Each cycle consisted of: 95 °C (30s), 65 °C (2 min), and 4 °C as
final hold. LDR was performed at capillary temperature of 60°C, denaturation temperature of
90 °C (3 min), Injection at 2.0 kV (30 s) and separation at 6.0 kV (20 min). Peak a represent
the primer and peak b represents the LDR product. Capillary electrophoresis products for A) 0 B)
10 C) 20 D) 50 E) 100 F) 500 and G) 5000 cells of SW620. The insets in A and B show the
magnified scaled plot of products. H) LDR product for 50 cells of HT29.

containing 32 cells from HT29 cells, and a third sample containing 10 SW620 cells were
processed via the HTMSU and enriched with the electro-manipulation unit. The three
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samples were subjected to PCR/LDR/capillary gel electrophoresis and yielded the
results shown in Figures 5.2B-D. As expected, our results showed the presence of no
mutations in the whole blood that contained no CTCs (Figure 5.2B) which served as a
negative control. The sample containing 34 HT29 cells did not show any product (Figure
5.2C) because it does not harbor 12.2V point mutation and served as a wild-type in this
assay. Conversely, the results of whole blood that contained 10 SW620 cells produced
43 nt long LDR product indicative of 12.2V point mutation as shown in Figure 5.2D.
5.4 Conclusions

Previously, it has been reported a positive selection of MCF-7 and LNCaP cancer
cells from peripheral blood using affinity agents such as antibodies and aptamers
immobilized HTMSU. In here, I have integrated HTMSU with electrokinetic enrichment
microfluidic unit for performance of single recombinant low-abundance CTC cell-based
assay. A series of analytical processes were carried out, including immunoaffinity
selection of rare CTCs, quantification of selected cells via conductivity impedance and
electrophoretic enrichment of selected cells for PCR/LDR/CE interrogation for detection
of low abundant point mutations in genomic DNA. We also showed the ability to recover
cells with ∼96±4% efficiency from the whole blood and ~100% efficient electrokinetic
enrichment of selected CTCs for molecular profiling. The strategy developed offered the
ability to effectively profile low-abundant point mutations harbored in rare CTCs in
patients‘ blood without the interferences of highly abundant leukocytes.

The entire

series of processing steps can be implemented in under 40 min for 1 mL of blood
sample, and the processing volume could significantly be increased by increasing the
throughput of the fluidic chip through the use of more fluidic vials that are deeper can
provide the opportunity to process 10 mL of input blood directly. In addition, moving the
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PCR/LDR step to the chip can also reduce processing time significantly and improve the
sensitivity due to the more efficient thermal management properties of microscale
molecular profiling.
5.5 References

1. Peek, RM., Jr. Cancer Chemother. Pharmacol. 2004, 54, S50.
2. Ang, C-S.; Nice, EC. J. Proteome Res. ACS ASAP.
3. Takahashi, H.; Hosono, K.; Uchiyama, T.; Sugiyama, M.; Sakai, E.; et al., PPAR Res.
2010, No pp given.
4. Allard, WJ.; Matera, J.; Miller, MC.; Repollet, M.; Connelly MC.; et al., Clin. Cancer
Res. 2004, 10, 6897.
5. Vidaurreta, M.; Sastre, J.; Sanz-Casla MT.; Maestro ML.; Rafael, S.; et al., Med. Clin.
2007, 129, 333.
6. Midgley, RS.; Kerr, DJ. Expert Rev. Anticancer Ther.2003, 3, 63.
7. Cristofanilli, M.; Budd, GT.; Ellis, MJ.; Stopeck, A.; Matera, J.; et al., New England J.
Med. 2004, 351, 781.
8. Helo, P.; Cronin, AM.; Danila, DC.; Wenske, S.; Gonzalez-Espinoza, R.; et al., Clin.
Chem. 2009, 55, 765.
9. Han, HJ.; Yanagisawa, A.; Kato, Y.; Park, JG.; Nakamura, Y. Cancer Res. 1993, 53,
5087.
10. Sieuwerts, AM.; Kraan, J.; Bolt-de VJ.; Spoel, P.; Mostert, B.; et al., Breast Cancer
Res. Treat. 2009, 118, 455.
11. Cohen, SJ.; Alpaugh, RK.; Gross, S.; O'Hara, SM.; Smirnov, DA.; et al., Clin.
Colorectal Cancer 2006, 6, 125.
12. Allan AL.; Keeney, M. J. Oncol. 2010, 2010, 426218.
13. Campos, M.; Prior, C.; Warleta, F.; Zudaire, I.; Ruiz-Mora, J.; et al., J. Histochem.
Cytochem. 2008, 56, 667.
14. Wlodkowic, D.; Faley, S.; Skommer, J.; McGuinness, D.; Cooper, J. M. Anal. Chem.
2009, 81, 9828.

146

15. Hou, J-M.; Greystoke, A.; Lancashire, L.; Cummings, J.; Ward, T.; et al., American J.
Pathol. 2009, 175, 808.
16. Nagrath, S.; Sequist, LV.; Maheswaran, S.; Bell, DW.; Irimia, D.; et al., Nature 2007,
450, 1235.
17. Adams, AA.; Okagbare, PI.; Feng, J.; Hupert, ML.; Patterson, D.; et al., J. Am.
Chem. Soc. 2008, 130, 8633.
18. Dharmasiri, U.; Balamurugan, S.; Adams, AA.; Okagbare, PI.; Obubuafo, A.; Soper,
SA. Electrophoresis 2009, 30, 3289.
19. Miller, MC.; Doyle Gerald, V.; Terstappen Leon, WMM. J. Oncol. 2010, 2010,
617421.
20. Bouche, O.; Beretta, GD.; Alfonso, PG.; Geissler, M. Cancer Treat. Rev. 2010, 36,
S1.
21. Yang, M-J.; Chiu, H-H.; Wang, H-M.; Yen, L-C.; Tsao, D-A.; et al., Ann. Surg. Oncol.
2010, 17, 624.
22. Bilchik, AJ.; Nora, DT.; Saha, S.; Turner, R.; Wiese, D.; et al., Arch. Surg. 2002, 137,
1377.
23. Svoboda, K.; Block, SM. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 247.
24. Wu, JR. J. Acoust. Soc. Am. 1991, 89, 2140.
25. Jung, DR.; Kapur, R.; Adams, T.; Giuliano, K. A.; Mrksich, M.; et al., Crit. Rev.
Biotechnol. 2001, 21, 111.
26. Melville, D.; Paul, F.; Roath, S. IEEE Trans. Magn. 1975, MAG11, 1701.
27. Radbruch, A.; Mechtold, B.; Thiel, A.; Miltenyi, S.; Pfluger, E. Methods Cell Biol.
1994, 42 Pt B, 387.
28. Grimm, S. Nat. Rev. Genet. 2004, 5, 179.
29. Andersson, H.; van den BA. Curr. Opin. Biotechnol. 2003, 15, 44.
30. Voldman, J.; Gray, ML.; Schmidt, MA. Annu. Rev. Biomed. Eng. 1999, 1, 401.
31. Faley, S.; Seale, K.; Hughey, J.; Schaffer, DK.; VanCompernolle, S.;et al., Lab Chip
2008, 8, 1700.
32. Wlodkowic, D.; Faley, S.; Zagnoni, M.; Wikswo JP.; Cooper JM. Anal. Chem. 2009,
81, 5517.
147

33. Hashimoto, M.; Barany, F.; Soper, SA. Biosensors & Bioelectronics 2006, 21, 1915.
34. Sinville, R.; Coyne, J.; Meayher, RJ.; Cheng, YW.; Barany, F.; et al., Electrophoresis
2008, 29, 4751.
35. Gerry, NP.; Witowski, NE.; Day, J.; Hammer, RP.; Barany, G.; et al., Mol. Biol. 1999,
292, 251.
36. Khanna, M.; Cao, WG.; Zirvi, M.; Paty, P.; Barany, F. Clin. Biochem. 1999, 32, 287.
37. Hashimoto, M.; Barany, F.; Soper, SA. Biosensors & Bioelectronics 2006, 21, 1915.
38. Thomas, G.; Sinville, R.; Sutton, S.; Farquar, H.; Hammer, RP.; et al.,
Electrophoresis 2004, 25, 1668.
39. Wabuyele, MB.; Farquar, H.; Stryjewski, W.; Hammer, RP.; Soper, SA.; et al., J. Am.
Chem. Soc. 2003, 125, 6937.
40. Huang, X.; Gordon, MJ.; Zare, RN. Anal. Chem. 1988, 60, 1837.
41. Hosokawa, M.; Hayata, T.; Fukuda, Y.; Arakaki, A.; Yoshino, T.; et al., Anal. Chem.
2010, 82, 6629.
42. Stephan JP.; Schanz, S.; Wong, A.; Schow, P.; Wong WLT. Am. J. Pathol. 2002,
161, 787.
43. Chang, K-C.; Hammer, DA. Biophys.l J. 1999, 76, 1280.
44. Willuda, J.; Honegger, A.; Waibel, R.; Schubiger, PA.; Stahel, R.; et al., Cancer Res.
1999, 59, 5758.
45. Ayadi, MA.; Leuliet, JC.; Chopard, F.; Berthou, M.; Lebouche, M. Innovative Food
Science Emerging Tech. 2004, 5, 465.
46. Mehrishi, JN.; Bauer, J. Electrophoresis 2002, 23, 1984.
47. Weiss, L. Exp. Cell Res. 1974, 86, 223.
48. Lipman, KM.; Dodelson, R.; Hays, RM. J.Gen. Physiol. 1966, 49, 501.
49. Righetti, PG. Electrokinet. Sep. Methods 1979, 389.
50. Kuhr, WG. Anal. Chem. 1990, 62, 403R.
51. Li, PCH.; Harrison, DJ. Anal. Chem. 1997, 69, 1564.
148

52. Kang, Y.; Li, D. Microfluid. Nanofluid. 2009, 6, 431.
53. Witek, MA.; Wei, S.; Vaidya, B.; Adams, AA.; Zhu, L.; et al., Lab Chip 2004, 4, 464.
54. Korson, L.; Drost-Hansen, W.; Millero, FJ. J. Phys. Chem. 1969, 73, 34.
55. Xuan, X.; Raghibizadeh, S.; Li, D. J. Colloid Interface Science 2006, 296, 743.
56. Keh, HJ.; Chiou, JY. AIChE J. 1996, 42, 1397.
57. Novillo, C.; Castanera, P.; Ortego, F. Insect Biochem. Mol. Biol. 1999, 29, 177.
58. Mazda, T.; Makino, K.; Ohshima, H. Colloids Surfaces, B: Biointerfaces 1995, 5, 75.
59. Uhlenbruck, G.; Rothe, A.; Pardoe, GI. Immunol. 1968, 136, 79.
60. The, TH.; Feltkamp, TEW. Immunol. 1970, 18, 865.
61. Hashimoto, M.; Hupert, ML.; Murphy, MC.; Soper, SA.; Cheng, Y-W.; et al., Anal.
Chem. 2005, 77, 3243.
62. Barany, F. Proc. Natl. Acad. Sci. USA. 1991, 88, 189.
63. Favis, R.; Day, JP.; Gerry, NP.; Phelan, C.; Narod, S.; et al., Nature Biotech. 2000,
18, 561.
64. Khanna, M.; Park, P.; Zirvi, M.; Cao, W.; Picon, A.; et al., Oncogene 1999, 18, 27.
65. Wang, Y.; Vaidya, B.; Farquar, H. D.; Stryjewski, W.; Hammer, R. P.; et al., Anal.
Chem. 2003, 75, 1130.
66. Situma, C.; Wang, Y.; Hupert, M.; Barany, F.; McCarley, et al., Anal. Biochem. 2005,
340, 123.
67. Khanna, M.; Cao, W.; Zirvi, M.; Paty, P.; Barany, F. Clin. Biochem. 1999, 32, 287.
68. Cheng, YW.; Shawber, C.; Notterman, D.; Paty, P.; Barany, F. Genome Res. 2006,
16, 282.
69. Bos, JL. Mutat. Res. 1988, 195, 255.
70. Breivik, J.; Meling, GI.; Spurkland, A.; Rognum, TO.; Gaudernack, G. Br. J. Cancer
1994, 69, 367.
71. Capella, G.; Cronauer-Mitra, S.; Pienado, MA.; Perucho, M. Environ. Health
Perspect. 1991, 93, 125.
149

72. Finkelstein, SD.; Sayegh, R.; Bakker, A.; Swalsky, P. Arch. Surg. 1993, 128, 526.
73. Forrester, K.; Almoguera, C.; Han, K.; Grizzle, WE.; Perucho, M. Nature 1987, 327,
298.
74. Losi, L.; Benhattar, J.; Costa, J. Eur. J. Cancer 1992, 28A, 1115.
75. Smith, AJ.; Stern, HS.; Penner, M.; Hay, K.; Mitri, A.; et al., Cancer Res. 1994, 54,
5527.
76. Vogelstein, B.; Fearon, ER.; Hamilton, SR.; Kern, SE.; Preisinger, AC.; et al., N.
Engl. J. Med. 1988, 319, 525.
77. Andersen, SN.; Lovig, T.; Breivik, J.; Lund, E.; Gaudernack, G.; et al., Scand J
Gastroenterol. 1997, 32, 62.
78. Chiang, JM. Cancer Lett. 1998, 126, 179.
79. Rothschild, CB.; Brewer, CS.; Loggie, B.; Beard, GA.; Triscott, MX. J. Immunol.
Methods 1997, 206, 11.

150

CHAPTER 6 FUTURE WORK: HIGHLY EFFICIENT SEPARATION OF PURE
HEMATOPOIETIC STEM CELLS FROM WHOLE BLOOD
6.1 Introduction

The stem cells that generate blood and immune cells are termed as
hematopoietic stem cells (HSCs). Recently, it has been found that HSCs are able to
form epithelial cells, such as muscle, blood vessels, and bone. 1 Lagasse et al.
demonstrated that the liver can be repaired by purified HSCs; therefore, HSCs have the
potential to integrate into and grow in some epithelial tissues. This may eventually make
it possible to use HSCs to replace a wider array of cells and tissues. 2 In addition, there
have been suggestions that umbilical cord blood contains stem cells having the
capability of developing cells of multiple germ layers (multipotent) or even all germ
layers, e.g., endoderm, ectoderm, and mesoderm (pluripotent). 3 Another potential use
of HSCs is in the treatment of hereditary blood disorders such as aplastic anemia, betathalassemia, Blackfan-Diamond syndrome, globoid cell leukodystrophy, sickle-cell
anemia, severe combined immunodeficiency, X-linked lymphoproliferative syndrome,
and Wiskott-Aldrich syndrome.4 Also, HSCs can be utilized for the replacement of blood
cells that are destroyed by chemotherapy. Thus, these cells can be stored while the
patient undergoes intensive chemotherapy or radiotherapy that is used to destroy the
cancer cells. Once the drugs are washed out of the patient's body, the patient receives
a transfusion using the stored HSCs.5 One problem with the use of autologous HSCs
transplants in cancer therapy is that circulating tumor cells (CTCs) are sometimes
inadvertently collected and reinfused into the patient along with the HSCs.
Reintroduction of CTCs can be eliminated by specific selection and separation of HSCs
from whole blood.6
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To harvest HSCs, an intravenous tube is inserted into the donor's vein and the
blood is passed through a filtering system that pulls out CD34 white blood cells (WBCs)
and returns the red blood cells (RBCs) to the donor. The most common approach to
identify HSCs is to utilize membrane markers such as CD34, CD59, CD38, Thy1 and/or
SCA-1.9 Unfortunately, these markers are non-specific for HSCs and they have been
occasionally expressed in WBCs and RBCs when in an activated state. 10 Therefore, of
the cells collected, only 5-20% are genuine HSCs and the remainder are a mixture of
WBCs of various degrees of maturity.7
In addition, another major issue with selection of HSC levels is the lowabundance or rare-event nature of these cells among a higher number of spectator cells
in peripheral blood. For example, ~1,000 HSCs are in whole blood, which is composed
of >109 erythrocytes and >106 leukocytes per mL. In addition, there are multiple types of
stem cells with rare, long-term replicating ability, which are morphologically similar to
WBCs or bone marrow cells.8
SELEX (systematic evolution of ligands by exponential enrichment) is a method
used to generate DNA or RNA aptamers from a combinatorial library. Aptamers with
high affinity and specificity for cells have already been produced successfully,
demonstrating that complex targets, including tumor cells and tissues, are compatible
with the SELEX process.12 Guo et al. generated aptamers for the isolation of HSCs from
whole bone marrow. When bound to a surface, the aptamers could be used for HSCs
tracking. Furthermore, they found that after immobilizing the aptamers targeted against
osteoblasts on titanium, the aptamer-coated titanium surface could enrich osteoblasts
quickly and efficiently.11

152

Aptamer technology has been used for protein-protein interaction research and
for molecular recognition. It is a robust technology to identify specific targets. The cellSELEX process allows the selection of highly specific aptamers with high binding
affinities without prior knowledge of any biomarkers or proteins on the cell membrane. 13
It has been reported that cell-SELEX can be used to identify minor molecular-level
differences among similar categories of cells.14 In addition, The cell-SELEX process
allows for aptamers to be selected from cells in their native state. In fact, through
biomarker discovery, the molecular nature of the membrane can then be explored to
derive even more information by the selected aptamers for an understanding of the
molecular foundation of the cell membrane, which has been preliminarily demonstrated
by Blank and co-workers.18
On the other hand, improved performance of microsystem technologies is
emerging as fundamental to high-sensitivity cellular analysis technologies. In particular,
microsystem platforms enable one to handle small numbers of cells without loss. 15
Already, aptamers and antibodies have been incorporated into microsystems to
effectively isolate low-abundance CTCs.13,16,17 The challenge for imposing lowabundance cell–selection assays to microsystems is sampling; to generate a high
statistical probability of selecting the low-abundance cells, large input volumes must be
processed and most microsystems cannot handle large-volume inputs in reasonable
times. Adams et al. recently reported a microsystem having high-throughput
capabilities.16,17 In this system, 1 mL of blood could be processed in ~30 min.
Therefore, proposed herein is a novel approach to selectively isolate HSCs from
peripheral blood using an ultra-high-throughput microsystem. The cell-SELEX
procedure will be implemented to generate HSCs specific aptamers. The developed
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HSCs specific aptamers will be immobilized onto ultra-high aspect ratio microstructures
for high-throughput selection of HSCs from whole blood. The isolated HSCs will be
released into solution a using complementary oligonucleotide, pH or ionic strength
changes in the medium. As such, viability and physiological integrity of the selected
HSCs will be conserved for downstream clinical applications.
6.2 Materials and Methods
6.2.1

Cell Suspensions
HSCs (ATCC) will be cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s

Medium supplemented with high glucose containing 1.5 g L -1 sodium bicarbonate
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper
(Mediatech, Inc.) solution will be used to harvest the HSCs from the culturing plate.
HSCs will be stained with PKH67 for microscopic visualization experiments using
fluorescence. Cell counts for seeding experiments into whole blood will be determined
by counting three aliquots of cells in succession using a hemacytometer.
6.2.2

Cell-SELEX Library and Primers
The HPLC-purified library will contain a central randomized sequence of 45

nucleotides

(nt)

flanked

by

20-nt

primer

hybridization

(ACGCTCGGATGCCACTACAG-45nt-CTCATGGACGTGCTGGTGAC)

sites
(Applied

Biosystems). 5‘-primer (5‘-FITC- ACGCTCGGATGCCACTACAG-3‘) and a biotinylated
(Bio) 3‘-primer (5‘-Bio- GTCACCAGCACGTCCATGAG-3‘) (Applied Biosystems) will be
used in the PCR reactions for the synthesis of DNA molecules. After denaturing in 0.2 M
NaOH, the ssDNA aptamer will be separated from the biotinylated antisense ssDNA
strand by streptavidin-coated sepharose beads (Amersham Bioscience) and used for
next round selection.14
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6.2.3

Cell-SELEX Procedures for Generation of Panel of Aptamers for HSCs
The ssDNA pool will be dissolved in a binding buffer. The binding buffer will be

prepared by adding yeast tRNA (0.1 mg mL-1; Sigma) and BSA (1 mg mL-1) (Fisher) into
wash buffer. Then, the ssDNA pool will be incubated with a target HSCs (ATCC)
monolayer in a T25 flask on ice for 30 min. The adherent cells will be scraped from the
culturing medium and washed. The bound DNAs on the cells‘ membrane will be eluted
by heating at 95 °C for 5 min in a binding buffer. The eluted DNAs will then be incubated
with a WBC and RBC monolayer in a dish (control cells) for counter selection on ice for
1 h. The supernatant will be desalted with a NAP 5 column (GE Healthcare) and then
amplified by PCR with biotin-labeled primers (10-20 cycles of 0.5 min at 94 °C, 0.5 min
at 58 °C, and 0.5 min at 72 °C, followed by 5 min at 72 °C; Taq-polymerase and
dNTP‘s). The selected sense ssDNA will be separated from the biotinylated antisense
ssDNA strand by streptavidin-coated sepharose beads. In the first round, the amount of
initial ssDNA pool will be dissolved in 1 mL of binding buffer and the counter selection
step will be eliminated. In order to acquire aptamers with high affinity and specificity, the
wash strength will be enhanced gradually by extending wash time (e.g. from 1 to 10
min), increasing the volume of the wash buffer (e.g. from 1 to 5 mL) and the number of
washes (e.g. from 3 to 5). Additionally, 20% FBS and 50-300-fold molar excess of an
88-mer random DNA library will be added to the incubation solution to reduce the
nonspecific binding of the selected pool. After 16 rounds of selection, the selected
ssDNA pool will be PCR-amplified using unmodified primers and cloned into
Escherichia coli using the TA cloning kit (Invitrogen). Cloned sequences will be
determined by genome sequencing.14
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6.2.4

ultra-High-Throughput Microsampling Unit (uHTMSU) Fabrication
The proposed microfluidic will consist of multiple fluidic conduits (460) to reduce

the pressure drop across the device while allowing for high volume throughput. (e.g. 10
mL of blood in 20 mins at 2 mm s-1 linear velocity flow). The device will consist of a
series parallel high-aspect ratio channels sharing common input/output ports. Initially,
microstructures will be milled onto the surface of a brass plate with a high-precision
micromilling machine (KERN MMP 2522, KERN Micro-und Feinwerktechnik GmbH &
Co.KG; Germany). The devices will be replicated from a mold masters using hot
embossing. The substrate selected for the HTMSU will be PMMA due to its high fidelity
of forming structures with high-aspect ratios via micro-replication, minimal non-specific
adsorption of biological components to its surface and its ability to generate functional
surface-scaffolds through UV irradiation for the attachment of a variety of biological
moieties.
6.2.5

Aptamer Immobilization
The uHTMSU devices will be loaded with a 10 mM aptamer solution also

containing 4 mg mL-1 EDC and 40 mg mL-1 NHS in 150 mM MES (pH=6). The solution
will be allowed to incubate in the device for 2 h at room temperature. The device will
then be rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound
constituents.
6.2.6

HSCs Selection Using the uHTMSU
The blood/reagent container will be made up in 50 mL thin wall plastic tubes.

Helium gas will be used to pressurize the system for infusing the solution into the
uHTMSU. The reagent/blood container will be connected to a helium gas regulator and
to the input port of the HTMSU via a plastic tube with 250 µm internal diameter. The
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flow rate of the system will be proportional to the helium gas pressure applied.
Therefore, the flow rate of the input blood/solution can be controlled by regulating

the

helium gas pressure.
The aptamer immobilized uHTMSU will be subjected to a pre-cell capture rinse
with 0.2 mL of 150 mM PBS at 50 mm s-1 linear velocity. Then, the appropriate volume
of cell (~10 mL) suspension will be introduced into the uHTMSU at the appropriate
linear velocity to isolate the HSCs. Next, a post-capture rinse will be performed with 0.2
mL of 150 mM PBS at 50 mm s-1 to remove any non-specifically adsorbed cells. In
cases where the cells require optical visualization to assist in the operational
optimization of the uHTMSU, the PMMA devices will be fixed to a programmable
motorized stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) microscope and
video images were collected during each experiment at 30 frames per second using a
monochrome CCD (JAI CV252, San Jose, CA).
6.2.7

HSCs Release from the uHTMSU
Following a post cell capture rinse performed with 0.2 mL of 150 mM PBS, the

cell releasing step can be implemented. The released cells should be viable and have
conserved physiological integrity for downstream clinical applications. It has been
reported that aptamer-target complexes can be disrupted by changing medium pH, ionic
strength or introducing the complementary oligonucleotide. Each method will be
implemented to find the ideal conditions for releasing viable HSCs into solution. The cell
releasing process will be observed via microscopy.
6.3 Expected Results and Significance

The HSCs specific aptamers will be tethered to the channel walls, dynamic
interactions between aptamer specific cell membrane‘s receptors and the channel wall
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is important for the recovery of HSCs. An optimal linear velocity would be expected to
guarantee the highest frequency of interaction between surface bound aptamers and
HSCs. The optimum linear velocity depends upon the association constant between cell
membrane antigen and the aptamer. Here, panel of aptamers will be utilized and
multiple cell surface biomarkers will be targeted. Therefore, determination of optimum
linear velocity for maximum cell recovery in the presence of multiple interactions will be
an interesting factor to investigate.
The panel of aptamers will selectively and specifically immobilize HSCs without
prior knowledge of any cell membrane biomarkers. Isolated cells will be released using
the complementary aptamers,13 changing pH or changing ionic strength of the
medium.14 These cell releasing methods will have minimal impact on the integrity and
viability of the cell. Therefore, the cells harvested will be suitable for downstream
applications such as clinical cell implantations.
6.4 Dissertation Summary

After brief overview of low-abundance cell selection techniques in chapter 1 and
circulating tumor cells in chapter 2, this dissertation initially focuses on the development
of aptamer incorporated high-throughput microfluidic techniques to select rare
circulation prostate cancer cells (LNCaP) directly from whole blood. The compelling
advantage of this methodology was that no sample pre-treatment was necessary and
the throughput, recovery, and purity were extremely high, contrary to what has been
seen in other low-abundance cell selection formats utilizing size or affinity capture. The
ability to quantify the selected cells with near 100% detection efficiency using a
conductivity readout format allows for the use of this simple system at the point-of-care
for the management of cancer-related diseases from a simple blood test.
158

Then, we extended the technology to environmental samples to improve
sensitivity and portability of traditional groundwater assessment. As a model biopathogen, E. coli O157:H7 was chosen due to its toxicity and adverse impact on
recreational waters. Low-abundance (<100 cells mL-1) E. coli O157:H7 cells were
isolated and enriched from environmental water samples using a microfluidic chip that
its capture beds were covalently decorated with E.coli O157:H7 specific polyclonal
antibodies. After cell selection, the cells were released and enumerated using bench-top
real-time quantitative polymerase chain reaction (PCR), targeting genes which
effectively discriminated the O157:H7 serotype from other nonpathogenic bacteria. The
strategy developed offered the ability to monitor water quality without the need for a
time-consuming cell culture step. We subsequently performed analysis of lake and
wastewater samples. The simplicity in manufacturing and ease of operation makes this
device attractive for the selection of pathogenic species from a variety of water supplies
suspected of containing bacterial pathogens at extremely low frequencies. We envision
the potential to probe for a large number of different strains of enterohemorrhagic E. coli,
which includes more than 100 different non-O157 strains. By proper choice of pAbs and
specific probes for the real-time qPCR, one could monitor a large panel of suspected E.
coli strains from a single sample.
Finally, we have integrated HTMSU with electrokinetic enrichment microfluidic
unit for performance of single recombinant low-abundance CTC cell-based assay. A
series of analytical processes were carried out, including immunoaffinity selection of
rare CTCs, quantification of selected cells via conductivity impedance and
electrophoretic enrichment of selected cells for PCR/LDR/CE interrogation for detection
of low-abundance point mutations in genomic DNA. The HTMSU was equipped with a
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conductivity sensor utilized for CTC selection and automatic quantitation. Following
enumeration of the CTCs, they were hydrodynamically transported to an on-chip
electro-manipulation unit for preconcentration of the CTCs into a receiving reservoir in a
controlled manner. The preconcentrated CTCs could then be genetically profiled to
search for point mutations using a PCR/LDR/CE assay. The DNA was extracted from
the CTCs and subjected to a primary polymerase chain reaction (PCR) with the
amplicons used for a ligase detection reaction (LDR) to probe for K-ras G12.2V
oncogene mutations. This system directs towards a self-contained and fully integrated
fluidic system for the molecular profiling of low-abundance CTCs (~10 cell mL-1 of whole
scattered among peripheral-blood nucleated cells (~106 cells mL-1 of whole

blood)
blood).

6.5 Immediate Projections

With minor modifications to the techniques, such as increasing the number of
capture channels, changing the channels dimensions, changing the immobilized affinity
agents, changing the releasing agent and changing the electric field strength of the cell
manipulation section, this technology will be widely applicable for different cell selection,
and enrichment assays. In addition, moving the PCR/LDR step to the chip can also
reduce processing time significantly and improve the sensitivity greatly due to the more
efficient thermal management properties of microscale molecular profiling. In addition,
the cells can be subjected to further investigations such as viability and culturing for
development of new array of personalized cell lines. Experimental optimization of the
parameters will have significant impact on extending the applicability in disease
diagnostics and prognostics. Further, in the environmental regime, investigation with
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these devices will yield assessment of environmental samples for low-abundance biopathogens.
6.6 References

1. Alison, MR.; Poulsom, R.; Jeffery, R.; Dhillon, AP.; Quaglia, A.; et al., Nature 2000,
406, 257.
2. Lagasse, E.; Connors, H.; Al-Dhalimy, M.; Reitsma, M.; Dohse, M.; et al., Nature
2000, 6, 1229.
3. Dzierzak, E.; Medvinsky, A.; de Bruijn, M. Immun. 1998, 19, 228.
4. Dzierzak, E. Ann. N.Y. Acad. Sci. 1999, 872, 256.
5. Cutler, C.; Li, S.; Kim, HT.; Laglenne, P.; Szeto, KC.; Hoffmeister, L.; et al., Bio.
Blood and Marrow Trans. 2005, 11, 383.
6. Bittner, R. E.; Schofer, C.; Weipoltshammer, K.; Ivanova, S.; Streubel, B.; et al., Anat.
Embry. 1999, 199, 391.
7. Baum, C. M.; Weissman, IL.; Tsukamoto, AS.; Buckle, AM.; Peault, B. Proc. Natl.
Acad. Sci. U.S.A. 1992, 89, 2804.
8. Chen, J.; Astle, CM.; Harrison, DE. Exp. Hematol. 1999, 27, 928.
9. Weissman, IL.; Anderson, DJ.; Gage, F. Ann. Rev. Cell Dev. Biol. 2001, 17, 387.
10. Audet, J.; Miller, CL.; Rose-John, S.; Piret, JM.; Eaves, CJ. Proc. Natl. Aca. Sci.
U.S.A. 2001, 98, 1757.
11. Guo, K-T.; Paul, A.; Schichor, C.; Ziemer, G.; Wendel, HP. Intl. J. Mol. Sci. 2008, 9,
668.
12. Jayasena, SD. Clin. Chem. 1999, 45, 1628.
13. Shangguan, D.; Meng, L.; Cao, Z. C.; Xiao, Z.; Fang, X.; et al., Anal. Chem. 2008,
80, 721.
14. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z. C.; Chen, H. W.; Mallikaratchy, P.; et al.,
Proc. Natl. Aca. Sci. U.S.A. 2006, 103, 11838.
15. Dharmasiri, U.; Witek MA.; Adams AA.; Soper SA. Ann. Rev. Anal. Chem. 2010, 3,
409.

161

16. Dharmasiri, U.; Balamurugan, S.; Adams, AA.; Okagbare, PI.; Obubuafo, A.; Soper,
SA. Electrophoresis 2009, 30, 3289.
17. Adams, AA.; Okagbare, PI.; Feng, J.; Hupert, ML.; Patterson, D.; et al., JACS 2008,
130, 8633.

162

APPENDIX : PERMISSIONS

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Vita
Udara Rasika Dharmasiri was born to Mr. A.W. Dharmasiri and Mrs. S.C. Kaldera in
Kandy, Sri Lanka. He attended Ananda College, Colombo, Sri Lanka, from 1991–2000.
Shortly after the schooling, Udara enrolled at University of Peradeniya, Sri Lanka. He
obtained Bachelor of Science in Chemistry in April, 2004. Upon receiving the degree he
was recruited as a Teaching Assistant in the Department of Chemistry, University of
Peradeniya. In April 2005, Udara entered the postgraduate Institute of Science,
University of Peradeniya, where he obtained Master of Science in analytical chemistry
in August 2006. While still at the University of Peradeniya, he followed Chartered
Institute of Management Accountants (CIMA) (UK) exams and completed CIMA degree
up to Intermediate level. In the Fall of 2006, he was accepted to Graduate School
doctoral program at Louisiana State University (LSU) in the Department of Chemistry. In
the graduate school, he received the James W. Robinson Award for Outstanding
Research in Analytical Sciences. He has been a member the American Chemical
Society (ACS), Louisiana Volunteers in Action (LAVA) and Chartered Institute of
Management Accountants (CIMA). He is also a member of two national honor societies:
Phi Kappa Phi and Gamma Beta Phi. Udara Rasika Dharmasiri is currently a candidate
for the Doctor of Philosophy in bioanalytical chemistry, which will be awarded to him at
the December 2010 Commencement at LSU, Baton Rouge.

181

